%PDF-1.4
1 0 obj
<< /Type /Catalog /Pages 2 0 R >>
endobj
2 0 obj
<< /Type /Pages /Kids [ 4 0 R 6 0 R 8 0 R 10 0 R 12 0 R 14 0 R 16 0 R 18 0 R 20 0 R 22 0 R 24 0 R 26 0 R 28 0 R 30 0 R 32 0 R 34 0 R 36 0 R 38 0 R 40 0 R 42 0 R 44 0 R 46 0 R 48 0 R 50 0 R 52 0 R 54 0 R 56 0 R 58 0 R 60 0 R 62 0 R 64 0 R 66 0 R 68 0 R 70 0 R 72 0 R 74 0 R 76 0 R 78 0 R 80 0 R 82 0 R 84 0 R 86 0 R 88 0 R 90 0 R 92 0 R 94 0 R 96 0 R 98 0 R 100 0 R 102 0 R 104 0 R 106 0 R 108 0 R 110 0 R 112 0 R 114 0 R ] /Count 56 >>
endobj
3 0 obj
<< /Length 1840 >>
stream
BT
/F1 10 Tf
72 720 Td
(Exhibit 10.2) Tj
0 -12 Td
() Tj
0 -12 Td
(______________________________________________________________________________) Tj
0 -12 Td
() Tj
0 -12 Td
(CO-PROMOTION AGREEMENT) Tj
0 -12 Td
() Tj
0 -12 Td
(by and between) Tj
0 -12 Td
() Tj
0 -12 Td
(DOVA PHARMACEUTICALS, INC.) Tj
0 -12 Td
() Tj
0 -12 Td
(and) Tj
0 -12 Td
() Tj
0 -12 Td
(VALEANT PHARMACEUTICALS NORTH AMERICA LLC) Tj
0 -12 Td
() Tj
0 -12 Td
(September 26, 2018) Tj
0 -12 Td
() Tj
0 -12 Td
(______________________________________________________________________________) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(TABLE OF CONTENTS) Tj
0 -12 Td
() Tj
0 -12 Td
(Page) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 1 DEFINITIONS 1) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 2 RIGHTS AND OBLIGATIONS 8) Tj
0 -12 Td
() Tj
0 -12 Td
(2.1 Engagement; Grant of Rights. 8) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2 Retention of Rights. 9) Tj
0 -12 Td
() Tj
0 -12 Td
(2.3 Non-Competition; Non-Solicitation. 9) Tj
0 -12 Td
() Tj
0 -12 Td
(2.4 Dova Trademarks and Copyrights. 10) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 3 JOINT STEERING COMMITTEE 11) Tj
0 -12 Td
() Tj
0 -12 Td
(3.1 Formation of the JSC. 11) Tj
0 -12 Td
() Tj
0 -12 Td
(3.2 Meetings and Minutes. 11) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3 Purpose of the JSC. 11) Tj
0 -12 Td
() Tj
0 -12 Td
(3.4 Decision Making. 13) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
4 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 3 0 R >>
endobj
5 0 obj
<< /Length 1936 >>
stream
BT
/F1 10 Tf
72 720 Td
(3.5 Marketing Sub-Committee. 13) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 4 VALEANT ACTIVITIES FOR THE PRODUCT 14) Tj
0 -12 Td
() Tj
0 -12 Td
(4.1 Valeant Activities. 14) Tj
0 -12 Td
() Tj
0 -12 Td
(4.2 Detailing. 15) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3 Compliance with Applicable Law. 17) Tj
0 -12 Td
() Tj
0 -12 Td
(4.4 Field Force Personnel Training; Product Materials. 19) Tj
0 -12 Td
() Tj
0 -12 Td
(4.5 Provisions Related to Field Force Personnel. 21) Tj
0 -12 Td
() Tj
0 -12 Td
(4.6 Responsibility for Valeant Activity Costs and Expenses. 22) Tj
0 -12 Td
() Tj
0 -12 Td
(4.7 Data Sharing. 22) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 5 REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS 23) Tj
0 -12 Td
() Tj
0 -12 Td
(5.1 Dova Responsibility. 23) Tj
0 -12 Td
() Tj
0 -12 Td
(5.2 Valeant Involvement. 23) Tj
0 -12 Td
() Tj
0 -12 Td
(5.3 Inspections. 23) Tj
0 -12 Td
() Tj
0 -12 Td
(5.4 Pharmacovigilance. 24) Tj
0 -12 Td
() Tj
0 -12 Td
(5.5 Unsolicited Requests for Medical Information. 24) Tj
0 -12 Td
() Tj
0 -12 Td
(5.6 Recalls and Market Withdrawals. 25) Tj
0 -12 Td
() Tj
0 -12 Td
(5.7 Certain Reporting Responsibilities. 25) Tj
0 -12 Td
() Tj
0 -12 Td
(5.8 Booking of Sales Revenues. 25) Tj
0 -12 Td
() Tj
0 -12 Td
(5.9 Returns. 25) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(i) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
6 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 5 0 R >>
endobj
7 0 obj
<< /Length 1759 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(TABLE OF CONTENTS \(continued\)) Tj
0 -12 Td
() Tj
0 -12 Td
(5.10 Manufacturing; Distribution; Marketing. 25) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 6 FINANCIAL PROVISIONS 26) Tj
0 -12 Td
() Tj
0 -12 Td
(6.1 Promotion Fee. 26) Tj
0 -12 Td
() Tj
0 -12 Td
(6.2 Milestone Payment. 27) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3 Reports; Payments. 27) Tj
0 -12 Td
() Tj
0 -12 Td
(6.4 Taxes. 28) Tj
0 -12 Td
() Tj
0 -12 Td
(6.5 Determination of Specialty. 29) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 7 AUDIT RIGHTS 30) Tj
0 -12 Td
() Tj
0 -12 Td
(7.1 Recordkeeping. 30) Tj
0 -12 Td
() Tj
0 -12 Td
(7.2 Valeant Rights. 30) Tj
0 -12 Td
() Tj
0 -12 Td
(7.3 Dova Rights. 31) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 8 INTELLECTUAL PROPERTY 32) Tj
0 -12 Td
() Tj
0 -12 Td
(8.1 Ownership of Intellectual Property. 32) Tj
0 -12 Td
() Tj
0 -12 Td
(8.2 Title to Trademarks and Copyrights. 32) Tj
0 -12 Td
() Tj
0 -12 Td
(8.3 Protection of Trademarks and Copyrights. 32) Tj
0 -12 Td
() Tj
0 -12 Td
(8.4 Disclosure of Know-How. 33) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 9 CONFIDENTIALITY 33) Tj
0 -12 Td
() Tj
0 -12 Td
(9.1 Confidential Information. 33) Tj
0 -12 Td
() Tj
0 -12 Td
(9.2 Public Announcements. 34) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 10 REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS 35) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1 Representations and Warranties of Dova. 35) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2 Representations and Warranties of Valeant. 37) Tj
0 -12 Td
() Tj
0 -12 Td
(10.3 Disclaimer of Warranty. 38) Tj
0 -12 Td
() Tj
0 -12 Td
(10.4 Additional Covenants. 39) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 11 INDEMNIFICATION; LIMITATIONS ON LIABILITY 39) Tj
0 -12 Td
() Tj
0 -12 Td
(11.1 Indemnification by Dova. 39) Tj
0 -12 Td
ET
endstream
endobj
8 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 7 0 R >>
endobj
9 0 obj
<< /Length 1703 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(11.2 Indemnification by Valeant. 39) Tj
0 -12 Td
() Tj
0 -12 Td
(11.3 Indemnification Procedures. 40) Tj
0 -12 Td
() Tj
0 -12 Td
(11.4 Limitation of Liability. 40) Tj
0 -12 Td
() Tj
0 -12 Td
(11.5 Insurance. 40) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 12 TERM AND TERMINATION 41) Tj
0 -12 Td
() Tj
0 -12 Td
(12.1 Term. 41) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2 Early Termination for Cause. 41) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(12.3 Other Early Termination. 42) Tj
0 -12 Td
() Tj
0 -12 Td
(12.4 Effects of Termination. 42) Tj
0 -12 Td
() Tj
0 -12 Td
(12.5 Tail Period. 42) Tj
0 -12 Td
() Tj
0 -12 Td
(ii) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(TABLE OF CONTENTS \(continued\)) Tj
0 -12 Td
() Tj
0 -12 Td
(12.6 Survival. 43) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 13 MISCELLANEOUS 43) Tj
0 -12 Td
() Tj
0 -12 Td
(13.1 Force Majeure. 43) Tj
0 -12 Td
() Tj
0 -12 Td
(13.2 Assignment. 43) Tj
0 -12 Td
() Tj
0 -12 Td
(13.3 Severability. 44) Tj
0 -12 Td
() Tj
0 -12 Td
(13.4 Notices. 44) Tj
0 -12 Td
() Tj
0 -12 Td
(13.5 Governing Law. 45) Tj
0 -12 Td
ET
endstream
endobj
10 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 9 0 R >>
endobj
11 0 obj
<< /Length 2274 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(13.6 Dispute Resolution. 45) Tj
0 -12 Td
() Tj
0 -12 Td
(13.7 Waiver of Jury Trial. 45) Tj
0 -12 Td
() Tj
0 -12 Td
(13.8 Entire Agreement; Amendments. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.9 Headings. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.10 Independent Contractors. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.11 Third Party Beneficiaries. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.12 Waiver. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.13 Cumulative Remedies. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.14 Waiver of Rule of Construction. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.15 Use of Names. 46) Tj
0 -12 Td
() Tj
0 -12 Td
(13.16 Further Actions and Documents. 47) Tj
0 -12 Td
() Tj
0 -12 Td
(13.17 Certain Conventions. 47) Tj
0 -12 Td
() Tj
0 -12 Td
(13.18 Counterparts. 47) Tj
0 -12 Td
() Tj
0 -12 Td
(iii) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(CO-PROMOTION AGREEMENT) Tj
0 -12 Td
() Tj
0 -12 Td
(This Co-Promotion Agreement \(this "Agreement"\) is entered into and dated as of September) Tj
0 -12 Td
(26, 2018 \(the "Effective Date"\) by and between Dova Pharmaceuticals, Inc., a Delaware) Tj
0 -12 Td
(corporation \("Dova"\), and Valeant Pharmaceuticals North America LLC, a Delaware limited) Tj
0 -12 Td
(liability company \("Valeant"\). Dova and Valeant are each referred to individually as a) Tj
0 -12 Td
("Party" and together as the "Parties".) Tj
0 -12 Td
() Tj
0 -12 Td
(RECITALS) Tj
0 -12 Td
() Tj
0 -12 Td
(WHEREAS, Dova has developed and has rights to market and sell the Product \(as defined) Tj
0 -12 Td
(below\) in the Territory;) Tj
0 -12 Td
() Tj
0 -12 Td
(WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on) Tj
0 -12 Td
(promotional activities for the Product and, accordingly, Dova desires that Valeant conduct) Tj
0 -12 Td
ET
endstream
endobj
12 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 11 0 R >>
endobj
13 0 obj
<< /Length 3933 >>
stream
BT
/F1 10 Tf
72 720 Td
(certain promotional activities, and Valeant desires to conduct such activities, for the) Tj
0 -12 Td
(Product in the Territory;) Tj
0 -12 Td
() Tj
0 -12 Td
(NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for) Tj
0 -12 Td
(other good and valuable consideration the adequacy and sufficiency of which are hereby) Tj
0 -12 Td
(acknowledged, the Parties agree as follows:) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 1   DEFINITIONS) Tj
0 -12 Td
() Tj
0 -12 Td
(1.1 "Act" shall mean the Federal Food, Drug and Cosmetic Act, 21 U.S.C.   301 et seq., as) Tj
0 -12 Td
(it may be amended from time to time, and the regulations promulgated thereunder.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.2 "Adverse Event" shall mean any untoward medical occurrence in a patient or clinical) Tj
0 -12 Td
(investigation subject who is administered the Product, but which does not necessarily have) Tj
0 -12 Td
(a causal relationship with the treatment for which the Product is used. An "Adverse Event") Tj
0 -12 Td
(can include any unfavorable and unintended sign \(including an abnormal laboratory) Tj
0 -12 Td
(finding\), symptom or disease temporally associated with the use of the Product, whether or) Tj
0 -12 Td
(not related to the Product. A pre-existing condition that worsened in severity after) Tj
0 -12 Td
(administration of the Product would be considered an "Adverse Event".) Tj
0 -12 Td
() Tj
0 -12 Td
(1.3 "Affiliate" shall mean, with respect to any Person, any other Person that directly or) Tj
0 -12 Td
(indirectly controls, is controlled by or is under common control with such Person. A) Tj
0 -12 Td
(Person shall be deemed to control another Person if such Person possesses the power to) Tj
0 -12 Td
(direct or cause the direction of the management, business and policies of such Person,) Tj
0 -12 Td
(whether through the ownership of fifty percent \(50%\) or more \(or such lesser percentage) Tj
0 -12 Td
(which is the maximum allowed to be owned by a foreign corporation in a particular) Tj
0 -12 Td
(jurisdiction\) of the voting securities of such Person, by contract or otherwise.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.4 "Agreement" shall have the meaning set forth in the preamble to this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.5 "Alliance Managers" shall have the meaning set forth in Section 4.1.4.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.6 "Alternate Product" shall mean a pharmaceutical product that is commercialized by) Tj
0 -12 Td
(Valeant or its Affiliates in the Territory and that is part of the Salix business segment) Tj
0 -12 Td
(of Valeant's parent company, Bausch Health Companies, Inc. \(or, in the event that such) Tj
0 -12 Td
(business segments are restructured, that is part of the Salix business unit\), and which) Tj
0 -12 Td
(product is complementary to the Product with regard to Target Professionals in the) Tj
0 -12 Td
(Specialty.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.7 "Applicable Laws" shall mean all applicable statutes, ordinances, regulations, codes,) Tj
0 -12 Td
(rules, or orders of any kind whatsoever of any Governmental Authority in the Territory) Tj
0 -12 Td
(pertaining to any of the activities and obligations contemplated by this Agreement,) Tj
0 -12 Td
(including, as applicable, the Act, the Generic Drug Enforcement Act of 1992 \(21 U.S.C.) Tj
0 -12 Td
(335a et seq.\), the Anti- Kickback Statute \(42 U.S.C.   1320a-7b et seq.\), the Health) Tj
0 -12 Td
ET
endstream
endobj
14 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 13 0 R >>
endobj
15 0 obj
<< /Length 3796 >>
stream
BT
/F1 10 Tf
72 720 Td
(Insurance Portability and Accountability Act of 1996, the Federal False Claims Act \(31) Tj
0 -12 Td
(U.S.C.    3729-3733\) \(and applicable state false claims acts\), the Physician Payments) Tj
0 -12 Td
(Sunshine Act, the Code, the Department of Health and Human Services Office of Inspector) Tj
0 -12 Td
(General Compliance Program Guidance for Pharmaceutical Manufacturers, released April 2003,) Tj
0 -12 Td
(the Antifraud and Abuse Amendment to the Social Security Act, the American Medical) Tj
0 -12 Td
(Association guidelines on gifts to physicians, generally accepted standards of good) Tj
0 -12 Td
(clinical practices adopted by current FDA regulations, as well as any state laws and) Tj
0 -12 Td
(regulations \(i\) impacting the promotion of pharmaceutical products, \(ii\) governing the) Tj
0 -12 Td
(provision of meals and other gifts to medical professionals, including pharmacists, or) Tj
0 -12 Td
(\(iii\) governing consumer) Tj
0 -12 Td
() Tj
0 -12 Td
(2) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(protection and deceptive trade practices, including any state anti-kickback/fraud and) Tj
0 -12 Td
(abuse related laws, all as amended from time to time.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.8 "Business Day" means each day of the week, excluding Saturday, Sunday or a day on) Tj
0 -12 Td
(which banking institutions in New York, New York, USA are closed.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.9 "Calendar Quarter" shall mean each successive period of three \(3\) calendar months) Tj
0 -12 Td
(commencing on January 1, April 1, July 1 and October 1, except that the first Calendar) Tj
0 -12 Td
(Quarter of the Term shall commence on the Effective Date and end on the day immediately) Tj
0 -12 Td
(prior to the first to occur of January 1, April 1, July 1 or October 1 after the Effective) Tj
0 -12 Td
(Date, and the last Calendar Quarter shall end on the last day of the Term.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.10 "Calendar Year" shall mean each successive period of twelve \(12\) months commencing on) Tj
0 -12 Td
(January 1 and ending on December 31, except that the first Calendar Year of the Term shall) Tj
0 -12 Td
(commence on the Effective Date and end on December 31 of the year in which the Effective) Tj
0 -12 Td
(Date occurs, and the last Calendar Year of the Term shall commence on January 1 of the) Tj
0 -12 Td
(year in which the Term ends and end on the last day of the Term.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.11 "Claims" shall mean all charges, complaints, actions, suits, proceedings, hearings,) Tj
0 -12 Td
(investigations, claims, demands, judgments, orders, decrees, stipulations or injunctions,) Tj
0 -12 Td
(in each case of a Third Party \(including any Governmental Authority\).) Tj
0 -12 Td
() Tj
0 -12 Td
(1.12 "Code" shall mean the Code on Interactions with Healthcare Professionals promulgated) Tj
0 -12 Td
(by the Pharmaceutical Research and Manufacturers of America \(PhRMA\)/BIO, as it may be) Tj
0 -12 Td
(amended.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.13 "Compensation Report" shall have the meaning set forth in Section 4.2.2\(b\).) Tj
0 -12 Td
() Tj
0 -12 Td
(1.14 "Compliance Manager" shall have the meaning set forth in Section 4.3.9.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.15 "Compliance Report" shall have the meaning set forth in Section 4.2.2\(c\).) Tj
0 -12 Td
ET
endstream
endobj
16 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 15 0 R >>
endobj
17 0 obj
<< /Length 3732 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(1.16 "Confidential Information" shall mean all secret, confidential, non-public or) Tj
0 -12 Td
(proprietary Know-How, whether provided in written, oral, graphic, video, computer or other) Tj
0 -12 Td
(form, provided by or on behalf of one Party to the other Party pursuant to this Agreement,) Tj
0 -12 Td
(including information relating to the disclosing Party's existing or proposed research,) Tj
0 -12 Td
(development efforts, promotional efforts, regulatory matters, patent applications or) Tj
0 -12 Td
(business and any other materials that have not been made available by the disclosing Party) Tj
0 -12 Td
(to the general public. All such information related to this Agreement disclosed by or on) Tj
0 -12 Td
(behalf of a Party \(or its Affiliate\) to the other Party \(or its Affiliate\) pursuant to the) Tj
0 -12 Td
(Confidentiality Agreement shall be deemed to be such Party's Confidential Information) Tj
0 -12 Td
(disclosed hereunder. For purposes of clarity, \(i\) Dova's Confidential Information shall) Tj
0 -12 Td
(include all Product Materials unless and until made available by Dova to the general) Tj
0 -12 Td
(public \(including through Valeant\) and \(ii\) the terms of this Agreement shall be) Tj
0 -12 Td
(considered Confidential Information of both Parties.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.17 "Confidentiality Agreement" shall have the meaning set forth in Section 9.1.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(3) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(1.18 "Designated Product" shall mean a specific pharmaceutical product marketed by Valeant) Tj
0 -12 Td
(which is agreed to in writing by the Parties on or prior to the Effective Date.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.19 "Detail\(s\)" shall mean a Product presentation during a face-to-face sales call) Tj
0 -12 Td
(between a Target Professional and a Sales Representative, during which a presentation of) Tj
0 -12 Td
(the Product's attributes, benefits, prescribing information and safety information are) Tj
0 -12 Td
(orally presented, for use in the Field in the Territory. Neither e-details, nor) Tj
0 -12 Td
(presentations made at conventions, exhibit booths, a sample drop, educational programs or) Tj
0 -12 Td
(speaker meetings, or similar gatherings, shall constitute a Detail.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.20 "Detail Report" shall have the meaning set forth in Section 4.2.2.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.21 "Dispute" shall have the meaning set forth in Section 13.6.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.22 "Dollar" or "$" shall mean United States dollar.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.23 "Dova Trademarks and Copyrights" shall mean the logos, trade dress, slogans, domain) Tj
0 -12 Td
(names and housemarks of Dova or any of its Affiliates as may appear on any Product) Tj
0 -12 Td
(Materials or Product Labeling, in each case, as may be updated from time to time by Dova.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.24 "Dova's Third Party Data Source" shall mean [***] or such other data source as) Tj
0 -12 Td
(selected by Dova and with which Dova enters into an agreement, at its cost.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.25 "Effective Date" shall have the meaning set forth in the preamble to this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
18 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 17 0 R >>
endobj
19 0 obj
<< /Length 3721 >>
stream
BT
/F1 10 Tf
72 720 Td
(1.26 "FDA" shall mean the United States Food and Drug Administration or any successor) Tj
0 -12 Td
(agency performing comparable functions.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.27 "Field" shall mean the treatment of thrombocytopenia in adult patients with chronic) Tj
0 -12 Td
(liver disease who are scheduled to undergo a procedure and any and all additional) Tj
0 -12 Td
(indications for which the Product is approved in the Territory.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.28 "Field Force Personnel" shall mean collectively, the Sales Representatives, the) Tj
0 -12 Td
(members of the institutional account management team described in Section 4.1.5, if any,) Tj
0 -12 Td
(that are engaged in Detailing the Product and any other employees of Valeant engaged in) Tj
0 -12 Td
(the Valeant Activities.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.29 "GAAP" shall mean United States generally accepted accounting principles.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.30 "Governmental Authority" shall mean any court, agency, authority, department,) Tj
0 -12 Td
(regulatory body or other instrumentality of any government or country or of any national,) Tj
0 -12 Td
(federal, state, provincial, regional, county, city or other political subdivision of any) Tj
0 -12 Td
(such government or any supranational organization of which any such country is a member,) Tj
0 -12 Td
(which has competent and binding authority to decide, mandate, regulate, enforce, or) Tj
0 -12 Td
(otherwise control the activities of the Parties contemplated by this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(4) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(1.31 "Gross to Net Fraction" shall mean, for each SKU of the Product, a fraction \(i\) the) Tj
0 -12 Td
(numerator of which is the net sales of the SKU of the Product in the Territory for an) Tj
0 -12 Td
(applicable period \(based on the gross-to-net discounts for all sales of such SKU of the) Tj
0 -12 Td
(Product \(i.e., sales attributable to the Specialty, as well as all other sales of such SKU) Tj
0 -12 Td
(of the Product\), and \(ii\) the denominator of which is gross sales of such SKU of the) Tj
0 -12 Td
(Product in the Territory for an applicable period, in each case, as determined in) Tj
0 -12 Td
(accordance with Dova's revenue recognition policies, which is in accordance with GAAP \(on) Tj
0 -12 Td
(a consistent basis\), for quarterly financial reporting purposes, as reported in Dova's) Tj
0 -12 Td
(quarterly filings with the U.S. Securities Exchange Commission.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.32 "Indemnified Party" shall have the meaning set forth in Section 11.3.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.33 "Indemnifying Party" shall have the meaning set forth in Section 11.3.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.34 "Intellectual Property" shall have the meaning set forth in Section 8.1.2.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.35 "Intermediary" shall mean any wholesaler or distributor who sells Product to Retail) Tj
0 -12 Td
(Pharmacies and Non-Retail Institutions, but not patients, and with which Dova \(or its) Tj
0 -12 Td
(Affiliates\) has entered into an agreement or otherwise has arrangements.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.36 "Inventions" shall have the meaning set forth in Section 8.1.2.) Tj
0 -12 Td
ET
endstream
endobj
20 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 19 0 R >>
endobj
21 0 obj
<< /Length 3383 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(1.37 "JSC" shall have the meaning set forth in Section 3.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.38 "Know-How" shall mean information, whether or not in written form, including) Tj
0 -12 Td
(biological, chemical, pharmacological, toxicological, medical or clinical, analytical,) Tj
0 -12 Td
(quality, manufacturing, research, or sales and marketing information, including processes,) Tj
0 -12 Td
(methods, procedures, techniques, plans, programs and data.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.39 "Losses" shall mean any and all amounts paid or payable to Third Parties with respect) Tj
0 -12 Td
(to a Claim \(including any and all losses, damages, obligations, liabilities, fines, fees,) Tj
0 -12 Td
(penalties, awards, judgments, interest\), together with all documented out-of- pocket costs) Tj
0 -12 Td
(and expenses, including attorney's fees, reasonably incurred.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.40 "Net Sales" shall mean, for an applicable period, the aggregate amount, without) Tj
0 -12 Td
(duplication, equal to the Specialty Pharmacy Net Sales for each SKU, the Retail Net Sales) Tj
0 -12 Td
(for each SKU, if any, and the Non-Retail Net Sales for each SKU.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.41 "Non-Retail Institution" shall mean any institution \(other than the Specialty) Tj
0 -12 Td
(Pharmacies, Retail Pharmacies and Intermediaries\) to which Dova \(or its Affiliates or its) Tj
0 -12 Td
(Intermediaries\) sells and/or ships units of Product during the Term, which shall include) Tj
0 -12 Td
(group purchasing organizations \(GPOs\), hospitals, clinics, long term care facilities and) Tj
0 -12 Td
(any outlets that are a member of an Integrated Delivery Network \(IDN\), and with which Dova) Tj
0 -12 Td
(or its Affiliates do not have data agreements which enables Dova to track shipments of) Tj
0 -12 Td
(Product from such institution to patients based on the Target Professional prescribing) Tj
0 -12 Td
(such Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.42 "Non-Retail Net Sales" shall mean, for each SKU of the Product:) Tj
0 -12 Td
() Tj
0 -12 Td
(5) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(\(i\) the number of units of such SKU of Products shipped by Dova \(or its Affiliates or its) Tj
0 -12 Td
(Intermediaries\) to the Non-Retail Institutions in the Territory during an applicable) Tj
0 -12 Td
(period \(excluding any shipments in excess of one unit of either SKU shipped to such Non-) Tj
0 -12 Td
(Retail Institutions based on the initial orders from such Non-Retail Institutions\):) Tj
0 -12 Td
() Tj
0 -12 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(ii\) the applicable Specialty Fraction for such SKU of the Product for the applicable) Tj
0 -12 Td
(period,) Tj
0 -12 Td
() Tj
0 -12 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(iii\) the applicable WAC for such SKU of the Product for the applicable period,) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
22 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 21 0 R >>
endobj
23 0 obj
<< /Length 3283 >>
stream
BT
/F1 10 Tf
72 720 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(iv\) the Gross to Net Fraction for such SKU of the Product for the applicable period.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.43 "Party" shall have the meaning set forth in the preamble to this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.44 "Person" shall mean any individual, corporation, partnership, limited liability) Tj
0 -12 Td
(company, association, joint-stock company, trust, unincorporated organization or other) Tj
0 -12 Td
(entity, or government or political subdivision thereof.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.45 "Product" shall mean the product approved pursuant to New Drug Application \(NDA\) No.) Tj
0 -12 Td
(210238, as such approval may be supplemented from time to time \(including by way of) Tj
0 -12 Td
(supplemental new drug application \(sNDA\)\), currently marketed as DOPTELET  \(avatrombopag\)) Tj
0 -12 Td
(in the Territory and shall include an authorized generic version of such Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.46 "Product Labeling" shall mean the labels and other written, printed or graphic matter) Tj
0 -12 Td
(upon \(a\) any container or wrapper utilized with the Product or \(b\) any written material) Tj
0 -12 Td
(accompanying the Product, including Product package inserts, in each case as approved by) Tj
0 -12 Td
(the FDA.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.47 "Product Materials" shall have the meaning set forth in Section 4.4.1\(a\).) Tj
0 -12 Td
() Tj
0 -12 Td
(1.48 "Product Training Materials" shall have the meaning set forth in Section 4.4.1\(a\).) Tj
0 -12 Td
() Tj
0 -12 Td
(1.49 "Quarterly Average Sales Force Size" shall have the meaning set forth in Section) Tj
0 -12 Td
(4.2.2.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.50 "Quarterly Minimum Details" for an applicable Calendar Quarter shall mean [***].) Tj
0 -12 Td
() Tj
0 -12 Td
(1.51 "Regulatory Approval" shall mean any and all necessary approvals, licenses,) Tj
0 -12 Td
(registrations or authorizations from any Governmental Authority, in each case, necessary) Tj
0 -12 Td
(to commercialize the Product in the Territory.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.52 "Retail Pharmacy" shall mean an outlet which dispenses the Product directly to a) Tj
0 -12 Td
(patient in a retail setting or through mail order services.) Tj
0 -12 Td
() Tj
0 -12 Td
(6) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(1.53 "Retail Net Sales" shall mean, for each SKU of the Product:) Tj
0 -12 Td
() Tj
0 -12 Td
(\(i\) the number of units of such SKU of the Product shipped from Retail Pharmacies to) Tj
0 -12 Td
(patients based on prescriptions written by the Specialty in the Territory \(as determined) Tj
0 -12 Td
(by data reported by data aggregator\) or such other data source with which Dova enters into) Tj
0 -12 Td
(an agreement at its cost\),) Tj
0 -12 Td
ET
endstream
endobj
24 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 23 0 R >>
endobj
25 0 obj
<< /Length 3765 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(ii\) the applicable WAC for such SKU of the Product for the applicable period,) Tj
0 -12 Td
() Tj
0 -12 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(iii\) the Gross to Net Fraction for such SKU of the Product for the applicable period.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.54 "Sales Representative" shall mean an individual employed and compensated by Valeant) Tj
0 -12 Td
(as a full-time employee as part of its sales forces and who engages in Detailing of the) Tj
0 -12 Td
(Designated Product \(or the Alternate Product, as the case may be\) in the Territory, and) Tj
0 -12 Td
(who is also trained with respect to the Product in accordance with this Agreement) Tj
0 -12 Td
(\(including the Product Labeling and the use of the Promotional Materials\) to deliver) Tj
0 -12 Td
(Details for the Product in the Field in the Territory.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.55 "Senior Officer" shall mean, with respect to Dova, its President and Chief Executive) Tj
0 -12 Td
(Officer \(or such officer's designee\), and with respect to Valeant, its [***] \(or such) Tj
0 -12 Td
(officer's designee\). From time to time, each Party may change its Senior Officer by giving) Tj
0 -12 Td
(written notice to the other Party.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.56 "Specialty" shall mean \(i\) Target Professionals with a primary or secondary specialty) Tj
0 -12 Td
(designation of Gastroenterology, Colorectal Surgery or Proctology \(excluding any such) Tj
0 -12 Td
(Target Professionals with a primary or secondary specialty designation of Hepatology) Tj
0 -12 Td
(\(including Transplant Hepatology\), in each case, as determined by data reported by Dova's) Tj
0 -12 Td
(Third Party Data Source, subject to any adjustments determined pursuant to the process set) Tj
0 -12 Td
(out in Section 6.5, and \(ii\) all healthcare professionals with Nurse or Physician) Tj
0 -12 Td
(Assistant specialty designations affiliated with the Target Professionals described in) Tj
0 -12 Td
(subsection \(i\), as adjusted.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.57 "Specialty Fraction" shall mean, for each SKU of the Product, a fraction \(i\) the) Tj
0 -12 Td
(numerator of which is the number of units of such SKU of the Product shipped from the) Tj
0 -12 Td
(Specialty Pharmacies or the Retail Pharmacies to patients based on prescriptions written) Tj
0 -12 Td
(by the Specialty in the Territory \(as determined by data reported pursuant to agreements) Tj
0 -12 Td
(between Dova \(or its Affiliates\) and the Specialty Pharmacies or the data aggregators,) Tj
0 -12 Td
(applicable\), and \(ii\) the denominator of which is the number of units of such SKU of the) Tj
0 -12 Td
(Product shipped from the Specialty Pharmacies or the Retail Pharmacies to all patients in) Tj
0 -12 Td
(the Territory \(namely based on prescriptions written by the Specialty and outside the) Tj
0 -12 Td
(Specialty\) \(as determined by data reported pursuant to agreements between Dova \(or its) Tj
0 -12 Td
(Affiliates\) and the Specialty Pharmacies or the data aggregators, as applicable\).) Tj
0 -12 Td
() Tj
0 -12 Td
(1.58 "Specialty Pharmacy Net Sales" shall mean, for each SKU of the Product:) Tj
0 -12 Td
() Tj
0 -12 Td
(7) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
26 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 25 0 R >>
endobj
27 0 obj
<< /Length 3721 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(\(i\) the number of units of such SKU of the Product shipped from the Specialty Pharmacies) Tj
0 -12 Td
(to all patients based on prescriptions written by the Specialty in the Territory during an) Tj
0 -12 Td
(applicable period \(as determined by data reported pursuant to agreements between Dova \(or) Tj
0 -12 Td
(its Affiliates\) and the Specialty Pharmacies or the data aggregators, as applicable\); and) Tj
0 -12 Td
() Tj
0 -12 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(ii\) the applicable WAC for such SKU of the Product for the applicable period,) Tj
0 -12 Td
() Tj
0 -12 Td
(MULTIPLIED BY) Tj
0 -12 Td
() Tj
0 -12 Td
(\(iii\) the Gross to Net Fraction for such SKU of the Product for the applicable period.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.59 "Specialty Pharmacy" shall mean those specialty pharmacies to which Dova \(or its) Tj
0 -12 Td
(Affiliates\) sells and/or ships units of Product during the Term and for which Dova or its) Tj
0 -12 Td
(Affiliates have agreements with that include data provisions or provide for separate data) Tj
0 -12 Td
(agreements which enables Dova to track shipments of Product from such Specialty Pharmacy) Tj
0 -12 Td
(to patients based on the Target Professional prescribing such Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.60 "Tail Period" shall mean the period commencing on the day after the last day of the) Tj
0 -12 Td
(Term and ending on the earlier of \(i\) [***] and \(ii\) [***], unless terminated early) Tj
0 -12 Td
(pursuant to Section 2.3.1\(a\) of the Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.61 "Target Professionals" shall mean physicians, nurse practitioners, physician) Tj
0 -12 Td
(assistants and any other medical professionals in the Territory with prescribing authority) Tj
0 -12 Td
(\(as authorized under Applicable Law\) in the Territory for the Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.62 "Term" shall have the meaning set forth in Section 12.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.63 "Territory" shall mean the United States of America and its territories and) Tj
0 -12 Td
(possessions.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.64 "Third Party\(ies\)" shall mean any person or entity other than Dova and Valeant and) Tj
0 -12 Td
(their respective Affiliates.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.65 "Third Party Agreements" shall mean the agreements described on Schedule 1.65 hereto.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.66 "Valeant Activities" shall mean any and all promotional activities \(including) Tj
0 -12 Td
(Detailing\) conducted by Valeant to encourage the appropriate use of the Product in the) Tj
0 -12 Td
(Specialty in the Field in the Territory in accordance with the terms of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.67 "Valeant Property" shall have the meaning set forth in Section 8.1.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(1.68 "WAC" shall mean, for each SKU of the Product, Dova's list price for a unit of the) Tj
0 -12 Td
(SKU of the Product to wholesalers or direct purchasers in the Territory, as reported in) Tj
0 -12 Td
(wholesale price guides or other nationally recognized publications of drug pricing data.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 2  RIGHTS AND OBLIGATIONS) Tj
0 -12 Td
() Tj
0 -12 Td
(2.1 Engagement; Grant of Rights. During the Term, subject to the terms and conditions of) Tj
0 -12 Td
(this Agreement, Dova hereby grants to Valeant the right, on a co-exclusive basis \(solely) Tj
0 -12 Td
(with Dova and its Affiliates\), to Detail and promote the Product in the Specialty in the) Tj
0 -12 Td
(Territory in the Field, and to conduct the Valeant Activities and the activities of the) Tj
0 -12 Td
(institutional account management team \(pursuant to and subject to the terms of Section) Tj
0 -12 Td
ET
endstream
endobj
28 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 27 0 R >>
endobj
29 0 obj
<< /Length 4030 >>
stream
BT
/F1 10 Tf
72 720 Td
(4.1.5\) for the Product in the Territory in the Field in accordance with the terms and) Tj
0 -12 Td
(conditions of this Agreement. Notwithstanding the foregoing, Dova retains and reserves the) Tj
0 -12 Td
(right for Dova and its Affiliates to promote the Product in the Territory including in the) Tj
0 -12 Td
(Specialty. Valeant shall have no other rights relating to the Product, except as) Tj
0 -12 Td
(specifically set forth in this Agreement and, without limiting the foregoing, except as) Tj
0 -12 Td
(set out in Section 4.1.5, if agreed upon, Valeant shall have no right to, and shall not,) Tj
0 -12 Td
(conduct the Valeant Activities for the Product outside the Specialty or outside the) Tj
0 -12 Td
(Territory or for use outside the Field. Except to Affiliates of Valeant, Valeant's rights) Tj
0 -12 Td
(and obligations under this Section 2.1 are non-transferable, non-assignable, and non-) Tj
0 -12 Td
(delegable. Except to Affiliates of Valeant, Valeant shall not subcontract the Valeant) Tj
0 -12 Td
(Activities with any Third Party \(including any contract sales force\). Any obligation of) Tj
0 -12 Td
(Valeant under or pursuant to this Agreement may be satisfied, met or fulfilled, in whole) Tj
0 -12 Td
(or in part, at Valeant's sole and exclusive option, either by Valeant or its Affiliates.) Tj
0 -12 Td
(Valeant guarantees the performance of all actions, agreements and obligations to be) Tj
0 -12 Td
(performed by its Affiliates under the terms and conditions of this Agreement. For clarity,) Tj
0 -12 Td
(Valeant shall not have any license rights hereunder nor any rights to sublicense any) Tj
0 -12 Td
(rights hereunder.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(2.2 Retention of Rights. Except with respect to the exclusive rights granted to Valeant to) Tj
0 -12 Td
(conduct the Valeant Activities for the Product in the Specialty in the Territory in the) Tj
0 -12 Td
(Field pursuant to Section 2.1 and, and if agreed upon, outside the Specialty in the) Tj
0 -12 Td
(Territory in the Field pursuant to Section 4.1.5, Dova retains all rights in and to the) Tj
0 -12 Td
(Product. Without limiting the generality of the foregoing \(and without limiting Dova's) Tj
0 -12 Td
(retained rights set forth in Section 2.1\), Dova specifically retains the following rights) Tj
0 -12 Td
(\(and Valeant and its Affiliates shall have no rights to the following, except as set forth) Tj
0 -12 Td
(below in this Section 2.2\):) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2.1 responsibility for promoting the Product outside the Specialty;) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2.2 responsibility for the manufacture and distribution of the Product, and any future) Tj
0 -12 Td
(development of the Product;) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2.3 responsibility for all decisions regarding regulatory submissions and, except as) Tj
0 -12 Td
(expressly set forth herein, for interactions with any Governmental Authority, including) Tj
0 -12 Td
(but not limited to FDA, with respect to the Product;) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2.4 responsibility for final approval of all Product Materials content \(including) Tj
0 -12 Td
(submission of Promotional Materials to FDA's Office of Prescription Drug Promotion\) with) Tj
0 -12 Td
(respect to the conduct of the Valeant Activities for Product, except as expressly set) Tj
0 -12 Td
(forth herein;) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2.5 selling and booking all sales of the Product; and) Tj
0 -12 Td
() Tj
0 -12 Td
(2.2.6 responsibility for handling all safety related activities related to Product as set) Tj
0 -12 Td
(forth in ARTICLE 5 \(including submitting all safety reports and interacting with) Tj
0 -12 Td
(Governmental Authorities with respect thereto\) and initiating and managing any Product) Tj
0 -12 Td
(recalls.) Tj
0 -12 Td
() Tj
0 -12 Td
(For clarity, except as provided in Sections 2.1 or 2.4, Valeant shall not acquire any) Tj
0 -12 Td
ET
endstream
endobj
30 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 29 0 R >>
endobj
31 0 obj
<< /Length 4592 >>
stream
BT
/F1 10 Tf
72 720 Td
(license or other intellectual property interest, by implication or otherwise, in any) Tj
0 -12 Td
(technology, Know-How or other intellectual property owned or controlled by Dova or any of) Tj
0 -12 Td
(its Affiliates, and Dova is not providing any such technology, Know-How or other) Tj
0 -12 Td
(intellectual property, or any assistance related thereto, to Valeant for any use other) Tj
0 -12 Td
(than for the mutual benefit of the Parties as expressly contemplated hereby.) Tj
0 -12 Td
() Tj
0 -12 Td
(2.3 Non-Competition; Non-Solicitation.) Tj
0 -12 Td
() Tj
0 -12 Td
(2.3.1 Non-Competition. \(a\) [***], neither Valeant nor its Affiliates shall, directly or) Tj
0 -12 Td
(indirectly, [***] in the Territory other than the Product; provided that if the Agreement) Tj
0 -12 Td
(is terminated by Dova pursuant to [***], then any Tail Period shall be immediately) Tj
0 -12 Td
(terminated if either Valeant or any of its Affiliates, directly or indirectly, [***] in) Tj
0 -12 Td
(the Territory other than the Product during such Tail Period. Notwithstanding the) Tj
0 -12 Td
(foregoing, this Section 2.3.1\(a\) shall not apply to any products marketed, promoted,) Tj
0 -12 Td
(detailed, offered for sale, or sold by any business \(or any portion thereof\), other) Tj
0 -12 Td
(Person, or group of Persons, [***].) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) [***], neither Dova nor is Affiliates shall, directly or indirectly, [***].) Tj
0 -12 Td
(Notwithstanding the foregoing, this Section 2.3.1\(b\) shall not apply to any products) Tj
0 -12 Td
(marketed, promoted, detailed, offered for sale, or sold by any business \(or any portion) Tj
0 -12 Td
(thereof\), other Person, or group of Persons[***].) Tj
0 -12 Td
() Tj
0 -12 Td
(2.3.2 Non-Solicitation. [***], neither Valeant nor Dova \(nor any of their respective) Tj
0 -12 Td
(Affiliates\) shall directly or indirectly solicit for hire or employee as an employee,) Tj
0 -12 Td
(consultant or otherwise any of the other Party's professional personnel who have had) Tj
0 -12 Td
(direct involvement with the JSC, with the Valeant Activities under this Agreement \(which,) Tj
0 -12 Td
(in the case of Valeant, includes the Field Force Personnel\) or with Dova's) Tj
0 -12 Td
(commercialization activities for the Product, without the other Party's prior written) Tj
0 -12 Td
(consent. Notwithstanding anything to the contrary, in no event shall the restrictions set) Tj
0 -12 Td
(forth in this Section 2.3.2 apply to [***].) Tj
0 -12 Td
() Tj
0 -12 Td
(2.4 Dova Trademarks and Copyrights.) Tj
0 -12 Td
() Tj
0 -12 Td
(2.4.1 Valeant shall have the non-exclusive right to use the Dova Trademarks and Copyrights) Tj
0 -12 Td
(solely on Product Materials in order to perform the Valeant Activities and solely in) Tj
0 -12 Td
(accordance with the terms and conditions of this Agreement. Dova shall promptly notify) Tj
0 -12 Td
(Valeant of any updates or changes to the Dova Trademarks and Copyrights on the Product) Tj
0 -12 Td
(Materials, and Valeant shall thereafter solely use such updated Product Materials in) Tj
0 -12 Td
(performing its obligations under this Agreement. Valeant shall promptly notify Dova upon) Tj
0 -12 Td
(becoming aware of any violation of this Section 2.4.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(2.4.2 Valeant shall follow all instructions and guidelines of Dova \(of which Dova has) Tj
0 -12 Td
(provided Valeant copies\) in connection with the use of any Dova Trademarks and Copyrights,) Tj
0 -12 Td
(and, if Dova reasonably objects to the manner in which any such Dova Trademarks and) Tj
0 -12 Td
(Copyrights are being used, Valeant shall cease the use of any such Dova Trademarks and) Tj
0 -12 Td
(Copyrights in such manner upon written notice from Dova thereof. Without limiting the) Tj
0 -12 Td
(foregoing, Valeant shall also adhere to at least the same quality control provisions as) Tj
0 -12 Td
(companies in the pharmaceutical industry adhere to for their own trademarks and) Tj
0 -12 Td
(copyrights. In all cases, Valeant shall use the Dova Trademarks and Copyrights with the) Tj
0 -12 Td
(necessary trademark \(and copyright, as applicable\) designations, and shall use the Dova) Tj
0 -12 Td
(Trademarks and Copyrights in a manner that does not derogate from Dova's rights in the) Tj
0 -12 Td
(Dova Trademarks and Copyrights. Valeant shall not at any time during the Term knowingly do) Tj
0 -12 Td
(or allow to be done any act or thing which will in any way impair or diminish the rights) Tj
0 -12 Td
(of Dova in or to the Dova Trademarks and Copyrights. All goodwill and) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
32 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 31 0 R >>
endobj
33 0 obj
<< /Length 4273 >>
stream
BT
/F1 10 Tf
72 720 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(improved reputation generated by Valeant's use of the Dova Trademarks and Copyrights shall) Tj
0 -12 Td
(inure to the benefit of Dova, and any use of the Dova Trademarks and Copyrights by Valeant) Tj
0 -12 Td
(shall cease at the end of the Term. Valeant shall have no rights under this Agreement in) Tj
0 -12 Td
(or to the Dova Trademarks and Copyrights except as specifically provided herein. During) Tj
0 -12 Td
(the Term, Valeant will not contest the ownership of the Dova Trademarks and Copyrights,) Tj
0 -12 Td
(their validity, or the validity of any registration therefor. During the Term, Valeant) Tj
0 -12 Td
(will not knowingly register and/or use any marks \(including in connection with any domain) Tj
0 -12 Td
(names\) that are confusingly similar to the Dova Trademarks and Copyrights.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 3  JOINT STEERING COMMITTEE) Tj
0 -12 Td
() Tj
0 -12 Td
(3.1 Formation of the JSC. As soon as practicable, but no later than twenty \(20\) days after) Tj
0 -12 Td
(the Effective Date, the Parties shall form a joint steering committee \("JSC"\) whose) Tj
0 -12 Td
(responsibilities during the Term shall be to oversee the activities set forth in Section) Tj
0 -12 Td
(3.3. The JSC shall consist of three \(3\) representatives from each Party, each with) Tj
0 -12 Td
(suitable seniority and relevant experience and expertise to enable such person to address) Tj
0 -12 Td
(matters falling within the purview of the JSC. From time to time, each Party may change) Tj
0 -12 Td
(any of its representatives on the JSC by giving written notice to the other Party. The) Tj
0 -12 Td
(meetings of the JSC will be chaired by a representative from Dova or Valeant, on an) Tj
0 -12 Td
(alternating basis. The JSC shall determine a meeting schedule; provided, that, in any) Tj
0 -12 Td
(event, meetings shall be conducted no less frequently than quarterly by teleconference or) Tj
0 -12 Td
(in person, or as otherwise agreed by the Parties. In person meetings shall occur at such) Tj
0 -12 Td
(places as mutually agreed by the Parties. Employees or consultants of either Party that) Tj
0 -12 Td
(are not representatives of the Parties on the JSC may attend meetings of the JSC;) Tj
0 -12 Td
(provided, that such attendees \(i\) shall not participate in the decision-making process of) Tj
0 -12 Td
(the JSC, and \(ii\) are bound by obligations of confidentiality and non-disclosure) Tj
0 -12 Td
(equivalent to those set forth in ARTICLE 9.) Tj
0 -12 Td
() Tj
0 -12 Td
(3.2 Meetings and Minutes. Meetings of the JSC may be called by either Party on no less) Tj
0 -12 Td
(than thirty \(30\) days' notice during the Term. Each Party shall make all proposals for) Tj
0 -12 Td
(agenda items and shall provide all appropriate information with respect to such proposed) Tj
0 -12 Td
(items at least ten \(10\) days in advance to the applicable meeting; provided that under) Tj
0 -12 Td
(exigent circumstances requiring input by the JSC, a Party may provide its agenda items to) Tj
0 -12 Td
(the other Party within a shorter period of time in advance of the meeting, or may propose) Tj
0 -12 Td
(that there not be a specific agenda for that particular meeting, so long as the other) Tj
0 -12 Td
(Party consents to such later addition of such agenda items or the absence of a specific) Tj
0 -12 Td
(agenda for such meeting, such consent not to be unreasonably withheld. The chairperson) Tj
0 -12 Td
(shall prepare and circulate for review and approval of the Parties minutes of each meeting) Tj
0 -12 Td
(within thirty \(30\) days after the meeting. Each Party shall bear its own costs for its) Tj
0 -12 Td
(members to attend such meetings.) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3 Purpose of the JSC. The purposes of the JSC shall be to, subject to Section 3.4:) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.1 provide a forum to discuss and coordinate the Parties' activities under this) Tj
0 -12 Td
(Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.2 provide a forum to discuss and coordinate the promotion of the Product in the) Tj
0 -12 Td
(Territory, including in and outside the Specialty;) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
34 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 33 0 R >>
endobj
35 0 obj
<< /Length 3575 >>
stream
BT
/F1 10 Tf
72 720 Td
(3.3.3 provide a forum to discuss Product Materials \(it being understood that the JSC shall) Tj
0 -12 Td
(not have the right to approve such Product Materials\);) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.4 facilitate the flow of information and otherwise promote the communications and) Tj
0 -12 Td
(collaboration within and among the Parties relating to this Agreement and the promotion of) Tj
0 -12 Td
(the Product;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.5 discuss planning and implementation of all Valeant Activities, including but not) Tj
0 -12 Td
(limited to training of Sales Representatives and, if agreed upon, the activities of the) Tj
0 -12 Td
(institutional account management team referred to in Section 4.1.5;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.6 decide on the acceptable form of and review and discuss the Detail Reports and) Tj
0 -12 Td
(reports of Net Sales;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.7 decide on the acceptable form of and review and discuss the Compensation Reports and) Tj
0 -12 Td
(the incentive compensation matters described in Section 4.1.3, including any applicable) Tj
0 -12 Td
(adjustments to the Product-related sales goals and targets of the Sales Representatives;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.8 review and discuss any matters brought to its attention by either Party's Alliance) Tj
0 -12 Td
(Manager;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.9 review, discuss and decide on the Alternate Product described in Section 4.2.1\(c\) or) Tj
0 -12 Td
(any additional product that may be Detailed by Valeant described in Section 4.2.1\(d\);) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.10 discuss the Promotional Materials matters described in Section 4.4.1\(b\);) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.11 discuss supply or distribution issues relating to the Product, such as any supply) Tj
0 -12 Td
(shortages;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.12 discuss the pricing of the Product \(provided that Dova shall have sole authority to) Tj
0 -12 Td
(determine pricing of the Product\); Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.13 act as a first level escalation to address disagreements or disputes between the) Tj
0 -12 Td
(Parties;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.14 form and oversee any sub-committee or working group in furtherance of the) Tj
0 -12 Td
(activities contemplated by this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.15 decide on the acceptable form of and review and discuss the Compliance Reports; and) Tj
0 -12 Td
() Tj
0 -12 Td
(3.3.16 perform such other responsibilities as may be mutually agreed upon by the Parties) Tj
0 -12 Td
(in writing from time to time; provided, however, for clarity the JSC shall have no) Tj
0 -12 Td
(authority to amend or modify any provisions of this Agreement and no authority to waive or) Tj
0 -12 Td
(definitively interpret the provisions of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(3.4 Decision Making. Meetings of the JSC will occur only if at least one representative of) Tj
0 -12 Td
(each Party is present at the meeting. Each Party shall have one \(1\) vote. The JSC will use) Tj
0 -12 Td
(good faith efforts to reach consensus on all matters properly brought before it. If the) Tj
0 -12 Td
(JSC does not reach unanimous consensus on an issue at a meeting or within a period of) Tj
0 -12 Td
([***] thereafter, then the JSC shall submit in writing the respective positions of the) Tj
0 -12 Td
(Parties to the Senior Officers of the Parties. Such Senior Officers shall use good faith) Tj
0 -12 Td
ET
endstream
endobj
36 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 35 0 R >>
endobj
37 0 obj
<< /Length 4433 >>
stream
BT
/F1 10 Tf
72 720 Td
(efforts to resolve promptly such matter, which good faith efforts shall include at least) Tj
0 -12 Td
(one \(1\) teleconference between such Senior Officers within [***] after the JSC's) Tj
0 -12 Td
(submission of such matter to them. Any final decision mutually agreed to in writing by the) Tj
0 -12 Td
(Senior Officers shall be conclusive and binding on the Parties. If the Senior Officers are) Tj
0 -12 Td
(not able to agree on the resolution of any such issue within [***] after such issue was) Tj
0 -12 Td
(first referred to them, then \(i\) Valeant shall have the right to conclusively determine) Tj
0 -12 Td
(all matters related to Valeant Activities and Detailing of the Product, including matters) Tj
0 -12 Td
(relating to the institutional account manager team, the incentive compensation of the) Tj
0 -12 Td
(Sales Representatives and targeting for Details, provided that such determination and any) Tj
0 -12 Td
(related activities comply with the terms and conditions of this Agreement, and \(ii\) Dova) Tj
0 -12 Td
(shall have the right to conclusively determine all other matters; provided, however, for) Tj
0 -12 Td
(clarity any such determination shall not amend, modify or waive any provisions of this) Tj
0 -12 Td
(Agreement or definitively interpret the provisions of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(3.5 Marketing Sub-Committee.) Tj
0 -12 Td
() Tj
0 -12 Td
(3.5.1 Promptly after the Effective Date, the JSC shall facilitate the formation of a) Tj
0 -12 Td
(Marketing Sub-Committee comprised of an equal number of representatives from each Party.) Tj
0 -12 Td
(Such sub-committee shall meet from time to time and discuss, among other things:) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) the number of speaker programs for the Product to be conducted by Dova in each) Tj
0 -12 Td
(Calendar Year;) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) the Promotional Materials and quantities thereof;) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) the annual brand plan; and) Tj
0 -12 Td
() Tj
0 -12 Td
(\(d\) the annual conference strategy.) Tj
0 -12 Td
() Tj
0 -12 Td
(3.5.2 [***] shall constitute the "Speaker Program Threshold". If Dova wishes to conduct) Tj
0 -12 Td
(speaker programs in any Calendar Year after 2018 in excess of the Speaker Program) Tj
0 -12 Td
(Threshold, then the Parties shall meet, through the Marketing Sub-Committee, to discuss) Tj
0 -12 Td
(such excess speaker programs and the costs thereof. If the Marketing Sub-Committee) Tj
0 -12 Td
(unanimously agrees that such excess speaker programs should be conducted, then the) Tj
0 -12 Td
(following costs and expenses will be shared equally by the Parties: \(i\) the costs and) Tj
0 -12 Td
(expenses associated with conducting the excess number of speaker programs and \(ii\) the) Tj
0 -12 Td
(additional incremental costs and expenses associated with training necessary to address) Tj
0 -12 Td
(the number of the speaker programs above and below the Speaker Program Threshold. In) Tj
0 -12 Td
(addition, if the Parties unanimously agree that such excess speaker programs should be) Tj
0 -12 Td
(conducted, then, as a condition of the payment by Valeant of its share of such costs,) Tj
0 -12 Td
(Valeant shall have the right to review and approve \(acting reasonably and in good faith\)) Tj
0 -12 Td
(any such excess speaker programs, including with respect to the number of speakers) Tj
0 -12 Td
(approved to speak on the Product as part of the speaker programs, the rates paid to) Tj
0 -12 Td
(speakers at such speaker programs and the rules regarding attendees who may attend such) Tj
0 -12 Td
(speaker programs \(including frequency of attendance\). For greater certainty, if Valeant) Tj
0 -12 Td
(does not agree to conduct speaker programs above the Speaker Program Threshold, then the) Tj
0 -12 Td
(costs described herein for any speaker programs conducted by Dova in excess of the Speaker) Tj
0 -12 Td
(Program Threshold shall not be shared by the Parties, but shall be borne solely by Dova.) Tj
0 -12 Td
(In the event that Dova incurs costs and expenses for which Valeant is responsible under) Tj
0 -12 Td
(this Section 3.5.2, Dova may deduct such amounts from the payments due under Section 6.3) Tj
0 -12 Td
(and shall include a description thereof in the applicable report under Section 6.3.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 4  VALEANT ACTIVITIES FOR THE PRODUCT) Tj
0 -12 Td
() Tj
0 -12 Td
(4.1 Valeant Activities.) Tj
0 -12 Td
ET
endstream
endobj
38 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 37 0 R >>
endobj
39 0 obj
<< /Length 4422 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(4.1.1 General. Valeant shall conduct the Valeant Activities for the Product in the) Tj
0 -12 Td
(Specialty in the Field in the) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(Territory in accordance with this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing,) Tj
0 -12 Td
([***]\) and continuing throughout the remainder of the Term, Valeant shall maintain at) Tj
0 -12 Td
(least one hundred \(100\) Sales Representatives with responsibility to Detail the Product in) Tj
0 -12 Td
(the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for) Tj
0 -12 Td
(breach of this Section 4.1.2 shall be \(i\) the adjustment to the promotion fee as set forth) Tj
0 -12 Td
(in Section 6.1.2 and \(ii\) the termination right set out in Section 12.2.2.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.1.3 Target Incentive Compensation. In addition, [***] and continuing throughout the) Tj
0 -12 Td
(remainder of the Term, Valeant shall ensure the incentive compensation package for each) Tj
0 -12 Td
(Sales Representatives requires that at least fifty percent \(50%\) of the target incentive) Tj
0 -12 Td
(compensation is derived from achieving target sales of the Product. On at least a) Tj
0 -12 Td
(quarterly basis, the Parties will meet, through the JSC, to review the target incentive) Tj
0 -12 Td
(compensation and the actual incentive compensation paid out to the Sales Representatives) Tj
0 -12 Td
(to discuss, in good faith, any appropriate adjustments to the sales targets and goals) Tj
0 -12 Td
(related to the Product \(but not to the above-mentioned fifty percent \(50%\) threshold of) Tj
0 -12 Td
(the target incentive compensation\), with the intent of achieving, on average, an actual) Tj
0 -12 Td
(payout to the Sales Representatives of 50% of their incentive compensation relating to) Tj
0 -12 Td
(sales of the Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.1.4 Alliance Managers. Each Party shall appoint a person who shall oversee interactions) Tj
0 -12 Td
(between the Parties for all matters related to this Agreement, and any related agreements) Tj
0 -12 Td
(between the Parties \(each an "Alliance Manager"\). The Alliance Managers shall endeavor to) Tj
0 -12 Td
(ensure clear and responsive communication between the Parties and the effective exchange) Tj
0 -12 Td
(of information, and shall serve as a single point of contact for all matters arising under) Tj
0 -12 Td
(this Agreement. The Alliance Managers shall have the right to attend all JSC meetings and) Tj
0 -12 Td
(if applicable, subcommittee meetings as non-voting participants and may bring to the) Tj
0 -12 Td
(attention of the JSC or, if applicable, subcommittee any matters or issues either of them) Tj
0 -12 Td
(reasonably believes should be discussed, and shall have such other responsibilities as the) Tj
0 -12 Td
(Parties may mutually agree in writing. Each Party may designate different Alliance Mangers) Tj
0 -12 Td
(by notice in writing to the other Party.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.1.5 Institutional Account Management Team. Upon prior mutual agreement of the Parties in) Tj
0 -12 Td
(writing, Valeant may maintain a team of institutional account managers who, among other) Tj
0 -12 Td
(products, promote the Product in the Territory at liver transplant centers and large) Tj
0 -12 Td
(academic institutions only, and for purposes of this Section 4.1.5 only, both inside and) Tj
0 -12 Td
(outside the Specialty. Prior to any promotion of the Product by any institutional account) Tj
0 -12 Td
(managers, the Parties will discuss in good faith \(acting reasonably\) the number of) Tj
0 -12 Td
(institutional account managers that will promote the Product in the Territory, the) Tj
0 -12 Td
(appropriate portion of such institutional account managers' target incentive compensation) Tj
0 -12 Td
(to be derived from sales of the Product and the liver transplant centers or large academic) Tj
0 -12 Td
(institutions such institutional account managers will be responsible for. Such) Tj
0 -12 Td
(institutional account managers shall not be counted for purposes of determining the) Tj
0 -12 Td
(Quarterly Average Sales Force Size or the Quarterly Minimum Details. The Parties agree) Tj
0 -12 Td
ET
endstream
endobj
40 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 39 0 R >>
endobj
41 0 obj
<< /Length 4021 >>
stream
BT
/F1 10 Tf
72 720 Td
(that these institutional account managers shall not be required to achieve any minimum) Tj
0 -12 Td
(number of Details. The Parties agree that such team may be added or removed by the mutual) Tj
0 -12 Td
(written agreement of the Parties without the need to amend this Agreement in accordance) Tj
0 -12 Td
(with Section 13.8.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.2 Detailing.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.2.1 Detail Requirements.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) Commencing promptly upon completion of training of the Field Force Personnel that are) Tj
0 -12 Td
(engaged in Detailing the Product as described in Section 4.4.1 \(but on the condition that) Tj
0 -12 Td
(Promotional Materials have been approved and delivered\), Valeant shall deploy its Field) Tj
0 -12 Td
(Force Personnel that are engaged in Detailing to Detail the Product in accordance with the) Tj
0 -12 Td
(terms of this Agreement. Subject to compliance with the terms of this Agreement, Valeant) Tj
0 -12 Td
(shall be responsible, in its discretion, acting reasonably, for determining the manner in) Tj
0 -12 Td
(which it allocates and prioritizes the Details, provided that, in so allocating the) Tj
0 -12 Td
(Details, Valeant shall take into consideration geographic territory, frequency of calls,) Tj
0 -12 Td
(prescribing levels and other reasonable considerations. Except as set forth in this) Tj
0 -12 Td
(Agreement, without the prior written consent of Dova \(not to be unreasonably withheld,) Tj
0 -12 Td
(delayed or conditioned\), Valeant shall not conduct any Valeant Activities, other than) Tj
0 -12 Td
(Detailing, with respect to the Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) [***]) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) Beginning after [***], Valeant may initiate discussions with Dova, upon at least [***]) Tj
0 -12 Td
(notice to Dova \(which notice shall specify the proposed Alternate Product\), regarding the) Tj
0 -12 Td
(potential replacement of the Designated Product with an Alternate Product. Following such) Tj
0 -12 Td
(notice period the Parties shall meet, through the JSC, and discuss in good faith \(acting) Tj
0 -12 Td
(reasonably\), for a period of up to [***], the potential replacement of the Designated) Tj
0 -12 Td
(Product with the Alternate Product. If the Parties agree on an Alternate Product, then the) Tj
0 -12 Td
(Parties shall make such agreement in writing and thereafter such Alternate Product shall) Tj
0 -12 Td
(be the Designated Product for purposes of this Agreement. If the Parties cannot agree on) Tj
0 -12 Td
(the Alternate Product during such period, then Valeant may give to Dova a written notice) Tj
0 -12 Td
(\(the "Alternate Product Notice"\) designating the proposed Alternate Product as the) Tj
0 -12 Td
(Alternate Product and, effective [***] after the Alternate Product Notice, such designated) Tj
0 -12 Td
(Alternate Product shall be the Designated Product for purposes of this Agreement; provided) Tj
0 -12 Td
(however that, notwithstanding the foregoing, Dova shall have the right to terminate this) Tj
0 -12 Td
(Agreement upon [***] written notice to Valeant after the Alternate Product Notice,) Tj
0 -12 Td
(provided further that if the Alternate Product is being proposed by Valeant as a result of) Tj
0 -12 Td
(an anticipated or the existence of a generic version of the) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(Designated Product, a decision, judgment, ruling or other requirement of a Government) Tj
0 -12 Td
(Authority, including the FDA relating to or impacting the Designated Product in the) Tj
0 -12 Td
(Territory, a material safety concern regarding the Designated Product or a mandatory) Tj
0 -12 Td
(recall or withdrawal of the Designated Product, then Dova shall have no right to terminate) Tj
0 -12 Td
(this Agreement pursuant to this Section 4.2.1\(c\).) Tj
0 -12 Td
() Tj
0 -12 Td
(\(d\) [***]) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
42 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 41 0 R >>
endobj
43 0 obj
<< /Length 4919 >>
stream
BT
/F1 10 Tf
72 720 Td
(\(e\) Notwithstanding the terms of this Section 4.2.1, Valeant shall have the right, from) Tj
0 -12 Td
(time to time, during the Term, to include in the incentive compensation package of all or) Tj
0 -12 Td
(some of the Sales Representatives a spiff, spiv or other similar incentive bonus that is) Tj
0 -12 Td
(based on [***], provided that the actual, maximum payout from such incentive bonuses does) Tj
0 -12 Td
(not exceed, in the aggregate, an amount equal to [***] for each Sales Representative for) Tj
0 -12 Td
(each Calendar Quarter. Any such spiff, spiv or other similar incentive bonus shall not be) Tj
0 -12 Td
(included in the calculation of the applicable Sales Representatives incentive compensation) Tj
0 -12 Td
(package in determining Valeant's compliance with the terms of Section 4.1.3.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.2.2 Records and Reports.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) Valeant shall keep accurate and complete records, consistent with pharmaceutical) Tj
0 -12 Td
(industry standards, of each Detail and its obligations hereunder in connection therewith.) Tj
0 -12 Td
(Such records shall be kept for the longer of \(i\) [***] after the end of the Calendar Year) Tj
0 -12 Td
(to which they relate and \(ii\) such period of time as required by Applicable Laws. Within) Tj
0 -12 Td
([***] following the end of each Calendar Quarter during the Term, Valeant shall provide) Tj
0 -12 Td
(Dova with a written report \(each a "Detail Report"\), setting out \(i\) the quarterly average) Tj
0 -12 Td
(number of Sales Representatives during such Calendar Quarter \(calculated by taking the sum) Tj
0 -12 Td
(of the number of Sales Representatives employed by Valeant \(or its affiliates\) that have) Tj
0 -12 Td
(incentive compensation packages that comply with the terms of Section 4.1.3 on each) Tj
0 -12 Td
(Business Day of the Calendar Quarter divided by the number of Business Days in such) Tj
0 -12 Td
(Calendar Quarter\) \(the "Quarterly Average Sales Force Size"\), and \(ii\) the aggregate) Tj
0 -12 Td
(actual number of Details for the Product made by its Sales Representatives during such) Tj
0 -12 Td
(Calendar Quarter, and the number of Details broken down by the name of the Target) Tj
0 -12 Td
(Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of) Tj
0 -12 Td
(Detail Report.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall) Tj
0 -12 Td
(provide Dova with a written report \(each a "Compensation Report"\), which describes \(i\) the) Tj
0 -12 Td
(details of the incentive compensation package of each Sales Representative as it relates) Tj
0 -12 Td
(to the Product and the Designated Product \(or Alternate Product, as the case may be\) \(but,) Tj
0 -12 Td
(in the case of the Designated Product or Alternate Product, such details shall be limited) Tj
0 -12 Td
(to information regarding what portion of the Sales Representatives' target incentive) Tj
0 -12 Td
(compensation package is derived from achieving sales targets or goals of the Designated) Tj
0 -12 Td
(Product \(or Alternate Product\) , but shall not include any sales targets or goals for the) Tj
0 -12 Td
(Designated Product \(or Alternate Product\)\), and \(ii\) the actual incentive compensation) Tj
0 -12 Td
(payouts for each Sales Representatives as described in Section 4.1.3. Through the JSC, the) Tj
0 -12 Td
(Parties shall agree on a mutually acceptable form of Compensation Report.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) Within [***] following the end of each Calendar Quarter during the Term, Valeant shall) Tj
0 -12 Td
(provide Dova with a written report \(each a "Compliance Report"\), which sets out a summary) Tj
0 -12 Td
(of Valeant's compliance monitoring and auditing of the Field Force Personnel that are) Tj
0 -12 Td
(engaged in Detailing \(as such monitoring is further described in Section 4.5.1\(b\)\), a) Tj
0 -12 Td
(summary of any compliance-related disciplinary actions relating to any Field Force) Tj
0 -12 Td
(Personnel that are engaged in Detailing and any associated remedial actions, a summary of) Tj
0 -12 Td
(all compliance investigations conducted by Valeant of any of the Field Force Personnel) Tj
0 -12 Td
(that are engaged in Detailing and any associated outcome, and, for the fourth Calendar) Tj
0 -12 Td
(Quarter only, a summary of the compliance-related training \(including a reasonable) Tj
0 -12 Td
(description of each training topic\) received by each Field Force Personnel that are) Tj
0 -12 Td
(engaged in Detailing during the Calendar Year. Through the JSC, the Parties shall agree on) Tj
0 -12 Td
(a mutually acceptable form of Compliance Report.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3 Compliance with Applicable Law.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.1 In conducting the Valeant Activities hereunder, Valeant shall, and shall require all) Tj
0 -12 Td
ET
endstream
endobj
44 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 43 0 R >>
endobj
45 0 obj
<< /Length 3931 >>
stream
BT
/F1 10 Tf
72 720 Td
(Field Force Personnel to, comply in all respects with Applicable Laws. In addition, Dova) Tj
0 -12 Td
(shall, and shall require all of its sales representatives to, comply in all respects with) Tj
0 -12 Td
(Applicable Laws in connection with its promotion of the Product in the Territory.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.2 Neither Valeant nor Field Force Personnel shall offer, pay, solicit or receive any) Tj
0 -12 Td
(remuneration to or from Target Professionals, in order to induce referrals of or purchase) Tj
0 -12 Td
(of the Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.3 In performing the activities contemplated by this Agreement, neither Valeant nor) Tj
0 -12 Td
(Field Force Personnel shall make any payment, either directly or indirectly, of money or) Tj
0 -12 Td
(other assets to government or political party officials, officials of international public) Tj
0 -12 Td
(organizations, candidates for public office, or representatives of other businesses or) Tj
0 -12 Td
(persons acting on behalf of any of the foregoing where such payment would constitute) Tj
0 -12 Td
(violation of any Applicable Law. In addition, Valeant shall not make any payment either) Tj
0 -12 Td
(directly or indirectly to officials if such payment is for the purpose of unlawfully) Tj
0 -12 Td
(influencing decisions or actions with respect to the subject matter of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.4 No employee of Valeant or its Affiliates shall have authority to give any direction,) Tj
0 -12 Td
(either written or oral,) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(relating to the making of any commitment by Dova or its agents to any Third Party in) Tj
0 -12 Td
(violation of terms of this or any other provision of this Agreement) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.5 Neither Valeant nor Dova shall undertake any activity under or in connection with) Tj
0 -12 Td
(this Agreement which violates any Applicable Law.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.6 Valeant's or Dova's material failure to abide by the provisions of this Section 4.3) Tj
0 -12 Td
(shall be deemed a material breach of this Agreement by Valeant or Dova \(as the case may) Tj
0 -12 Td
(be\) and subject to the terms of Section 12.2 hereof.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.7 Dova shall ensure that any patient assistance program used in connection with the) Tj
0 -12 Td
(Product \(and the services performed thereby in connection with the Product\) shall be) Tj
0 -12 Td
(operated in accordance with Applicable Law. Notwithstanding the immediately preceding) Tj
0 -12 Td
(sentence, Dova shall have no liability with respect to any breach or non-compliance with) Tj
0 -12 Td
(Applicable Law relating to any patient assistance program used in connection with the) Tj
0 -12 Td
(Product to the extent caused by the act or omission of any Field Force Personnel, which) Tj
0 -12 Td
(act or omission is not in compliance with the terms of this Agreement, Applicable Law or) Tj
0 -12 Td
(instructions of Dova.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.8 Dova shall ensure that government-insured patients do not receive co-pay support) Tj
0 -12 Td
(from Dova with respect to the Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.9 Dova shall ensure that its donations to, and interactions with, any 501\(c\)\(3\)) Tj
0 -12 Td
(charitable foundation that provides co-pay assistance to government-insured patients with) Tj
0 -12 Td
(respect to the Product are in full compliance with all Applicable Laws.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.10 If, during the Term, Valeant becomes aware of a material violation or failure to) Tj
0 -12 Td
(comply with Applicable Law or the terms of this Agreement by a member of the Field Force) Tj
0 -12 Td
(Personnel that are engaged in Detailing, it shall promptly, but no later than two \(2\)) Tj
0 -12 Td
ET
endstream
endobj
46 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 45 0 R >>
endobj
47 0 obj
<< /Length 4872 >>
stream
BT
/F1 10 Tf
72 720 Td
(Business Days after it becomes aware, notify Dova of such violation and, as promptly as) Tj
0 -12 Td
(possible thereafter, shall notify the steps it has taken or intends to take to remediate) Tj
0 -12 Td
(such violation.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.3.11 Compliance Managers. As soon as practicable, but no later than thirty \(30\) days) Tj
0 -12 Td
(after the Effective Date, each Party shall appoint a representative to act as its) Tj
0 -12 Td
(compliance manager under this Agreement, each of which is routinely responsible for) Tj
0 -12 Td
(advising such Party on compliance matters and has suitable seniority and other relevant) Tj
0 -12 Td
(experience and expertise \(each, a "Compliance Manager"\). From time to time, each Party may) Tj
0 -12 Td
(change its Compliance Manager by giving written notice to the other Party. The Compliance) Tj
0 -12 Td
(Managers shall serve as a key point of contact between the Parties for compliance-related) Tj
0 -12 Td
(matters. Each Compliance Manager shall facilitate the resolution of any compliance issue) Tj
0 -12 Td
(with the Compliance Manager of the other Party. The Compliance Managers will use good) Tj
0 -12 Td
(faith efforts to reach consensus on all compliance matters. If the Compliance Managers do) Tj
0 -12 Td
(not reach consensus on an issue promptly, then such issue shall be submitted to dispute) Tj
0 -12 Td
(resolution process described in Section 13.6. Upon the reasonable request of Dova from to) Tj
0 -12 Td
(time, Valeant shall deliver to Dova copies of Valeant's compliance program policies and) Tj
0 -12 Td
(compliance training materials which are applicable to the Field Force Personnel's) Tj
0 -12 Td
(promotion of the Product. Other than as expressly stated herein, Valeant shall not be) Tj
0 -12 Td
(required to modify its compliance policies or practices in connection with the compliance-) Tj
0 -12 Td
(related provisions herein.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.4 Field Force Personnel Training; Product Materials.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.4.1 Training, Training Materials and Promotional Materials.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) Subject to the terms of this Section 4.4.1, Dova shall prepare and control the content) Tj
0 -12 Td
(of \(i\) all Product training materials for Field Force Personnel \(the "Product Training) Tj
0 -12 Td
(Materials"\) and \(ii\) all Product marketing and educational materials \(the "Promotional) Tj
0 -12 Td
(Materials"\) \(the Product Training Materials and the Promotional Materials, collectively,) Tj
0 -12 Td
(the "Product Materials"\). Dova shall be solely responsible for ensuring that the Product) Tj
0 -12 Td
(Materials prepared and approved by it are in compliance with the Regulatory Approval for) Tj
0 -12 Td
(the Product, the Product Labeling and Applicable Law. Once approved by Dova, the content) Tj
0 -12 Td
(of the Product Materials shall be provided by Dova to Valeant in advance of the Valeant) Tj
0 -12 Td
(Activates to allow for Valeant to review such content and provide verbal feedback to Dova) Tj
0 -12 Td
(in advance of use of the Product Materials. Within [***] of receipt of such Product) Tj
0 -12 Td
(Materials, Valeant shall verbally provide to Dova any comments and/or proposed revisions) Tj
0 -12 Td
(to such Product Materials, which comments and revisions Dova shall reasonably consider so) Tj
0 -12 Td
(long as Dova deems such suggestions are acceptable in the promotion of the Product;) Tj
0 -12 Td
(provided that in any event, to the extent that Dova reasonably believes that such changes) Tj
0 -12 Td
(are not in compliance with Applicable Law, the Regulatory Approval for the Product or the) Tj
0 -12 Td
(applicable Product Labeling, then Dova shall not be required to incorporate any such) Tj
0 -12 Td
(suggestions from Valeant in the Product Materials. In the event of any disagreement) Tj
0 -12 Td
(between the Parties regarding any feedback received from Valeant with respect to the) Tj
0 -12 Td
(Product Materials, Dova shall have the right to conclusively determine such matter. If) Tj
0 -12 Td
(Valeant has provided comments to Dova on the Product Materials and Dova accepts some or) Tj
0 -12 Td
(all of such comments, then, once revised, Dova shall provide to Valeant the revised) Tj
0 -12 Td
(versions of such Product Materials for further review by Valeant, in accordance with the) Tj
0 -12 Td
(terms and timelines of this Section 4.4.1\(a\) above. Valeant shall use only Product) Tj
0 -12 Td
(Materials approved by Dova in the performance of Valeant Activities under this Agreement;) Tj
0 -12 Td
(provided, however, that Valeant shall not be required to use any Product Materials that) Tj
0 -12 Td
(have not been approved by Valeant or which have not incorporated comments) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
48 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 47 0 R >>
endobj
49 0 obj
<< /Length 4710 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(provided by Valeant and nothing herein shall require Valeant to use all Product Materials) Tj
0 -12 Td
(created or prepared by Dova and Valeant reserves the right not to use certain Product) Tj
0 -12 Td
(Materials. The content of Product Materials shall not be modified or changed by Valeant or) Tj
0 -12 Td
(Field Force Personnel at any time without the prior written approval of Dova in each) Tj
0 -12 Td
(instance. Dova shall be responsible for the costs and expenses of creation and development) Tj
0 -12 Td
(of the Product Materials and Valeant shall be responsible for the costs and expense of) Tj
0 -12 Td
(reproduction, printing and delivery of the Product Materials to and for Valeant. The) Tj
0 -12 Td
(Parties will coordinate the production and delivery of Product Materials to allow) Tj
0 -12 Td
(sufficient internal and field force review time to accommodate scheduled training meetings) Tj
0 -12 Td
(and distribution to Field Force Personnel that are engaged in Detailing. In the event that) Tj
0 -12 Td
(Dova incurs costs and expenses for which Valeant is responsible under this Section 4.4.1,) Tj
0 -12 Td
(Dova may deduct such amounts from the payments due under Section 6.3 and shall include a) Tj
0 -12 Td
(description thereof in the applicable report under Section 6.3. Promptly after the) Tj
0 -12 Td
(Effective Date, the Parties will collaborate to finalize the Product Materials in) Tj
0 -12 Td
(accordance with this Section 4.4.1\(a\), as soon as reasonably practical.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) Commencing with the Promotional Materials to be used for Calendar Year 2019 and for) Tj
0 -12 Td
(the remainder of the Term, Valeant and Dova shall meet to discuss the content of such) Tj
0 -12 Td
(Promotional Materials in order to ensure that such Promotional Materials appropriately) Tj
0 -12 Td
(address any messaging that may be desired for the Target Professionals in the Specialty.) Tj
0 -12 Td
(Such discussions may take place in the forum of the JSC. Dova shall in good faith) Tj
0 -12 Td
(reasonably consider all comments and suggestions of Valeant regarding the Promotional) Tj
0 -12 Td
(Materials.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) Promptly after the Effective Date, the Parties will collaborate to plan and schedule) Tj
0 -12 Td
(training for the Sales Representatives at a mutually acceptable time\(s\) and date\(s\),) Tj
0 -12 Td
(including a launch meeting for the Sales Representatives at a mutually acceptable) Tj
0 -12 Td
(location. Dova will lead such initial training and Valeant shall cooperate with any) Tj
0 -12 Td
(reasonable requests of Dova in order to support such training. The costs and expenses of) Tj
0 -12 Td
(such launch meeting will be shared equally by the Parties, other than travel and lodging) Tj
0 -12 Td
(for the Sales Representatives which shall be the responsibility of Valeant. All other) Tj
0 -12 Td
(training costs and expenses shall be the responsibility of Valeant. After the initial) Tj
0 -12 Td
(training, the Parties will collaborate to provide additional training at such frequency,) Tj
0 -12 Td
(times and places as the circumstances warrant and the Parties mutually agree. Valeant) Tj
0 -12 Td
(shall have the right, but not the obligation, to conduct such additional training itself,) Tj
0 -12 Td
(provided that the Valeant trainers have been trained by Dova, and provided further that) Tj
0 -12 Td
(Dova shall have the right to attend such training upon reasonable notice by Valeant to) Tj
0 -12 Td
(Dova. Valeant will certify in writing to Dova that all Field Force Personnel have) Tj
0 -12 Td
(completed the training described in this Section 4.4.1\(b\).) Tj
0 -12 Td
() Tj
0 -12 Td
(\(d\) Valeant and all Field Force Personnel that are engaged in Valeant Activities shall) Tj
0 -12 Td
(comply with the applicable provisions of the Code, and shall be trained on Valeant's) Tj
0 -12 Td
(compliance policies, including those that are consistent with the applicable provisions of) Tj
0 -12 Td
(Sec. 1128B\(b\) of the Social Security Act and the American Medical Association Ethical) Tj
0 -12 Td
(Guidelines for Gifts to Physicians from Industry \(which such training may have been) Tj
0 -12 Td
(accomplished prior to the Term\), prior to commencing any Valeant Activities. Valeant) Tj
0 -12 Td
(agrees that it shall train any employee or agent of Valeant who is involved in performing) Tj
0 -12 Td
(the activities contemplated by this Agreement on anti-corruption and anti-bribery at its) Tj
0 -12 Td
(own expense.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(e\) Field Force Personnel that are engaged in Detailing shall conduct the Valeant) Tj
0 -12 Td
ET
endstream
endobj
50 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 49 0 R >>
endobj
51 0 obj
<< /Length 4225 >>
stream
BT
/F1 10 Tf
72 720 Td
(Activities only after having undergone the training described in this Section 4.4 and,) Tj
0 -12 Td
(without limiting the foregoing, no Field Force Personnel member shall Detail the Product) Tj
0 -12 Td
(without having undergone such training. Subject to the foregoing, Valeant shall have the) Tj
0 -12 Td
(responsibility for on- going training of its Field Force Personnel that are engaged in) Tj
0 -12 Td
(Detailing in accordance with customary practice in the pharmaceutical industry.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.4.2 Ownership of Product Materials. As between the Parties, Dova shall own all right,) Tj
0 -12 Td
(title and interest in and to any Product Materials \(and all content contained therein\) and) Tj
0 -12 Td
(any Product Labeling \(and all content contained therein\), including applicable copyrights) Tj
0 -12 Td
(and trademarks \(other than any name, trademark, trade name or logo of Valeant or its) Tj
0 -12 Td
(Affiliates that may appear on such Product materials or Product Labeling\), and to the) Tj
0 -12 Td
(extent Valeant \(or any of its Affiliates\) obtains or otherwise has a claim to any of the) Tj
0 -12 Td
(foregoing, Valeant hereby assigns \(and shall cause any applicable Affiliate to assign\) all) Tj
0 -12 Td
(of its right, title and interest in and to such Product Materials \(and content\) and) Tj
0 -12 Td
(Product Labeling \(and content\) \(other than any name, trademark, trade name or logo of) Tj
0 -12 Td
(Valeant or its Affiliates that may appear on such Product materials or Product Labeling\)) Tj
0 -12 Td
(to Dova and Valeant agrees to \(and shall cause its applicable Affiliate to\) execute all) Tj
0 -12 Td
(documents and take all actions as are reasonably requested by Dova to vest title to such) Tj
0 -12 Td
(Product Materials \(and content\) and Product Labeling \(and content\) in Dova \(or its) Tj
0 -12 Td
(designated Affiliate\).) Tj
0 -12 Td
() Tj
0 -12 Td
(4.5 Provisions Related to Field Force Personnel.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.5.1 Activities of Field Force Personnel. Valeant hereby agrees and acknowledges that the) Tj
0 -12 Td
(following shall apply with respect to itself and the Field Force Personnel that are) Tj
0 -12 Td
(engaged in Detailing:) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) Valeant shall instruct and cause the Field Force Personnel that are engaged in) Tj
0 -12 Td
(Detailing to use only the Product Labeling and, subject to the terms of Section 4.4,) Tj
0 -12 Td
(Product Materials approved by Dova for the conduct of the Valeant Activities for the) Tj
0 -12 Td
(Product and consistent with Applicable Laws. Valeant shall instruct the Field Force) Tj
0 -12 Td
(Personnel that are engaged in Detailing to, and will monitor the Field Force Personnel) Tj
0 -12 Td
(that are engaged in Detailing to ensure that such Field Force Personnel, limit their) Tj
0 -12 Td
(claims of efficacy and safety for the Product to those claims which are consistent with) Tj
0 -12 Td
(and do not exceed the Product Labeling and any Promotional Materials.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) Valeant shall instruct the Field Force Personnel that are engaged in Detailing to) Tj
0 -12 Td
(conduct the Valeant Activities for the Product, and will monitor and audit \(in accordance) Tj
0 -12 Td
(with Valeant's standard practice\) the Field Force Personnel that are engaged in Detailing) Tj
0 -12 Td
(so that such personnel conduct the Valeant Activities for the Product in adherence in all) Tj
0 -12 Td
(respects with Applicable Laws.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) Valeant shall instruct the Field Force Personnel that are engaged in Detailing) Tj
0 -12 Td
(regarding provisions of this Agreement applicable to Details of the Product, including) Tj
0 -12 Td
(Section 4.2 and this Section 4.5.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(d\) Valeant acknowledges and agrees that Dova will not maintain or procure any worker's) Tj
0 -12 Td
(compensation, healthcare, or other insurance for or on behalf of the Field Force) Tj
0 -12 Td
(Personnel, all of which shall be Valeant's sole responsibility.) Tj
0 -12 Td
ET
endstream
endobj
52 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 51 0 R >>
endobj
53 0 obj
<< /Length 5021 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(\(e\) Valeant acknowledges and agrees that all Field Force Personnel are employees of) Tj
0 -12 Td
(Valeant and are not, and are not intended to be treated as, employees of Dova or any of) Tj
0 -12 Td
(its Affiliates, and that such individuals are not, and are not intended to be, eligible to) Tj
0 -12 Td
(participate in any benefits programs or in any "employee benefit plans" \(as such term is) Tj
0 -12 Td
(defined in section 3\(3\) of ERISA\) that are sponsored by Dova or any of its Affiliates or) Tj
0 -12 Td
(that are offered from time to time by Dova or its Affiliates to their own employees. All) Tj
0 -12 Td
(matters of compensation, benefits and other terms of employment for any such Field Force) Tj
0 -12 Td
(Personnel shall be solely a matter between Valeant and such individual. Dova shall not be) Tj
0 -12 Td
(responsible to Valeant, or to the Field Force Personnel, for any compensation, expense) Tj
0 -12 Td
(reimbursements or benefits \(including vacation and holiday remuneration, healthcare) Tj
0 -12 Td
(coverage or insurance, life insurance, severance or termination of employment benefits,) Tj
0 -12 Td
(pension or profit-sharing benefits and disability benefits\), payroll-related taxes or) Tj
0 -12 Td
(withholdings, or any governmental charges or benefits \(including unemployment and) Tj
0 -12 Td
(disability insurance contributions or benefits and workmen's compensation contributions or) Tj
0 -12 Td
(benefits\) that may be imposed upon or be related to the performance by Valeant or such) Tj
0 -12 Td
(individuals of this Agreement, all of which shall be the sole responsibility of Valeant,) Tj
0 -12 Td
(even if it is subsequently determined by any Governmental Authority that any such) Tj
0 -12 Td
(individual may be an employee or a common law employee of Dova or any of its Affiliates or) Tj
0 -12 Td
(is otherwise entitled to such payments and benefits.) Tj
0 -12 Td
() Tj
0 -12 Td
(\(f\) Valeant shall be solely responsible for the acts or omissions of the Field Force) Tj
0 -12 Td
(Personnel that are not in compliance with Applicable Law and the terms of this Agreement) Tj
0 -12 Td
(while performing any of the activities under this Agreement. Valeant shall be solely) Tj
0 -12 Td
(responsible and liable for all probationary and termination actions taken by it, as well) Tj
0 -12 Td
(as for the formulation, content and dissemination \(including content\) of all employment) Tj
0 -12 Td
(policies and rules \(including written probationary and termination policies\) applicable to) Tj
0 -12 Td
(its employees.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.5.2 Termination of Employment; Cessation of Valeant Activities. If any Field Force) Tj
0 -12 Td
(Personnel leaves the employ of Valeant \(or any of its Affiliates\), or otherwise ceases to) Tj
0 -12 Td
(conduct the Valeant Activities for the Product, Valeant shall, to the extent consistent) Tj
0 -12 Td
(with, and in a manner similar to, its practices with respect to departures of the sales) Tj
0 -12 Td
(representatives or other field force personnel, as applicable, promoting, marketing or) Tj
0 -12 Td
(detailing other products for Valeant, account for, and shall cause such departing Field) Tj
0 -12 Td
(Force Personnel to return to Valeant and delete from his/her computer files \(to the extent) Tj
0 -12 Td
(such materials or information have been provided in, or converted into, electronic form\)) Tj
0 -12 Td
(all materials relating to the Product that have been provided to such individual,) Tj
0 -12 Td
(including the Product Materials and account level information, including all copies of the) Tj
0 -12 Td
(foregoing.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.5.3 Discipline. If Dova has a reasonable basis for believing any member of the Field) Tj
0 -12 Td
(Force Personnel that are engaged in Detailing has violated any Applicable Laws, or failed) Tj
0 -12 Td
(to comply with this Agreement, then Dova shall notify Valeant of the alleged violation and) Tj
0 -12 Td
(Valeant shall promptly investigate the matter and, if the allegation turns out to be true,) Tj
0 -12 Td
(shall take the appropriate remedial action. Subject to the foregoing, Valeant shall be) Tj
0 -12 Td
(solely responsible for taking any disciplinary actions in connection with its Field Force) Tj
0 -12 Td
(Personnel that are engaged in Detailing. If, at any time, Dova has any other compliance-) Tj
0 -12 Td
(related concerns regarding any Field Force Personnel Detailing, Dova's Compliance Manager) Tj
0 -12 Td
(shall notify Valeant's Compliance Manager of such concerns in writing and the Compliance) Tj
0 -12 Td
(Managers will discuss and resolve such matters pursuant to Section 4.3.9.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.6 Responsibility for Valeant Activity Costs and Expenses. Other than as expressly set) Tj
0 -12 Td
(out herein, Valeant shall be solely responsible for any and all costs and expenses) Tj
0 -12 Td
(incurred by Valeant or any of its Affiliates in connection with the conduct of the Valeant) Tj
0 -12 Td
ET
endstream
endobj
54 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 53 0 R >>
endobj
55 0 obj
<< /Length 4331 >>
stream
BT
/F1 10 Tf
72 720 Td
(Activities for the Product hereunder, including all costs and expenses in connection with) Tj
0 -12 Td
(Sales Representatives, including salaries, travel expenses and other expenses,) Tj
0 -12 Td
(credentialing, licensing, providing benefits, deducting federal, state and local payroll) Tj
0 -12 Td
(taxes, and paying workers' compensation premiums, unemployment insurance contributions and) Tj
0 -12 Td
(any other payments required by Applicable Laws to be made on behalf of employees.) Tj
0 -12 Td
() Tj
0 -12 Td
(4.7 Data Sharing. Dova shall provide to Valeant certain information relating to the sale,) Tj
0 -12 Td
(commercialization, marketing and promotion of the Product, as may be mutually agreed by) Tj
0 -12 Td
(the Parties from time to time, for use by Valeant and the Field Force Personnel in) Tj
0 -12 Td
(connection with the Valeant Activities. Such information may include data from the) Tj
0 -12 Td
(applicable reimbursement HUB, specialty data aggregator, market research, and market) Tj
0 -12 Td
(access contracting and Third Party-provided brand performance data \([***]\). The timing of) Tj
0 -12 Td
(the delivery of such information shall be mutually agreed upon by the Parties, acting) Tj
0 -12 Td
(reasonably.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 5  REGULATORY, SAFETY AND SURVEILLANCE, COMMERCIAL MATTERS) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(5.1 Dova Responsibility. As between the Parties, except as expressly set out herein, all) Tj
0 -12 Td
(regulatory matters regarding the Product shall be the responsibility of Dova, including) Tj
0 -12 Td
(responsibility for all communications with Governmental Authorities, including but not) Tj
0 -12 Td
(limited to FDA, related to the Product, and Dova shall have sole responsibility to seek) Tj
0 -12 Td
(and/or obtain any necessary approvals of any Product Labeling and the Promotional) Tj
0 -12 Td
(Materials used in connection with the Product, and for determining whether the same) Tj
0 -12 Td
(requires approval. As between the Parties, Dova shall be responsible for any reporting of) Tj
0 -12 Td
(matters regarding the manufacture, sale or promotion of the Product \(including Adverse) Tj
0 -12 Td
(Events\) to or with the FDA and other relevant regulatory authorities, in accordance with) Tj
0 -12 Td
(Applicable Laws. Dova shall maintain, at its cost, the Regulatory Approvals for the) Tj
0 -12 Td
(Product and shall comply with all Applicable Law relevant to the conduct of Dova's) Tj
0 -12 Td
(business with respect to the Product or pursuant to this Agreement, including, without) Tj
0 -12 Td
(limitation, all applicable requirements under the Act.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.2 Valeant Involvement. Except as expressly permitted herein, Valeant shall not, without) Tj
0 -12 Td
(Dova's prior written consent, correspond or communicate with the FDA or with any other) Tj
0 -12 Td
(Governmental Authority concerning the Product, or otherwise take any action concerning any) Tj
0 -12 Td
(Regulatory Approval or other authorization under which the Product is marketed or sold. If) Tj
0 -12 Td
(not prohibited by any Government Authority or Applicable Law, Valeant shall provide to) Tj
0 -12 Td
(Dova, promptly upon receipt, copies of any communication from the FDA or other) Tj
0 -12 Td
(Governmental Authority related to the Product. If not prohibited by any Government) Tj
0 -12 Td
(Authority or Applicable Law, Dova has the right to review and comment on Valeant's draft) Tj
0 -12 Td
(responses to any Governmental Authorities relevant to Detail of the Product prior to) Tj
0 -12 Td
(Valeant's issuance of such response; and Valeant agrees to consider any comments or) Tj
0 -12 Td
(suggestions from Dova in good faith.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.3 Inspections.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.3.1 If not prohibited by any Government Authority or Applicable Law, Valeant shall) Tj
0 -12 Td
(notify Dova immediately upon receipt of any notice of inspection or investigation by any) Tj
0 -12 Td
(Governmental Authority related to or that Valeant reasonably believes may impact any) Tj
0 -12 Td
(aspect of the Valeant Activities. If not prohibited by any Government Authority or) Tj
0 -12 Td
ET
endstream
endobj
56 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 55 0 R >>
endobj
57 0 obj
<< /Length 5213 >>
stream
BT
/F1 10 Tf
72 720 Td
(Applicable Law, Dova shall have the right to have a representative present at any such) Tj
0 -12 Td
(portion of the inspection involving any Valeant Activities. In such cases, Valeant shall) Tj
0 -12 Td
(\(i\) keep Dova fully informed of the progress and status of any such inspection or) Tj
0 -12 Td
(investigation, \(ii\) prior to undertaking any action pursuant to this Section 5.3.1, notify) Tj
0 -12 Td
(Dova of the inspection or investigation, and disclose to Dova in writing the Governmental) Tj
0 -12 Td
(Authorities' assertions, findings and related results of such inspection or investigation) Tj
0 -12 Td
(pertaining to the Valeant Activities, and \(iii\) provide full disclosure to Dova with) Tj
0 -12 Td
(respect to any action undertaken or proposed to be undertaken pursuant to this Section) Tj
0 -12 Td
(5.3.1 prior to acting as it pertains to the Valeant Activities. In addition, if such) Tj
0 -12 Td
(findings or the Governmental Authority requests or suggests that Valeant should change any) Tj
0 -12 Td
(aspect of the Valeant Activities, the Parties will work together to make any such) Tj
0 -12 Td
(modification; provided, however, that notwithstanding anything to the contrary herein,) Tj
0 -12 Td
(Valeant will not be required to engage in any Valeant Activities to the extent any finding) Tj
0 -12 Td
(or Government Authority has requested or suggested that Valeant may not engage in such) Tj
0 -12 Td
(activity.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.3.2 If not prohibited by any Government Authority or Applicable Law, Dova shall notify) Tj
0 -12 Td
(Valeant immediately upon receipt of any notice of inspection or investigation by any) Tj
0 -12 Td
(Governmental Authority related to or that Dova reasonably believes may impact the Valeant) Tj
0 -12 Td
(Activities. In such cases, Dova shall \(i\) keep Valeant fully informed of the progress and) Tj
0 -12 Td
(status of any such inspection or investigation, \(ii\) disclose to Valeant in writing the) Tj
0 -12 Td
(Governmental Authorities' assertions, findings and related results of such inspection or) Tj
0 -12 Td
(investigation pertaining to the Product or its promotion, and \(iii\) provide full) Tj
0 -12 Td
(disclosure to Valeant with respect to any action undertaken or proposed to be undertaken) Tj
0 -12 Td
(pursuant to this Section 5.3.2 prior to acting as it pertains to the Valeant Activities.) Tj
0 -12 Td
(In addition, if such findings or the Governmental Authority requests or suggests that) Tj
0 -12 Td
(Valeant should change any aspect of the Valeant Activities, the Parties will work together) Tj
0 -12 Td
(to make any such modification; provided, however, that notwithstanding anything to the) Tj
0 -12 Td
(contrary herein, Valeant will not be required to engage in any Valeant Activities to the) Tj
0 -12 Td
(extent any finding or Government Authority has requested or suggested that Valeant may not) Tj
0 -12 Td
(engage in such activity.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.4 Pharmacovigilance. Subject to the terms of this Agreement, as soon as practicable) Tj
0 -12 Td
(following the Effective Date \(but in no event later than [***]\), Dova and Valeant \(under) Tj
0 -12 Td
(the guidance of their respective pharmacovigilance departments, or equivalent thereof\)) Tj
0 -12 Td
(shall identify and finalize the responsibilities the Parties shall employ to protect) Tj
0 -12 Td
(patients and promote their well- being in a separate safety data exchange agreement) Tj
0 -12 Td
(\("Pharmacovigilance Agreement"\). These responsibilities shall include mutually acceptable) Tj
0 -12 Td
(guidelines and procedures for the receipt, investigation, recordation, communication and) Tj
0 -12 Td
(exchange \(as between the Parties\) of safety information such as Adverse Events, lack of) Tj
0 -12 Td
(efficacy, misuse/abuse, and any other information concerning the safety of the Product.) Tj
0 -12 Td
(Such guidelines and procedures will be in accordance with, and enable the Parties and) Tj
0 -12 Td
(their Affiliates to fulfill, regulatory reporting obligations to Governmental Authorities.) Tj
0 -12 Td
(The Pharmacovigilance Agreement shall provide that: \(i\) Dova shall be responsible for all) Tj
0 -12 Td
(pharmacovigilance activities regarding the Product, including signal detection, medical) Tj
0 -12 Td
(surveillance, risk management, medical literature review and monitoring, Adverse Event) Tj
0 -12 Td
(reporting and responses to Governmental Authority requests or enquiries, and shall provide) Tj
0 -12 Td
(information related thereto to Valeant, and \(ii\) in the event Valeant receives safety) Tj
0 -12 Td
(information regarding the Product, or information regarding any safety-related regulatory) Tj
0 -12 Td
(request or inquiry, Valeant shall notify Dova as soon as practicable, but, in any event,) Tj
0 -12 Td
(within the timelines set forth in the Pharmacovigilance Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.5 Unsolicited Requests for Medical Information. Valeant shall direct to Dova any) Tj
0 -12 Td
(unsolicited requests for off-label medical information from health care professionals with) Tj
0 -12 Td
(respect to the Product promptly following receipt by Valeant \(but in no) Tj
0 -12 Td
ET
endstream
endobj
58 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 57 0 R >>
endobj
59 0 obj
<< /Length 4428 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(event later than [***] after receipt\). Dova shall, within [***] following receipt of any) Tj
0 -12 Td
(such request from Valeant, address any such requests directly.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.6 Recalls and Market Withdrawals. As between the Parties, Dova shall have the sole right) Tj
0 -12 Td
(to determine whether to implement, and to implement, a recall, field alert, withdrawal or) Tj
0 -12 Td
(other corrective action related to the Product. Dova shall bear the cost and expense of) Tj
0 -12 Td
(any such recall, field alert, withdrawal or other corrective action. Each Party shall) Tj
0 -12 Td
(promptly \(but in any case, not later than [***]\) notify the other Party in writing of any) Tj
0 -12 Td
(order, request or directive of a court or other Governmental Authority to recall or) Tj
0 -12 Td
(withdraw the Product.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.7 Certain Reporting Responsibilities. Notwithstanding the foregoing provisions of this) Tj
0 -12 Td
(ARTICLE 5, each Party shall be responsible for its own federal, state and local government) Tj
0 -12 Td
(pricing reporting and payment transparency reporting in the Territory arising from its) Tj
0 -12 Td
(Product promotional activities and related expenditures pursuant to Applicable Law. It is) Tj
0 -12 Td
(the intention of the Parties that any payments or transfer of value by a Party as it) Tj
0 -12 Td
(relates to the Product shall constitute transfers of value by that Party and such Party) Tj
0 -12 Td
(shall be responsible for the reporting described in the immediately preceding sentence.) Tj
0 -12 Td
(However, if a Party is deemed to have provided any payments or transfers of value to a) Tj
0 -12 Td
(Third Party on behalf of the other Party as it relates to the Product, then such Party) Tj
0 -12 Td
(shall provide to the other Party, in a format reasonably acceptable to such other Party,) Tj
0 -12 Td
(the data and other information on a timely basis \(i.e., in the case of manual reporting of) Tj
0 -12 Td
(such data and other information, within [***] following the end of each Calendar Quarter,) Tj
0 -12 Td
(and, in the case of automated reporting of such data and other information, on a periodic) Tj
0 -12 Td
(basis during each Calendar Quarter as reasonably requested by such other Party\) for such) Tj
0 -12 Td
(other Party's reporting under the Physician Payments Sunshine Act and other Applicable) Tj
0 -12 Td
(Laws.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.8 Booking of Sales Revenues. Dova shall retain ownership of the rights to the Product) Tj
0 -12 Td
(and record on its books all revenues from sales of the Product. Dova shall be exclusively) Tj
0 -12 Td
(responsible for accepting and filling purchase orders, billing, and returns with respect) Tj
0 -12 Td
(to the Product. If Valeant receives an order for the Product, it shall promptly transmit) Tj
0 -12 Td
(such order to Dova \(or its designee\) for acceptance or rejection. Dova shall have sole) Tj
0 -12 Td
(responsibility for shipping, distribution and warehousing of Product, and for the) Tj
0 -12 Td
(invoicing and billing of purchasers of the Product and for the collection of receivables) Tj
0 -12 Td
(resulting from the sales of the Product in the Territory.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.9 Returns. Valeant is not authorized to accept any Product returns. Valeant shall advise) Tj
0 -12 Td
(any customer who attempts to return any Product to Valeant \(or its Affiliates\) that such) Tj
0 -12 Td
(Product must be shipped by the customer to the facility designated by Dova from time to) Tj
0 -12 Td
(time \(and in accordance with other instructions provided by Dova\). Dova shall provide to) Tj
0 -12 Td
(Valeant written instructions as to how Valeant should handle any Product that is actually) Tj
0 -12 Td
(physically returned to Valeant. Valeant shall take no other actions with respect to such) Tj
0 -12 Td
(return without the prior written consent of Dova.) Tj
0 -12 Td
() Tj
0 -12 Td
(5.10 Manufacturing; Distribution; Marketing. Dova shall have the sole authority, at its) Tj
0 -12 Td
(cost, to manufacture, package, label, warehouse, sell and distribute the Product in the) Tj
0 -12 Td
(Territory. Dova shall use commercially reasonable efforts to cause sufficient quantities) Tj
0 -12 Td
ET
endstream
endobj
60 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 59 0 R >>
endobj
61 0 obj
<< /Length 3719 >>
stream
BT
/F1 10 Tf
72 720 Td
(of the Product to be available in inventory to promptly fill orders throughout the) Tj
0 -12 Td
(Territory and otherwise meet the forecasted demand for the Product in the Territory. If,) Tj
0 -12 Td
(despite such efforts, there is insufficient supply of Product to meet demand, then Dova) Tj
0 -12 Td
(shall use commercially reasonable efforts to promptly address such insufficiency. Dova) Tj
0 -12 Td
(shall contractually require \(and shall use commercially reasonable efforts to enforce such) Tj
0 -12 Td
(contractual provisions\) that all Product is manufactured, shipped, sold and distributed in) Tj
0 -12 Td
(accordance with all Product specifications and all Applicable Law and that its contract) Tj
0 -12 Td
(manufacturers and/or suppliers of Product operate their facilities in accordance with) Tj
0 -12 Td
(Applicable Law. Dova shall ensure that all Product Labeling complies with the applicable) Tj
0 -12 Td
(Regulatory Approval for the Product and Applicable Law. Other than as set forth in this) Tj
0 -12 Td
(Agreement, Dova shall be responsible for all marketing of the Product in the Territory,) Tj
0 -12 Td
(provided that Dova shall continue to invest in marketing that is targeted towards the) Tj
0 -12 Td
(Specialty.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 6  FINANCIAL PROVISIONS) Tj
0 -12 Td
() Tj
0 -12 Td
(6.1 Promotion Fee.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.1.1 Calculation of Promotion Fee. Commencing with the Calendar Quarter commencing on) Tj
0 -12 Td
(October 1, 2018, as consideration for the Valeant Activities performed by Valeant, Dova) Tj
0 -12 Td
(shall pay Valeant a promotion fee based on annual Net Sales during the Term, calculated as) Tj
0 -12 Td
(follows:) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) For any portion of Net Sales up to and equal [***] in a Calendar Year, an amount equal) Tj
0 -12 Td
(to [***] of such portion of Net Sales;) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) For any portion of Net Sales in excess of [***] and up to and equal [***] in a) Tj
0 -12 Td
(Calendar Year, an amount equal to [***] of such portion of Net Sales; and) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) For any portion of Net Sales in excess of [***] in a Calendar Year, [***] of such) Tj
0 -12 Td
(portion of Net Sales.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(6.1.2 Adjustment of Promotion Fee. The percentages set forth in Section 6.1.1 [***] shall) Tj
0 -12 Td
(each be referred to as an "Applicable Percentage".) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) If the aggregate actual number of Details for the Product made by the Sales) Tj
0 -12 Td
(Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for such) Tj
0 -12 Td
(Calendar Quarter, then in calculating the promotion fee due under Section 6.1.1, the) Tj
0 -12 Td
(Applicable Percentage for such Calendar Quarter shall be reduced to a new percentage equal) Tj
0 -12 Td
(to [***].) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) If the Quarterly Average Sales Force Size is less than [***] Sales Representatives for) Tj
0 -12 Td
(an applicable Calendar Quarter, then in calculating the promotion fee due under Section) Tj
0 -12 Td
(6.1.1, the Applicable Percentage for such Calendar Quarter shall be reduced to a new) Tj
0 -12 Td
(percentage equal to [***].) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) In the event that subsections \(a\) above and \(b\) above are both applicable in an) Tj
0 -12 Td
(applicable Calendar Quarter, then the Applicable Percentage shall be reduced to a new) Tj
0 -12 Td
(percentage equal to the lower of the percentages calculated under subsections \(a\) and \(b\).) Tj
0 -12 Td
ET
endstream
endobj
62 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 61 0 R >>
endobj
63 0 obj
<< /Length 5010 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(6.2 Milestone Payment. In addition to the promotion fee above and as additional) Tj
0 -12 Td
(consideration for the performance of such Valeant Activities, Dova shall pay to Valeant a) Tj
0 -12 Td
(milestone payment in the amount of Two Million Five Hundred Thousand Dollars \($2,500,000\)) Tj
0 -12 Td
(when aggregate Net Sales in a Calendar Year first reach [***], payable within [***] after) Tj
0 -12 Td
(the end of the Calendar Quarter in which such Net Sales are reached. For clarity, such) Tj
0 -12 Td
(payment shall be made only once during the Term.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3 Reports; Payments.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3.1 Quarterly Reports and Payments. Within [***] after the end of each Calendar Quarter) Tj
0 -12 Td
(during the Term, Dova shall provide to Valeant a written report setting forth in) Tj
0 -12 Td
(reasonable detail the calculation of the Net Sales for such Calendar Quarter and the) Tj
0 -12 Td
(promotion fee payable in respect of such Net Sales in accordance with Section 6.1,) Tj
0 -12 Td
(including \(i\) the number of units of the Product shipped from Specialty Pharmacies to) Tj
0 -12 Td
(patients in the Territory during such Calendar Quarter, together with an itemized list of) Tj
0 -12 Td
(such units by Target Professional writing the applicable prescription, \(ii\) the number of) Tj
0 -12 Td
(units of the Product shipped from Specialty Pharmacies to patients in the Territory based) Tj
0 -12 Td
(on prescriptions written by the Specialty only during such Calendar Quarter, together with) Tj
0 -12 Td
(an itemized list of such units by Target Professional in the Specialty writing the) Tj
0 -12 Td
(applicable prescription \(iii\) the number of units per shipment of Products \(and the number) Tj
0 -12 Td
(of such shipments\) sold by Dova \(or its Affiliates or Intermediaries\) to the Non-Retail) Tj
0 -12 Td
(Institutions during such Calendar Quarter, including details respecting which shipments) Tj
0 -12 Td
(are based on initial orders from such Non-Retail Institutions and which Non-Retail) Tj
0 -12 Td
(Institutions ordered the Product, \(iv\) the number of units of the Product shipped from) Tj
0 -12 Td
(Retail Pharmacies to patients in the Territory during such Calendar Quarter, together with) Tj
0 -12 Td
(an itemized list of such units by Target Professional writing the applicable prescription,) Tj
0 -12 Td
(\(v\) the number of units shipped from Retail Pharmacies to patients based on prescriptions) Tj
0 -12 Td
(written by the Specialty in the Territory during such Calendar Quarter, together with an) Tj
0 -12 Td
(itemized list of such units by Target Professional in the Specialty writing the applicable) Tj
0 -12 Td
(prescription, \(vi\) the applicable Specialty Fraction for such Calendar Quarter, \(vii\) the) Tj
0 -12 Td
(WAC applicable to each dispensable unit, \(ix\) the Gross to Net Fraction for the applicable) Tj
0 -12 Td
(period, together with the details respecting the calculation thereof \(including details) Tj
0 -12 Td
(regarding each of the categories of the deductions to gross sales for such Calendar) Tj
0 -12 Td
(Quarter\). Within sixty \(60\) days after the end of each Calendar Quarter during the Term,) Tj
0 -12 Td
(Dova shall pay to Valeant the undisputed portion of the promotion fee payable in respect) Tj
0 -12 Td
(of such Net Sales in accordance with Section 6.1. If this Agreement terminates or expires) Tj
0 -12 Td
(during a Calendar Quarter, the promotion fee payable to Valeant under Section 6.1 will be) Tj
0 -12 Td
(calculated only on the Net Sales that occurred during such Calendar Quarter prior to the) Tj
0 -12 Td
(effective date of such termination or expiration.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3.2 Monthly Reports. Within fifteen \(15\) days of the end of each month within each) Tj
0 -12 Td
(Calendar Quarter, Dova shall provide to Valeant a written report setting forth Dova's good) Tj
0 -12 Td
(faith estimate of the Net Sales and the estimated promotion fee payable in respect of such) Tj
0 -12 Td
(Net Sales for each of such calendar month and the Calendar Quarter-to-date period,) Tj
0 -12 Td
(together with its good faith estimates of each of the items described in Section 6.3.1) Tj
0 -12 Td
(above \(assuming there will be no adjustments made to the promotion fee pursuant to Section) Tj
0 -12 Td
(6.1.2\). The Parties acknowledge and agree that the monthly reports will only set forth) Tj
0 -12 Td
(Dova's good faith estimates of the items contained therein and are being provided to) Tj
0 -12 Td
(Valeant for information purposes only and shall not be determinative of the any amounts) Tj
0 -12 Td
(due hereunder.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3.3 Disputes. Promptly upon receipt of the quarterly or monthly reports described in) Tj
0 -12 Td
(this Section 6.3, Valeant shall review such reports and, in the event that Valeant) Tj
0 -12 Td
(disputes any of the items described in such report, Valeant shall promptly notify Dova of) Tj
0 -12 Td
ET
endstream
endobj
64 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 63 0 R >>
endobj
65 0 obj
<< /Length 4201 >>
stream
BT
/F1 10 Tf
72 720 Td
(any such disputes. The Parties shall meet promptly thereafter to attempt to resolve such) Tj
0 -12 Td
(disputes.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3.4 Data for Net Sales. During the Term, in the event Dova \(or its Affiliates\) enters) Tj
0 -12 Td
(into agreements with any specialty pharmacies \(other than Non-Retail Institutions\) in) Tj
0 -12 Td
(order to sell and/or ship units of the Product directly to such specialty pharmacies, Dova) Tj
0 -12 Td
(shall use commercially reasonable efforts to include in the agreements provisions relating) Tj
0 -12 Td
(to the supply of data by such specialty pharmacies to Dova that can be used to support the) Tj
0 -12 Td
(calculation of Net Sales or shall use commercially reasonable efforts to enter into) Tj
0 -12 Td
(separate data agreements with such specialty pharmacies that provide for the supply of) Tj
0 -12 Td
(data by such specialty pharmacies to Dova that can be used to support the calculation of) Tj
0 -12 Td
(Net Sales.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3.5 Manner of Payment. All payments under this Agreement shall be made in US Dollars by) Tj
0 -12 Td
(wire transfer or) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(ACH to a bank account designated in writing by Valeant or Dova, as applicable, which shall) Tj
0 -12 Td
(be designated at least five \(5\) Business Days before such payment is due.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.3.6 Late Payments. If Valeant does not receive payment of any sum due to it on or before) Tj
0 -12 Td
(the due date, simple interest shall thereafter accrue on the sum due to Valeant from the) Tj
0 -12 Td
(due date until the date of payment at the Prime Rate plus [***] or the maximum rate) Tj
0 -12 Td
(allowable by Applicable Law, whichever is less; provided, however, if it is discovered) Tj
0 -12 Td
(that any payment is past due as of the result of any audit conduct by Valeant pursuant to) Tj
0 -12 Td
(Section 7.2, such interest shall not accrue until [***] after the completion of such audit) Tj
0 -12 Td
(and not at the time the payment was originally due. Notwithstanding the foregoing, if the) Tj
0 -12 Td
(reason for any late payment is resulting from or arising out of any act or omission on the) Tj
0 -12 Td
(part of Valeant, including but not limited to any delay providing the requisite reports in) Tj
0 -12 Td
(Section 4.2.2, or the payment instructions pursuant to Section 6.3.4, such interest shall) Tj
0 -12 Td
(not accrue.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.4 Taxes. To the extent Dova is required to deduct and withhold taxes from any payment to) Tj
0 -12 Td
(Valeant, Dova shall pay the amounts of such taxes to the proper Governmental Authority in) Tj
0 -12 Td
(a timely manner and promptly transmit to Valeant an official tax receipt or other evidence) Tj
0 -12 Td
(of timely payment sufficient to enable Valeant to claim the payment of such taxes as a) Tj
0 -12 Td
(deduction or tax credit. Valeant may provide to Dova any tax forms that may be reasonably) Tj
0 -12 Td
(necessary in order for Dova to not withhold tax and Dova shall dispense with withholding,) Tj
0 -12 Td
(as applicable. Dova shall provide Valeant with reasonable assistance to enable the) Tj
0 -12 Td
(recovery, as permitted by Applicable Laws, of withholding taxes.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.5 Determination of Specialty.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.5.1 No later than [***] \(or in the case of the first full Calendar Quarter following the) Tj
0 -12 Td
(Effective Date, promptly following the Effective Date\), Dova shall provide Valeant with a) Tj
0 -12 Td
(list of Target Professionals in the Territory, together with their primary and secondary) Tj
0 -12 Td
(specialty designation, as generated by Dova's Third Party Data Source. Promptly following) Tj
0 -12 Td
(receipt by Valeant of such list, but no later than [***] after receipt of the list of) Tj
0 -12 Td
(Target Professionals, Valeant may present to Dova a list of Target Professionals that,) Tj
0 -12 Td
(acting in good faith, it reasonably believes have a primary specialty designation of or) Tj
0 -12 Td
ET
endstream
endobj
66 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 65 0 R >>
endobj
67 0 obj
<< /Length 5103 >>
stream
BT
/F1 10 Tf
72 720 Td
(otherwise currently practice in the specialty of Gastroenterology, Colorectal Surgery or) Tj
0 -12 Td
(Proctology. For greater certainty, this list may include, but not be limited to, Target) Tj
0 -12 Td
(Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery) Tj
0 -12 Td
(or Proctology and a secondary specialty designation of Hepatology, for which Valeant) Tj
0 -12 Td
(wishes to confirm the primary specialty.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.5.2 Promptly following receipt by Dova of such list from Valeant, the Parties shall meet) Tj
0 -12 Td
(and discuss, acting reasonably and in good faith, such list and their appropriate primary) Tj
0 -12 Td
(specialty. If the parties agree that the Target Professional included on such list has \(or) Tj
0 -12 Td
(should have\) a primary specialty designation of or otherwise currently practices in the) Tj
0 -12 Td
(specialty of Gastroenterology, Colorectal Surgery or Proctology, then Dova will submit an) Tj
0 -12 Td
(inquiry to Dova's Third Party Data Source for each such Target Professional, requesting) Tj
0 -12 Td
(that Dova's Third Party Data Source conduct an investigation to determine the primary) Tj
0 -12 Td
(specialty designation of each such Target Professional. In addition, if the Parties do not) Tj
0 -12 Td
(agree, but Valeant, acting reasonably and in good faith, still believes that the Target) Tj
0 -12 Td
(Professional has \(or should have\) a primary specialty designation of or otherwise) Tj
0 -12 Td
(currently practices in the specialty of Gastroenterology, Colorectal Surgery or) Tj
0 -12 Td
(Proctology, then Dova will submit an inquiry to Dova's Third Party Data Source for each) Tj
0 -12 Td
(such Target Professional, requesting that Dova's Third Party Data Source conduct an) Tj
0 -12 Td
(investigation to determine the primary specialty designation of each such Target) Tj
0 -12 Td
(Professional. The Parties shall equally share in the incremental costs to Dova of any such) Tj
0 -12 Td
(investigations by Dova's Third Party Data Source. For greater certainty, if, under Dova's) Tj
0 -12 Td
(agreement with Dova's Third Party Data Source, Dova is entitled to a certain number of) Tj
0 -12 Td
(investigations at no additional cost, and such investigations requested by Valeant causes) Tj
0 -12 Td
(Dova to incur additional costs that it would not have, but for such investigations) Tj
0 -12 Td
(requested by Valeant, then Valeant shall still be required to share in any costs of) Tj
0 -12 Td
(investigations \(pursuant to Dova's Third Party Data Source's standard rates\) that would) Tj
0 -12 Td
(otherwise be a no-cost investigations. In the event that Dova incurs costs for which) Tj
0 -12 Td
(Valeant is responsible under this Section 6.5, Dova may deduct such amounts from the) Tj
0 -12 Td
(payments due under Section 6.3 and shall include a description thereof in the applicable) Tj
0 -12 Td
(report under Section 6.3.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.5.3 In the event that Dova's Third Party Data Source agrees to conduct such) Tj
0 -12 Td
(investigation, and then based on the results of such investigation, Dova's Third Party) Tj
0 -12 Td
(Data Source changes the primary designation of the Target Professional to) Tj
0 -12 Td
(Gastroenterology, Colorectal Surgery or Proctology or, in the case of those Target) Tj
0 -12 Td
(Professionals with a primary specialty designation of Gastroenterology, Colorectal Surgery) Tj
0 -12 Td
(or Proctology and a secondary specialty designation of Hepatology, confirms that the) Tj
0 -12 Td
(primary specialty designation should remain Gastroenterology, Colorectal Surgery or) Tj
0 -12 Td
(Proctology, then, commencing with the Calendar Quarter in which such investigations were) Tj
0 -12 Td
(conducted, such Target Professionals shall be deemed to be in the Specialty \(regardless of) Tj
0 -12 Td
(whether their secondary specialty designation remains or becomes Hepatology\). In the event) Tj
0 -12 Td
(that, following such investigation, Dova's Third Party Data source does not change the) Tj
0 -12 Td
(primary specialty designation to Gastroenterology, Colorectal Surgery or Proctology or, in) Tj
0 -12 Td
(the case of those Target Professionals with a primary specialty designation of) Tj
0 -12 Td
(Gastroenterology, Colorectal Surgery or Proctology and a secondary specialty designation) Tj
0 -12 Td
(of Hepatology, changes the primary specialty designation to a specialty other than) Tj
0 -12 Td
(Gastroenterology, Colorectal Surgery or Proctology, then those Target Professionals shall) Tj
0 -12 Td
(be deemed not to be in the Specialty. For those Target Professionals that were not the) Tj
0 -12 Td
(subject of an inquiry to or an investigation by Dova's Third Party Data Source, then the) Tj
0 -12 Td
(specialty designations set out in the original list generated by Dova's Third Party Data) Tj
0 -12 Td
(Source shall apply for such Calendar Quarter, namely those Target Professionals that have) Tj
0 -12 Td
(either a) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
ET
endstream
endobj
68 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 67 0 R >>
endobj
69 0 obj
<< /Length 4558 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(primary or a secondary specialty designation of Gastroenterology, Colorectal Surgery or) Tj
0 -12 Td
(Proctology and that do not have either a primary or a secondary specialty designation of) Tj
0 -12 Td
(Hepatology shall be deemed to be in the Specialty.) Tj
0 -12 Td
() Tj
0 -12 Td
(6.5.4 The process described in this Section 6.5 shall be repeated for each Calendar) Tj
0 -12 Td
(Quarter of the Term; provided, however, that, pursuant to the process described above, if) Tj
0 -12 Td
(Dova's Third Party Data Source has confirmed that a Target Professional's primary) Tj
0 -12 Td
(specialty designation should be or should remain Gastroenterology, Colorectal Surgery or) Tj
0 -12 Td
(Proctology, it is not necessary for Valeant to seek this confirmation in subsequent) Tj
0 -12 Td
(Calendar Quarters; provided, further, that, if Dova's Third Party Data Source is) Tj
0 -12 Td
(subsequently updated \(by Dova or any Third Party\) to change the specialty designation) Tj
0 -12 Td
(\(primary or secondary\) of a Target Professional, pursuant to a request by Dova or a Third) Tj
0 -12 Td
(Party, then the process described in this Section 6.5 shall be repeated with respect to) Tj
0 -12 Td
(such Target Professional.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 7  AUDIT RIGHTS) Tj
0 -12 Td
() Tj
0 -12 Td
(7.1 Recordkeeping. Each Party shall maintain complete and accurate books and records in) Tj
0 -12 Td
(sufficient detail, in accordance with GAAP \(to the extent applicable and in accordance) Tj
0 -12 Td
(with the Agreement\) and all Applicable Law, to enable verification of the performance of) Tj
0 -12 Td
(such Party's obligations under this Agreement and any payments due to a Party under this) Tj
0 -12 Td
(Agreement. Unless otherwise specified herein, the books and records for a given Calendar) Tj
0 -12 Td
(Year of the Term shall be maintained for a period of [***] after the end of such Calendar) Tj
0 -12 Td
(Year or longer if required by Applicable Law.) Tj
0 -12 Td
() Tj
0 -12 Td
(7.2 Valeant Rights. Valeant shall have the right, at its own expense, during normal) Tj
0 -12 Td
(business hours and upon reasonable prior notice, through certified public accounting firm) Tj
0 -12 Td
(or other auditor selected by Valeant and reasonably acceptable to Dova and upon execution) Tj
0 -12 Td
(of a confidentiality agreement reasonably satisfactory to Dova in form and substance, to) Tj
0 -12 Td
(inspect and audit the applicable records and books maintained by Dova for purposes of) Tj
0 -12 Td
(verifying Dova's payment obligations within this Agreement, including the applicable) Tj
0 -12 Td
(records and books of account maintained by Dova, or any Affiliate, as applicable, with) Tj
0 -12 Td
(respect to Net Sales in order to confirm the accuracy and completeness of such records and) Tj
0 -12 Td
(books of account and all payments hereunder; provided, however, that \(i\) such examination) Tj
0 -12 Td
(shall not take place more often than once per every twelve \(12\) months during the Term and) Tj
0 -12 Td
(once during the one \(1\) year period following the end of the Term, and \(ii\) such) Tj
0 -12 Td
(examination shall not cover a period of time that has previously been audited; provided) Tj
0 -12 Td
(that Valeant shall have the right to conduct additional "for cause" audits to the extent) Tj
0 -12 Td
(necessary to address significant problems relating to Dova's payment obligations) Tj
0 -12 Td
(hereunder. Dova shall reasonably cooperate in any such inspection or audit conducted by) Tj
0 -12 Td
(Valeant. Any undisputed adjustments required as a result of overpayments or underpayments) Tj
0 -12 Td
(identified through the exercise of audit rights shall be made by payment to the Party owed) Tj
0 -12 Td
(such adjustment within [***] after identification of such adjustment. Valeant shall bear) Tj
0 -12 Td
(the out-of-pocket costs and expenses incurred by the Parties in connection with any such) Tj
0 -12 Td
(inspection or audit, unless the audit shows an undisputed under-reporting or underpayment) Tj
0 -12 Td
(for that audited period in excess of [***] of the amounts properly determined, in which) Tj
0 -12 Td
(case, Dova shall reimburse Valeant for its audit fees and reasonable out-of-pocket) Tj
0 -12 Td
(expenses in connection with said audit, which reimbursement shall be due and payable) Tj
0 -12 Td
(within [***] of receiving appropriate invoices and other support for such audit-related) Tj
0 -12 Td
(costs.) Tj
0 -12 Td
ET
endstream
endobj
70 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 69 0 R >>
endobj
71 0 obj
<< /Length 4593 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(7.3 Dova Rights. Dova shall have the right, at its own expense, during normal business) Tj
0 -12 Td
(hours and upon reasonable prior notice, through a certified public accounting firm or) Tj
0 -12 Td
(other auditor selected by Dova and reasonably acceptable to Valeant and upon execution of) Tj
0 -12 Td
(a confidentiality agreement reasonably satisfactory to Valeant in form and substance, to) Tj
0 -12 Td
(inspect and audit the applicable records and books maintained by Valeant relating to the) Tj
0 -12 Td
(Valeant Activities for purposes of verifying Valeant's compliance with the terms of this) Tj
0 -12 Td
(Agreement, provided that \(i\) such examination shall not take place more often than once) Tj
0 -12 Td
(per every twelve \(12\) months during the Term and once during the one \(1\) year period) Tj
0 -12 Td
(following the end of the Term, and \(ii\) such examination shall not cover a period of time) Tj
0 -12 Td
(that has previously been audited; provided that Dova shall have the right to conduct) Tj
0 -12 Td
(additional "for cause" audits to the extent necessary to address significant compliance) Tj
0 -12 Td
(problems relating to Valeant's obligations hereunder or in response to any inquiry,) Tj
0 -12 Td
(inspection, investigation or other requirements of a Government Authority in the Territory) Tj
0 -12 Td
(relating to the Valeant Activities. For purposes of clarity, any such inspection or audit) Tj
0 -12 Td
(described in this Section 7.3 shall be limited to only those books and records of Valeant) Tj
0 -12 Td
(that are applicable to Valeant's performance of its obligations under this Agreement.) Tj
0 -12 Td
(Where necessary, on reasonable request, Dova's audit rights shall include interviewing) Tj
0 -12 Td
(Sales Representatives and other employees of Valeant. Valeant shall reasonably cooperate) Tj
0 -12 Td
(in any such inspection or audit conducted by Dova. Any undisputed adjustments required as) Tj
0 -12 Td
(a result of overreporting the aggregate actual number of Details for the Product made by) Tj
0 -12 Td
(the Sales Representatives for a Calendar Quarter or the Quarterly Average Sales Force Size) Tj
0 -12 Td
(identified through the exercise of audit rights shall be made by payment by Valeant to) Tj
0 -12 Td
(Dova within [***] after identification of such adjustment. Dova shall bear the out-of-) Tj
0 -12 Td
(pocket costs and expenses incurred by the Parties in connection with any such inspection) Tj
0 -12 Td
(or audit, unless the audit shows an undisputed over- payment for that audited period in) Tj
0 -12 Td
(excess of [***] of the amounts properly determined, in which case, Valeant shall reimburse) Tj
0 -12 Td
(Dova for its audit fees and reasonable out-of-pocket expenses in connection with said) Tj
0 -12 Td
(audit, which reimbursement shall be due and payable within [***] of receiving appropriate) Tj
0 -12 Td
(invoices and other support for such audit-related costs.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 8  INTELLECTUAL PROPERTY) Tj
0 -12 Td
() Tj
0 -12 Td
(8.1 Ownership of Intellectual Property.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(8.1.1 Valeant Property. Dova acknowledges that Valeant owns or is licensed to use certain) Tj
0 -12 Td
(Know-How relating to the proprietary sales and marketing information, methods and plans) Tj
0 -12 Td
(that has been independently developed or licensed by Valeant \(such Know-How, the "Valeant) Tj
0 -12 Td
(Property"\). The Parties agree that any improvement, enhancement or modification made,) Tj
0 -12 Td
(discovered, conceived, or reduced to practice by Valeant to any Valeant Property in) Tj
0 -12 Td
(performing its activities pursuant to this Agreement which is not primarily related to the) Tj
0 -12 Td
(Product, or which is not otherwise derived from the Confidential Information of Dova,) Tj
0 -12 Td
(shall be deemed Valeant Property. [***], Valeant hereby grants to Dova a fully paid-up,) Tj
0 -12 Td
(royalty free, non-transferable, non- exclusive license \(with a limited right to sub-) Tj
0 -12 Td
(license to its Affiliates\) to any Valeant Property that appears on, embodied on or) Tj
0 -12 Td
(contained in the Product materials or Product Labeling solely for use in connection with) Tj
0 -12 Td
(Dova's promotion or other commercialization of the Product in the Territory.) Tj
0 -12 Td
() Tj
0 -12 Td
(8.1.2 Dova Property. Subject to the terms of Section 8.1.1, Dova shall have and retain) Tj
0 -12 Td
ET
endstream
endobj
72 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 71 0 R >>
endobj
73 0 obj
<< /Length 4821 >>
stream
BT
/F1 10 Tf
72 720 Td
(sole and exclusive right, title and interest in and to all inventions, developments,) Tj
0 -12 Td
(discoveries, writings, trade secrets, Know-How, methods, practices, procedures, designs,) Tj
0 -12 Td
(improvements and other technology, whether or not patentable or copyrightable, and any) Tj
0 -12 Td
(patent applications, patents, or copyrights based thereon \(collectively, "Intellectual) Tj
0 -12 Td
(Property"\) relating to the Product that are \(i\) owned or controlled by Dova as of the) Tj
0 -12 Td
(Effective Date, \(ii\) made, discovered, conceived, reduced to practice or generated by Dova) Tj
0 -12 Td
(\(or its employees or representatives\) during the Term, or \(iii\) made, discovered,) Tj
0 -12 Td
(conceived, reduced to practice or generated by Valeant \(or its employees or) Tj
0 -12 Td
(representatives\) in performing its activities pursuant to this Agreement to the extent) Tj
0 -12 Td
(primarily related to the Product or which is otherwise derived from the Confidential) Tj
0 -12 Td
(Information of Dova \("Inventions"\). Valeant agrees to assign, and hereby does assign, to) Tj
0 -12 Td
(Dova \(and shall cause its Affiliates and its and their respective employees and other) Tj
0 -12 Td
(representatives to assign to Dova\) any and all right, title and interest that Valeant \(or) Tj
0 -12 Td
(any such Affiliates, employees or other representatives\) may have in or to any Invention.) Tj
0 -12 Td
(For clarity, any and all Inventions and any information contained therein or related) Tj
0 -12 Td
(thereto shall constitute Confidential Information of Dova.) Tj
0 -12 Td
() Tj
0 -12 Td
(8.2 Title to Trademarks and Copyrights. The ownership, and all goodwill from the use, of) Tj
0 -12 Td
(any Dova Trademarks and Copyrights shall at all times vest in and inure to the benefit of) Tj
0 -12 Td
(Dova, and Valeant shall assign, and hereby does assign, any rights it may have in the) Tj
0 -12 Td
(foregoing to Dova.) Tj
0 -12 Td
() Tj
0 -12 Td
(8.3 Protection of Trademarks and Copyrights. As between the Parties, Dova shall have the) Tj
0 -12 Td
(sole right \(but not the obligation\), as determined by Dova in its sole discretion, to \(i\)) Tj
0 -12 Td
(maintain the Dova Trademarks and Copyrights and/or \(ii\) protect, enforce and defend the) Tj
0 -12 Td
(Dova Trademarks and Copyrights. Valeant shall give notice to Dova of any infringement of,) Tj
0 -12 Td
(or challenge to, the validity or enforceability of the Dova Trademarks and Copyrights) Tj
0 -12 Td
(promptly after learning of such infringement or challenge. If Dova institutes an action) Tj
0 -12 Td
(against Third Party infringers or takes action to defend the Dova Trademarks and) Tj
0 -12 Td
(Copyrights, Valeant shall reasonably cooperate with Dova, at Dova's cost and expense. Any) Tj
0 -12 Td
(recovery obtained by Dova as a result of such proceeding or other actions, whether) Tj
0 -12 Td
(obtained by settlement or otherwise, shall be retained by Dova. Valeant shall not have any) Tj
0 -12 Td
(right to institute any action to defend or enforce the Dova Trademarks and Copyrights.) Tj
0 -12 Td
() Tj
0 -12 Td
(8.4 Disclosure of Know-How. For clarity, the Parties hereby agree and acknowledge that to) Tj
0 -12 Td
(the extent that either Party hereto has disclosed, or in the future discloses, to the) Tj
0 -12 Td
(other Party any Know-How or other intellectual property of such Party or its Affiliates) Tj
0 -12 Td
(pursuant to this Agreement, the other Party shall not acquire any ownership rights in such) Tj
0 -12 Td
(Know-How or other intellectual property by virtue of this Agreement or otherwise, and as) Tj
0 -12 Td
(between the Parties, all ownership rights therein shall remain with the disclosing Party) Tj
0 -12 Td
(\(or its Affiliate\).) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 9  CONFIDENTIALITY) Tj
0 -12 Td
() Tj
0 -12 Td
(9.1 Confidential Information.) Tj
0 -12 Td
() Tj
0 -12 Td
(9.1.1 Confidentiality and Non-Use. Each Party agrees that, during the Term and for a) Tj
0 -12 Td
(period of [***] thereafter, it shall keep confidential and shall not publish or otherwise) Tj
0 -12 Td
(disclose and shall not use for any purpose other than as provided for in this Agreement) Tj
0 -12 Td
(\(which includes the exercise of its rights or performance of any obligations hereunder\)) Tj
0 -12 Td
(any Confidential Information furnished to it by or on behalf of the other Party pursuant) Tj
0 -12 Td
(to this Agreement, except to the extent expressly authorized by this Agreement or) Tj
0 -12 Td
(otherwise agreed in writing by the Parties. Without limiting the foregoing, each Party) Tj
0 -12 Td
(will use at least the same standard of care as it uses to protect its own Confidential) Tj
0 -12 Td
(Information to ensure that its employees, agents, consultants and contractors do not) Tj
0 -12 Td
ET
endstream
endobj
74 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 73 0 R >>
endobj
75 0 obj
<< /Length 3886 >>
stream
BT
/F1 10 Tf
72 720 Td
(disclose or make any unauthorized use of such Confidential Information. Each Party will) Tj
0 -12 Td
(promptly notify the other upon discovery of any unauthorized use or disclosure of the) Tj
0 -12 Td
(other's Confidential Information. Any and all information and materials disclosed by a) Tj
0 -12 Td
(Party pursuant to the Confidentiality Agreement between the Parties dated [***] \(the) Tj
0 -12 Td
("Confidentiality Agreement"\) shall be deemed Confidential Information disclosed pursuant) Tj
0 -12 Td
(to this Agreement. The foregoing confidentiality and non-use obligations shall not apply) Tj
0 -12 Td
(to any portion of the other Party's Confidential Information that the receiving Party can) Tj
0 -12 Td
(demonstrate by competent tangible evidence:) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) was already known to the receiving Party or its Affiliate, other than under an) Tj
0 -12 Td
(obligation of confidentiality, at the time of disclosure by the other Party;) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) was generally available to the public or otherwise part of the public domain at the) Tj
0 -12 Td
(time of its disclosure to the receiving Party;) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) became generally available to the public or otherwise part of the public domain after) Tj
0 -12 Td
(its disclosure and other than through any act or omission of the receiving Party or its) Tj
0 -12 Td
(Affiliates in breach of this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(\(d\) was disclosed to the receiving Party or its Affiliate by a Third Party who has a legal) Tj
0 -12 Td
(right to make such disclosure and who did not obtain such information directly or) Tj
0 -12 Td
(indirectly from the other Party \(or its Affiliate\); or) Tj
0 -12 Td
() Tj
0 -12 Td
(\(e\) was independently discovered or developed by the receiving Party or its Affiliate) Tj
0 -12 Td
(without access to or aid, application, use of the other Party's Confidential Information,) Tj
0 -12 Td
(as evidenced by a contemporaneous writing.) Tj
0 -12 Td
() Tj
0 -12 Td
(9.1.2 Authorized Disclosure. Notwithstanding the obligations set forth in Section 9.1.1, a) Tj
0 -12 Td
(Party may disclose the other Party's Confidential Information and the terms of this) Tj
0 -12 Td
(Agreement to the extent:) Tj
0 -12 Td
() Tj
0 -12 Td
(\(a\) such disclosure is reasonably necessary \(x\) to comply with the requirements of) Tj
0 -12 Td
(Governmental Authorities; or \(y\) for the prosecuting or defending litigation as) Tj
0 -12 Td
(contemplated by this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(\(b\) such disclosure is reasonably necessary to its Affiliates, employees, agents,) Tj
0 -12 Td
(consultants and contractors on a need-to-know basis for the sole purpose of performing its) Tj
0 -12 Td
(obligations or exercising its rights under this Agreement; provided that in each case, the) Tj
0 -12 Td
(disclosees are bound by obligations of confidentiality and non-use consistent with those) Tj
0 -12 Td
(contained in this Agreement and the disclosing Party shall be liable for any failures of) Tj
0 -12 Td
(such disclosees to abide by such obligations of confidentiality and non-use; or) Tj
0 -12 Td
() Tj
0 -12 Td
(\(c\) such disclosure is reasonably necessary to comply with Applicable Laws, including) Tj
0 -12 Td
(regulations promulgated by applicable securities exchanges, court order, administrative) Tj
0 -12 Td
(subpoena or order.) Tj
0 -12 Td
() Tj
0 -12 Td
(Notwithstanding the foregoing, in the event a Party is required to make a disclosure of) Tj
0 -12 Td
(the other Party's Confidential Information pursuant to Section 9.1.2\(a\) or 9.1.2\(c\), such) Tj
0 -12 Td
(Party shall, if permitted, promptly notify the other Party of such required disclosure and) Tj
0 -12 Td
ET
endstream
endobj
76 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 75 0 R >>
endobj
77 0 obj
<< /Length 3983 >>
stream
BT
/F1 10 Tf
72 720 Td
(shall use reasonable efforts to assist the other Party \(at the other Party's cost\) in) Tj
0 -12 Td
(obtaining, a protective order preventing or limiting the required disclosure.) Tj
0 -12 Td
() Tj
0 -12 Td
(9.2 Public Announcements. The press release announcing the execution of this Agreement) Tj
0 -12 Td
(shall be issued in the form attached hereto as Exhibit A. No public announcement or) Tj
0 -12 Td
(statements \(including presentations to investor meetings and customer updates\) concerning) Tj
0 -12 Td
(the existence of or terms of this Agreement or incorporating the marks of the other Party) Tj
0 -12 Td
(or their respective Affiliates shall be made, either directly or indirectly, by either) Tj
0 -12 Td
(Party or a Party's Affiliates, without first obtaining the written approval of the other) Tj
0 -12 Td
(Party and agreement upon the nature, text and timing of such announcement or disclosure.) Tj
0 -12 Td
(Either Party shall have the right to make any such public announcement or other disclosure) Tj
0 -12 Td
(required by Applicable Law after such Party has provided to the other Party a copy of such) Tj
0 -12 Td
(announcement or disclosure and an opportunity to comment thereon and the disclosing Party) Tj
0 -12 Td
(shall reasonably consider the other Party's comments. Each Party agrees that it shall) Tj
0 -12 Td
(cooperate fully with the other with respect to all disclosures regarding this Agreement to) Tj
0 -12 Td
(the Securities Exchange Commission and any other Governmental Authorities, including) Tj
0 -12 Td
(requests for confidential treatment of proprietary information of either Party included in) Tj
0 -12 Td
(any such disclosure. Once any written statement is approved for disclosure by the Parties) Tj
0 -12 Td
(or information is otherwise made public in accordance with this Section 9.2, either Party) Tj
0 -12 Td
(may make a subsequent public disclosure of the same contents of such statement in the same) Tj
0 -12 Td
(context as such statement without further approval of the other Party. Notwithstanding) Tj
0 -12 Td
(anything to the contrary contained herein, in no event shall either Party disclose any) Tj
0 -12 Td
(financial information of the other without the prior written consent of such other Party,) Tj
0 -12 Td
(unless such financial information already has been publicly disclosed by the Party owning) Tj
0 -12 Td
(the financial information or otherwise has been made part of the public domain by no) Tj
0 -12 Td
(breach of a Party of its obligations under this ARTICLE 9.) Tj
0 -12 Td
() Tj
0 -12 Td
(8) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 10  REPRESENTATIONS AND WARRANTIES; ADDITIONAL COVENANTS) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1 Representations and Warranties of Dova. Dova represents and warrants to Valeant as of) Tj
0 -12 Td
(the Effective Date that:) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.1 it is a corporation duly organized and validly existing under the laws of the state) Tj
0 -12 Td
(or other jurisdiction of its incorporation;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.2 the execution, delivery and performance of this Agreement by it has been duly) Tj
0 -12 Td
(authorized by all requisite corporate action;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.3 it has the power and authority to execute and deliver this Agreement and to perform) Tj
0 -12 Td
(its obligations hereunder;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.4 this Agreement constitutes a legal, valid and binding obligation enforceable) Tj
0 -12 Td
ET
endstream
endobj
78 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 77 0 R >>
endobj
79 0 obj
<< /Length 4608 >>
stream
BT
/F1 10 Tf
72 720 Td
(against it in accordance with its terms, subject to the effects of bankruptcy, insolvency) Tj
0 -12 Td
(or other laws of general application affecting the enforcement of creditor rights,) Tj
0 -12 Td
(judicial principles affecting the availability of specific performance and general) Tj
0 -12 Td
(principles of equity \(whether enforceability is considered a proceeding at law or equity\);) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.5 the execution, delivery and performance of this Agreement by Dova does not require) Tj
0 -12 Td
(the consent of any Person \(including under the Third Party Agreements\) or the) Tj
0 -12 Td
(authorization of \(by notice or otherwise\) any Governmental Authority including the FDA;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.6 there is no action, suit or proceeding pending or, to the knowledge of Dova,) Tj
0 -12 Td
(threatened, against Dova or any of its Affiliates, or to the knowledge of Dova, any Third) Tj
0 -12 Td
(Party acting on their behalf, which would be reasonably expected to impair, restrict or) Tj
0 -12 Td
(prohibit the ability of Dova or Valeant to perform its obligations and enjoy the benefits) Tj
0 -12 Td
(of this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.7 it is in compliance in all material respects with all Applicable Laws applicable to) Tj
0 -12 Td
(the subject matter of this Agreement, including its donations to, and interactions with,) Tj
0 -12 Td
(any 501\(c\)\(3\) charitable foundation that provides co-pay assistance to government-insured) Tj
0 -12 Td
(patients with respect to the Product have been in compliance with all Applicable Laws;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.8 it has the right to market and sell the Product in the Territory as contemplated) Tj
0 -12 Td
(herein and has all licenses, authorizations, permissions, consents or approvals from any) Tj
0 -12 Td
(applicable Governmental Authority including the FDA necessary to make, use, sell and offer) Tj
0 -12 Td
(to sell the Product in the Territory and all such licenses, authorizations, permissions,) Tj
0 -12 Td
(consents or approvals are in good standing;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.9 it has the exclusive right to promote the Product in the Territory to the Target) Tj
0 -12 Td
(Professionals in the Specialty and the rights granted by it to Valeant hereunder do not) Tj
0 -12 Td
(conflict with any rights granted by Dova to any Third Party;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.10 to the knowledge of Dova, all manufacturing, stability testing, labeling,) Tj
0 -12 Td
(packaging, storing, shipping and distribution operations conducted by or on behalf of Dova) Tj
0 -12 Td
(relating to the commercial supply of the Product have been conducted in compliance with) Tj
0 -12 Td
(Applicable Law and it has no knowledge of any information indicating that Dova would be) Tj
0 -12 Td
(unable to manufacture and supply \(or have manufactured and supplied\) the Product in) Tj
0 -12 Td
(sufficient quantities to meet the reasonable demands in the Territory;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.11 it has no knowledge of any information relating to the safety or efficacy of the) Tj
0 -12 Td
(Product or any communications with any Governmental Authority, which would reasonably be) Tj
0 -12 Td
(expected to materially impair, restrict, prohibit or affect Dova's ability to perform its) Tj
0 -12 Td
(obligations and enjoy the benefits of this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.12 it is not a party to any agreement or arrangement with any Third Party or under) Tj
0 -12 Td
(any obligation or restriction agreement \(including any outstanding order, judgment or) Tj
0 -12 Td
(decree of any court or administrative agency\) which in any way limits or conflicts with) Tj
0 -12 Td
(its ability to execute and deliver this Agreement and to fulfill any of its obligations) Tj
0 -12 Td
(under this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.13 each of the Third Party Agreements constitutes a valid and binding obligation of) Tj
0 -12 Td
(Dova or its Affiliate, as applicable, and is enforceable against Dova or its Affiliate, as) Tj
0 -12 Td
(applicable, and, to the knowledge of Dova, each of the Third Party Agreements constitutes) Tj
0 -12 Td
(a valid and binding obligation of the counterparty thereto and is enforceable against such) Tj
0 -12 Td
(counterparty, except in each case as may be limited by bankruptcy, insolvency, fraudulent) Tj
0 -12 Td
(transfer, moratorium, reorganization, preference or similar laws of general applicability) Tj
0 -12 Td
(relating to or affecting the rights of creditors generally and subject to general) Tj
0 -12 Td
ET
endstream
endobj
80 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 79 0 R >>
endobj
81 0 obj
<< /Length 4084 >>
stream
BT
/F1 10 Tf
72 720 Td
(principles of equity \(regardless of whether enforcement is sought in equity or at law\).) Tj
0 -12 Td
(Dova or its Affiliate, as applicable, and to the knowledge of Dova, the applicable) Tj
0 -12 Td
(counterparty thereto, are not in material breach of or default under either of the Third) Tj
0 -12 Td
(Party Agreements. The) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(counterparty to each of the Third Party Agreements has not exercised or, to the knowledge) Tj
0 -12 Td
(of Dova, threatened in writing to exercise any termination right with respect to the) Tj
0 -12 Td
(applicable Third Party Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.14 neither Dova nor any of its personnel \(i\) have been debarred under the 21 U.S.C.) Tj
0 -12 Td
(335a, \(ii\) are excluded, debarred, suspended, or otherwise ineligible to participate in) Tj
0 -12 Td
(the Federal health care programs or in Federal procurement or nonprocurement programs,) Tj
0 -12 Td
(\(iii\) are convicted of a criminal offense that falls within the ambit of the Federal) Tj
0 -12 Td
(statute providing for mandatory exclusion from participation in Federal health care) Tj
0 -12 Td
(programs but has not yet been excluded, debarred, suspended, or otherwise declared) Tj
0 -12 Td
(ineligible to participate in those programs, \(iv\) are listed on the HHS/OIG List of) Tj
0 -12 Td
(Excluded Individuals/Entities \(available through the Internet at http://oig.hhs.gov\) or) Tj
0 -12 Td
(\(v\) are listed on the General Services Administration's List of Parties Excluded from) Tj
0 -12 Td
(Federal Programs \(available through the Internet at hhtp://epls.arnet.gov\). If, during the) Tj
0 -12 Td
(Term, Dova or any of its personnel becomes or is the subject of a proceeding that could) Tj
0 -12 Td
(lead to, as applicable, \(i\) debarment under 21 U.S.C.   335a, \(ii\) exclusion, debarment,) Tj
0 -12 Td
(suspension or ineligibility to participate in the Federal health care programs or in) Tj
0 -12 Td
(Federal procurement or nonprocurement programs, \(iii\) convicted \(or conviction\) of a) Tj
0 -12 Td
(criminal offense that falls within the ambit of the Federal statute providing for) Tj
0 -12 Td
(mandatory exclusion from participation in Federal healthcare programs, \(iv\) listed \(or) Tj
0 -12 Td
(listing\) on the HHS/OIG List of Excluded Individuals/Entities \(available through the) Tj
0 -12 Td
(Internet at http://oig.hhs.gov\) or \(v\) listed \(or listing\) on the General Services) Tj
0 -12 Td
(Administration's List of Parties Excluded from Federal Programs \(available through the) Tj
0 -12 Td
(Internet at hhtp://epls.arnet.gov\), Dova shall immediately notify Valeant, and Valeant) Tj
0 -12 Td
(shall have the option to prohibit such Person from performing work relating to this) Tj
0 -12 Td
(Agreement or the Product; and) Tj
0 -12 Td
() Tj
0 -12 Td
(10.1.15 any patient assistance program used in connection with the Product used in) Tj
0 -12 Td
(connection with the Product have each been operated in accordance with Applicable Law.) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2 Representations and Warranties of Valeant. Valeant represents and warrants to Dova as) Tj
0 -12 Td
(of the Effective Date that:) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.1 it is a limited liability company duly organized and validly existing under the) Tj
0 -12 Td
(laws of the state or other jurisdiction of its incorporation;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.2 the execution, delivery and performance of this Agreement by it has been duly) Tj
0 -12 Td
(authorized by all requisite corporate action;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.3 it has the power and authority to execute and deliver this Agreement and to perform) Tj
0 -12 Td
(its obligations hereunder;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.4 this Agreement constitutes a legal, valid and binding obligation enforceable) Tj
0 -12 Td
(against it in accordance with its terms, subject to the effects of bankruptcy, insolvency) Tj
0 -12 Td
ET
endstream
endobj
82 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 81 0 R >>
endobj
83 0 obj
<< /Length 4058 >>
stream
BT
/F1 10 Tf
72 720 Td
(or other laws of general application affecting the enforcement of creditor rights,) Tj
0 -12 Td
(judicial principles affecting the availability of specific performance and general) Tj
0 -12 Td
(principles of equity \(whether enforceability is considered a proceeding at law or equity\);) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.5 the execution, delivery and performance of this Agreement by Valeant does not) Tj
0 -12 Td
(require the consent of any Person or the authorization of \(by notice or otherwise\) any) Tj
0 -12 Td
(Governmental Authority or the FDA;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.6 there is no action, suit or proceeding pending or, to the knowledge of Valeant,) Tj
0 -12 Td
(threatened, against Valeant or any of its Affiliates, or to the knowledge of Valeant, any) Tj
0 -12 Td
(Third Party acting on their behalf, which would be reasonably expected to impair, restrict) Tj
0 -12 Td
(or prohibit the ability of Dova or Valeant to perform its obligations and enjoy the) Tj
0 -12 Td
(benefits of this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.7 it is in compliance in all material respects with all Applicable Laws applicable to) Tj
0 -12 Td
(the subject matter of this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.8 it has the right to market and sell the Designated Product in the Territory as) Tj
0 -12 Td
(contemplated herein and has all licenses, authorizations, permissions, consents or) Tj
0 -12 Td
(approvals from any applicable Governmental Authority including the FDA necessary to make,) Tj
0 -12 Td
(use, sell and offer to sell the Product in the Territory and all such licenses,) Tj
0 -12 Td
(authorizations, permissions, consents or approvals are in good standing;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.9 it is not a party to any agreement or arrangement with any Third Party or under any) Tj
0 -12 Td
(obligation or restriction agreement \(including any outstanding order, judgment or decree) Tj
0 -12 Td
(of any court or administrative agency\) which in any way limits or conflicts with its) Tj
0 -12 Td
(ability to execute and deliver this Agreement and to fulfill any of its obligations under) Tj
0 -12 Td
(this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.10 it has no knowledge of any information relating to any communications with any) Tj
0 -12 Td
(Governmental Authority, which would reasonably be expected to materially impair, restrict,) Tj
0 -12 Td
(prohibit or affect Valeant's ability to perform its obligations and enjoy the benefits of) Tj
0 -12 Td
(this Agreement;) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.11 neither Valeant nor any of its personnel \(i\) have been debarred under the 21) Tj
0 -12 Td
(U.S.C.   335a, \(ii\) are) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(excluded, debarred, suspended, or otherwise ineligible to participate in the Federal) Tj
0 -12 Td
(health care programs or in Federal procurement or nonprocurement programs, \(iii\) are) Tj
0 -12 Td
(convicted of a criminal offense that falls within the ambit of the Federal statute) Tj
0 -12 Td
(providing for mandatory exclusion from participation in Federal health care programs but) Tj
0 -12 Td
(has not yet been excluded, debarred, suspended, or otherwise declared ineligible to) Tj
0 -12 Td
(participate in those programs, \(iv\) are listed on the HHS/OIG List of Excluded) Tj
0 -12 Td
(Individuals/Entities \(available through the Internet at http://oig.hhs.gov\) or \(v\) are) Tj
0 -12 Td
(listed on the General Services Administration's List of Parties Excluded from Federal) Tj
0 -12 Td
(Programs \(available through the Internet at hhtp://epls.arnet.gov\). If, during the Term,) Tj
0 -12 Td
(Valeant or any of its personnel become or are the subject of a proceeding that could lead) Tj
0 -12 Td
(to, as applicable, \(i\) debarment under 21 U.S.C.   335a, \(ii\) exclusion, debarment,) Tj
0 -12 Td
(suspension or ineligibility to participate in the Federal health care programs or in) Tj
0 -12 Td
ET
endstream
endobj
84 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 83 0 R >>
endobj
85 0 obj
<< /Length 4719 >>
stream
BT
/F1 10 Tf
72 720 Td
(Federal procurement or nonprocurement programs, \(iii\) convicted \(or conviction\) of a) Tj
0 -12 Td
(criminal offense that falls within the ambit of the Federal statute providing for) Tj
0 -12 Td
(mandatory exclusion from participation in Federal healthcare programs, \(iv\) listed \(or) Tj
0 -12 Td
(listing\) on the HHS/OIG List of Excluded Individuals/Entities \(available through the) Tj
0 -12 Td
(Internet at http://oig.hhs.gov\) or \(v\) listed \(or listing\) on the General Services) Tj
0 -12 Td
(Administration's List of Parties Excluded from Federal Programs \(available through the) Tj
0 -12 Td
(Internet at hhtp://epls.arnet.gov\), Valeant shall immediately notify Dova, and Dova shall) Tj
0 -12 Td
(have the option to prohibit such Person from performing work under this Agreement; and) Tj
0 -12 Td
() Tj
0 -12 Td
(10.2.12 all Field Force Personnel that are engaged in Detailing are, and will be, licensed) Tj
0 -12 Td
(to the extent required and in accordance with all Applicable Laws.) Tj
0 -12 Td
() Tj
0 -12 Td
(10.3 Disclaimer of Warranty. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN THIS) Tj
0 -12 Td
(AGREEMENT, DOVA \(AND ITS AFFILIATES\) AND VALEANT \(AND ITS AFFILIATES\) MAKE NO) Tj
0 -12 Td
(REPRESENTATIONS AND NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF) Tj
0 -12 Td
(LAW, BY STATUTE OR OTHERWISE, AND DOVA \(AND ITS AFFILIATES\) AND VALEANT \(AND ITS) Tj
0 -12 Td
(AFFILIATES\) EACH SPECIFICALLY DISCLAIM ANY OTHER REPRESENTATIONS AND WARRANTIES, WHETHER) Tj
0 -12 Td
(WRITTEN OR ORAL, EXPRESS, STATUTORY OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,) Tj
0 -12 Td
(MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE) Tj
0 -12 Td
(VALIDITY OF ANY INTELLECTUAL PROPERTY OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY) Tj
0 -12 Td
(RIGHTS OF THIRD PARTIES.) Tj
0 -12 Td
() Tj
0 -12 Td
(10.4 Additional Covenants.) Tj
0 -12 Td
() Tj
0 -12 Td
(10.4.1 Initial Orders to Non-Retail Institutions. For initial orders of Product from Dova) Tj
0 -12 Td
(\(or its Affiliates or its Intermediaries\) to the Non-Retail Institutions, Dova shall not) Tj
0 -12 Td
(engage in any "channel stuffing" or any similar program, activity or other action) Tj
0 -12 Td
(\(including any rebate, discount, chargeback or refund policy or practice\) that in each) Tj
0 -12 Td
(case is intended by Dova to result in purchases by the Non-Retail Institutions that are) Tj
0 -12 Td
(materially in excess of purchases in the ordinary course of business or that is intended) Tj
0 -12 Td
(to materially adversely impact Valeant's promotion fee pursuant to this Agreement;) Tj
0 -12 Td
(provided, however, this Section10.4.1 shall not be applicable to any activity or action) Tj
0 -12 Td
(taken by Dova which applies to all or substantially all customers for the Product, or any) Tj
0 -12 Td
(activity or action taken by Dova in good faith and consistent with customary sales and) Tj
0 -12 Td
(marketing practices in the pharmaceutical industry.) Tj
0 -12 Td
() Tj
0 -12 Td
(10.4.2 Third Party Agreements. Dova shall remain solely responsible for the payment of) Tj
0 -12 Td
(royalty, milestone and other payment obligations, if any, due to Third Parties on \(or in) Tj
0 -12 Td
(connection with\) the sale of Product in the Territory, including under the Third Party) Tj
0 -12 Td
(Agreements.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 11  INDEMNIFICATION; LIMITATIONS ON LIABILITY) Tj
0 -12 Td
() Tj
0 -12 Td
(11.1 Indemnification by Dova. Dova shall defend, indemnify and hold harmless Valeant and) Tj
0 -12 Td
(its Affiliates and its and their respective officers, directors, employees, agents,) Tj
0 -12 Td
(representatives, successors and assigns from and against all Claims, and all associated) Tj
0 -12 Td
(Losses, to the extent incurred or suffered by any of them to the extent resulting from or) Tj
0 -12 Td
(arising out of \(a\) any misrepresentation or breach of any representations, warranties,) Tj
0 -12 Td
(agreements or covenants of Dova under this Agreement, \(b\) the negligence, willful) Tj
0 -12 Td
(misconduct or violation of Applicable Laws by Dova \(or any of its Affiliates or its or) Tj
0 -12 Td
(their respective officers, directors, employees, agents or representatives\), \(c\) the) Tj
0 -12 Td
(infringement of the intellectual property rights of any Third Party in connection with the) Tj
0 -12 Td
(Product, including from the use of the Dova Trademarks and Copyrights on Product Labeling) Tj
0 -12 Td
(or Product Materials in accordance with this Agreement, \(d\) death or personal injury to) Tj
0 -12 Td
(any person related to use of the Product, or \(e\) the failure to comply with Applicable) Tj
0 -12 Td
ET
endstream
endobj
86 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 85 0 R >>
endobj
87 0 obj
<< /Length 4613 >>
stream
BT
/F1 10 Tf
72 720 Td
(Laws by the Specialty Pharmacies, applicable reimbursement hub or any 501\(c\)\(3\) charitable) Tj
0 -12 Td
(foundation used in connection with the Product; except in each case to the extent any such) Tj
0 -12 Td
(Claims, and all associated Losses, are caused by an item for which Valeant is obligated to) Tj
0 -12 Td
(indemnify Dova pursuant to Section 11.2.) Tj
0 -12 Td
() Tj
0 -12 Td
(11.2 Indemnification by Valeant. Valeant shall defend, indemnify and hold harmless Dova) Tj
0 -12 Td
(and its Affiliates and its and their respective officers, directors, employees, agents,) Tj
0 -12 Td
(representatives, successors and assigns from and against all Claims and all associated) Tj
0 -12 Td
(Losses, to the extent incurred or suffered by any of them to the extent resulting from or) Tj
0 -12 Td
(arising out of \(a\) any misrepresentation or breach of any representations, warranties,) Tj
0 -12 Td
(agreements or covenants of Valeant under this Agreement, or \(b\) the negligence, willful) Tj
0 -12 Td
(misconduct, or violation of Applicable Laws by Valeant \(or any of its Affiliates or its) Tj
0 -12 Td
(and their respective) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(officers, directors, employees, agents or representatives\); except in each case to the) Tj
0 -12 Td
(extent any such Claims, and all associated Losses, are caused by an item for which Dova is) Tj
0 -12 Td
(obligated to indemnify Valeant pursuant to Section 11.1.) Tj
0 -12 Td
() Tj
0 -12 Td
(11.3 Indemnification Procedures. The Party seeking indemnification under Section 11.1 or) Tj
0 -12 Td
(11.2, as applicable \(the "Indemnified Party"\) shall give prompt notice to the Party) Tj
0 -12 Td
(against whom indemnity is sought \(the "Indemnifying Party"\) of the assertion or) Tj
0 -12 Td
(commencement of any Claim in respect of which indemnity may be sought under Section 11.1) Tj
0 -12 Td
(or 11.2, as applicable, and will provide the Indemnifying Party such information with) Tj
0 -12 Td
(respect thereto that the Indemnifying Party may reasonably request. The failure to give) Tj
0 -12 Td
(such notice will relieve the Indemnifying Party of any liability hereunder only to the) Tj
0 -12 Td
(extent that the Indemnifying Party has suffered actual prejudice thereby. The Indemnifying) Tj
0 -12 Td
(Party shall assume and control the defense and settlement of any such action, suit or) Tj
0 -12 Td
(proceeding at its own expense. The Indemnified Party shall, if requested by the) Tj
0 -12 Td
(Indemnifying Party, cooperate in all reasonable respects in such defense, at the) Tj
0 -12 Td
(Indemnifying Party's expense. The Indemnified Party will be entitled at its own expense to) Tj
0 -12 Td
(participate in such defense and to employ separate counsel for such purpose. For so long) Tj
0 -12 Td
(as the Indemnifying Party is diligently defending any proceeding pursuant to this Section) Tj
0 -12 Td
(11.3, the Indemnifying Party will not be liable under Section 11.1 or 11.2, as applicable,) Tj
0 -12 Td
(for any settlement effected without its consent. No Party shall enter into any compromise) Tj
0 -12 Td
(or settlement which commits the other Party to take, or to forbear to take, any action) Tj
0 -12 Td
(without the other Party's prior written consent \(and unless such compromise or settlement) Tj
0 -12 Td
(includes no payments by the Indemnified Party, an unconditional release of, and no) Tj
0 -12 Td
(admission of liability by, the Indemnified Party from all liability in respect of such) Tj
0 -12 Td
(Claim\).) Tj
0 -12 Td
() Tj
0 -12 Td
(11.4 Limitation of Liability. NOTWITHSTANDING ANY OTHER PROVISION CONTAINED HEREIN \(OTHER) Tj
0 -12 Td
(THAN AS SET FORTH IN THE SECOND SENTENCE OF THIS SECTION 11.4\), IN NO EVENT SHALL DOVA \(OR) Tj
0 -12 Td
(ITS AFFILIATES\) OR VALEANT \(OR ITS AFFILIATES\) BE LIABLE TO THE OTHER OR ANY OF THE OTHER) Tj
0 -12 Td
(PARTY'S AFFILIATES FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR) Tj
0 -12 Td
(EXEMPLARY DAMAGES \(INCLUDING LOST PROFITS\) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS) Tj
0 -12 Td
(AFFILIATES THAT ARISE OUT OF OR RELATE TO THIS AGREEMENT OR IN CONNECTION WITH A BREACH OR) Tj
0 -12 Td
(ALLEGED BREACH OF THIS AGREEMENT, WHETHER IN CONTRACT, TORT, STRICT LIABILITY OR) Tj
0 -12 Td
(OTHERWISE, AND REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. THE FOREGOING) Tj
0 -12 Td
(SENTENCE SHALL NOT LIMIT \(1\) THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY) Tj
0 -12 Td
ET
endstream
endobj
88 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 87 0 R >>
endobj
89 0 obj
<< /Length 3996 >>
stream
BT
/F1 10 Tf
72 720 Td
(FROM AND AGAINST THIRD PARTY CLAIMS UNDER SECTION 11.1 OR 11.2, AS APPLICABLE, OR \(2\)) Tj
0 -12 Td
(DAMAGES AVAILABLE FOR A PARTY'S BREACH OF THE CONFIDENTIALITY AND NON-USE OBLIGATIONS IN) Tj
0 -12 Td
(ARTICLE 9.) Tj
0 -12 Td
() Tj
0 -12 Td
(11.5 Insurance. Each Party acknowledges and agrees that during the Term, it shall) Tj
0 -12 Td
(maintain, through purchase or self- insurance, adequate insurance, including products) Tj
0 -12 Td
(liability coverage and comprehensive general liability insurance, adequate to cover its) Tj
0 -12 Td
(obligations under this Agreement and which are consistent with normal business practices) Tj
0 -12 Td
(of prudent companies similarly situated. Each Party shall provide reasonable written proof) Tj
0 -12 Td
(of the existence of such insurance to the other Party upon request. Dova does not and will) Tj
0 -12 Td
(not maintain or procure any worker's compensation, healthcare, or other insurance for or) Tj
0 -12 Td
(on behalf of any Field Force Personnel, all of which shall be Valeant's sole) Tj
0 -12 Td
(responsibility. For clarity, the insurance requirements of this Section 11.5 shall not be) Tj
0 -12 Td
(construed to create a limit of either Party's liability with respect to its) Tj
0 -12 Td
(indemnification obligations under this ARTICLE 11.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 12  TERM AND TERMINATION) Tj
0 -12 Td
() Tj
0 -12 Td
(12.1 Term. This Agreement shall become effective as of the Effective Date and, unless) Tj
0 -12 Td
(earlier terminated as provided in this ARTICLE 12, shall extend until the four \(4\) year) Tj
0 -12 Td
(anniversary of the Effective Date \(the "Term"\).) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2 Early Termination for Cause. A Party shall have the right to terminate this Agreement) Tj
0 -12 Td
(before the end of the Term as follows:) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.1 by a Party upon written notice to the other Party in the event of a material breach) Tj
0 -12 Td
(of this Agreement by such other Party where such breach is not cured \(if able to be cured\)) Tj
0 -12 Td
(within [***] following such other Party's receipt of written notice of such breach \(and) Tj
0 -12 Td
(any such termination shall become effective at the end of such [***] period unless the) Tj
0 -12 Td
(breaching Party has cured such breach prior to the expiration of such [***] period\);) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.2 by Dova if the Quarterly Average Sales Force Size is less than [***] Sales) Tj
0 -12 Td
(Representatives for [***] consecutive Calendar Quarters, upon [***] written notice to) Tj
0 -12 Td
(Valeant, such notice to be delivered no less than [***] following the end of the last) Tj
0 -12 Td
(consecutive Calendar Quarter in which the Quarterly Average Sales Force Size is less than) Tj
0 -12 Td
([***] Sales Representatives;) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.3 by Dova if the aggregate actual number of Details for the Product made by the Sales) Tj
0 -12 Td
(Representatives for a Calendar Quarter is less than the Quarterly Minimum Details for) Tj
0 -12 Td
([***] consecutive Calendar Quarters, upon [***] written notice to Valeant, such notice to) Tj
0 -12 Td
(be delivered no less than [***] following the end of the last consecutive Calendar Quarter) Tj
0 -12 Td
(in which the actual Details are less than the Quarterly Minimum Details;) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.4 by either Party upon [***] written notice to the other Party following the) Tj
0 -12 Td
(withdrawal of the Product from the market by Dova \(or the decision by Dova to withdraw the) Tj
0 -12 Td
(Product from the market\) due to \(i\) any decision, judgment, ruling or other requirement of) Tj
0 -12 Td
(the FDA, or \(ii\) material safety concern;) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.5 by Dova upon [***] written notice to Valeant upon the cessation of marketing by) Tj
0 -12 Td
ET
endstream
endobj
90 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 89 0 R >>
endobj
91 0 obj
<< /Length 4771 >>
stream
BT
/F1 10 Tf
72 720 Td
(Valeant of the Designated Product \(or the Alternate Product in accordance with Section) Tj
0 -12 Td
(4.2.1\(c\), as the case may be\);) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.6 by Dova pursuant to Section 4.2.1\(c\); and) Tj
0 -12 Td
() Tj
0 -12 Td
(12.2.7 by a Party immediately upon written notice to the other Party upon the filing or) Tj
0 -12 Td
(institution of bankruptcy, reorganization, liquidation or receivership proceedings with) Tj
0 -12 Td
(respect to such other Party, or upon an assignment of a substantial portion of the assets) Tj
0 -12 Td
(for the benefit of creditors by such other Party, or in the event a receiver or custodian) Tj
0 -12 Td
(is appointed for such other Party's business or a substantial portion of such other) Tj
0 -12 Td
(Party's business is subject to attachment or similar process; provided, however, in the) Tj
0 -12 Td
(case of any involuntary bankruptcy proceeding such right to terminate shall only become) Tj
0 -12 Td
(effective if the party consents to the involuntary bankruptcy or such proceeding is not) Tj
0 -12 Td
(dismissed within [***] after the filing thereof.) Tj
0 -12 Td
() Tj
0 -12 Td
(12.3 Other Early Termination.) Tj
0 -12 Td
() Tj
0 -12 Td
(12.3.1 Either Party shall have the right to terminate this Agreement before the end of the) Tj
0 -12 Td
(Term for its convenience upon [***] written notice to the other Party \(and any such) Tj
0 -12 Td
(termination shall become effective at the end of such [***]\); [***].) Tj
0 -12 Td
() Tj
0 -12 Td
(12.3.2 Either Party shall have the right to terminate this Agreement before the end of the) Tj
0 -12 Td
(Term upon [***] written notice to the other Party delivered within [***] after the) Tj
0 -12 Td
(conclusion of any Calendar Quarter, beginning with the Calendar Quarter commencing on) Tj
0 -12 Td
([***], in which the Net Sales in such Calendar Quarter are less [***] \(and any such) Tj
0 -12 Td
(termination shall become effective at the end of such [***] period\); provided that Valeant) Tj
0 -12 Td
(shall not have the right to terminate this Agreement pursuant to this Section 12.3.2 with) Tj
0 -12 Td
(respect to any Calendar Quarter for which the Quarterly Average Sales Force Size is less) Tj
0 -12 Td
(than [***] Sales Representatives.) Tj
0 -12 Td
() Tj
0 -12 Td
(12.4 Effects of Termination. Upon the expiration or effective date of termination of this) Tj
0 -12 Td
(Agreement, \(i\) all rights and obligations of both Parties hereunder shall immediately) Tj
0 -12 Td
(terminate, subject to any survival as set forth in Sections 12.5 and 12.6, \(ii\) Valeant,) Tj
0 -12 Td
(at Dova's direction, shall immediately return to Dova or destroy in accordance with all) Tj
0 -12 Td
(Applicable Laws all Product Materials, reports and other tangible items provided by or on) Tj
0 -12 Td
(behalf of Dova to Valeant or otherwise developed or obtained by Valeant pursuant to the) Tj
0 -12 Td
(terms of this Agreement \(other than Valeant Property\) \(and at the request of Dova, Valeant) Tj
0 -12 Td
(shall certify destruction of such materials if Valeant does not to return such materials) Tj
0 -12 Td
(to Dova\), \(iii\) Valeant shall immediately cease all Valeant Activities with respect to the) Tj
0 -12 Td
(Product, and \(iv\) each of Dova and Valeant shall, at the other Party's direction, either) Tj
0 -12 Td
(return to such other Party or destroy all Confidential Information of such other Party.) Tj
0 -12 Td
(Notwithstanding the foregoing, each Party may retain archival copies of any Confidential) Tj
0 -12 Td
(Information to the extent required by law, regulation or professional standards or copies) Tj
0 -12 Td
(of Confidential Information created pursuant to the automatic backing-up of electronic) Tj
0 -12 Td
(files where the delivery or destruction of such files would cause undue hardship to the) Tj
0 -12 Td
(receiving Party, so long as any such archival or electronic file back-up copies are) Tj
0 -12 Td
(accessible only to its legal or IT personnel, provided that such Confidential Information) Tj
0 -12 Td
(will continue to be subject to the terms of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(12.5 Tail Period. Solely in the event that Dova has terminated this Agreement pursuant to) Tj
0 -12 Td
(Section 12.3.1 and notwithstanding anything else herein, in consideration of the promotion) Tj
0 -12 Td
(services performed by Valeant during the Term, with respect to the Tail Period, Dova shall) Tj
0 -12 Td
(make payments to Valeant in an amount equal to [***] of the amounts that would have been) Tj
0 -12 Td
(payable by Dova to Valeant with respect to such Tail Period pursuant to Section 6.1 had) Tj
0 -12 Td
(the Agreement not been so terminated. Such payments shall be made within [***] following) Tj
0 -12 Td
ET
endstream
endobj
92 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 91 0 R >>
endobj
93 0 obj
<< /Length 4517 >>
stream
BT
/F1 10 Tf
72 720 Td
(the end of each calendar quarter in the Tail Period. Sections 6.3, 6.4 and 6.5 shall) Tj
0 -12 Td
(apply, mutatis mutandis, to such Tail Period payments. For clarity, no tail payment shall) Tj
0 -12 Td
(be due following any expiration or termination of this Agreement except as set forth in) Tj
0 -12 Td
(this Section 12.5.) Tj
0 -12 Td
() Tj
0 -12 Td
(12.6 Survival. Termination or expiration of this Agreement shall be without prejudice to) Tj
0 -12 Td
(any rights that shall have accrued to the benefit of any Party prior to such termination) Tj
0 -12 Td
(or expiration. Notwithstanding any expiration or termination of this Agreement, such) Tj
0 -12 Td
(expiration or termination shall not relieve any Party from obligations which are expressly) Tj
0 -12 Td
(or by implication intended to survive expiration or termination, including Sections 2.3, ,) Tj
0 -12 Td
(4.4.2, 5.7, 5.9, 6.3.6, 6.3.5, 11.1, 11.2, 11.3, 11.4, 12.4, 12.5 and 12.6, Articles 7, 8,) Tj
0 -12 Td
(9 and 13 \(to the extent applicable to implementation of the survival of the preceding) Tj
0 -12 Td
(Sections and Articles\) and, solely as it relates to the last Calendar Quarter, Sections) Tj
0 -12 Td
(6.1, 6.2 and 6.3, which shall survive and be in full force and effect.) Tj
0 -12 Td
() Tj
0 -12 Td
(ARTICLE 13  MISCELLANEOUS) Tj
0 -12 Td
() Tj
0 -12 Td
(13.1 Force Majeure. Neither Party shall be held liable to the other Party nor be deemed to) Tj
0 -12 Td
(have defaulted under or breached this Agreement for failure or delay in performing any) Tj
0 -12 Td
(obligation under this Agreement to the extent such failure or delay is) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(caused by or results from causes beyond the reasonable control of the affected Party,) Tj
0 -12 Td
(potentially including, embargoes, war, acts of war \(whether war be declared or not\), acts) Tj
0 -12 Td
(of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor) Tj
0 -12 Td
(disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting) Tj
0 -12 Td
(by any Governmental Authority. The affected Party shall notify the other Party of such) Tj
0 -12 Td
(force majeure circumstances as soon as reasonably practicable, and shall promptly) Tj
0 -12 Td
(undertake all reasonable efforts necessary to cure such force majeure circumstances and) Tj
0 -12 Td
(re-commence its performance hereunder as soon as practicable.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.2 Assignment. Except as provided in this Section 13.2, this Agreement may not be) Tj
0 -12 Td
(assigned or otherwise transferred, nor may any rights or obligations hereunder be assigned) Tj
0 -12 Td
(or transferred, by either Party, without the written consent of the other Party \(such) Tj
0 -12 Td
(consent not to be unreasonably withheld\); provided that a merger, sale of stock or) Tj
0 -12 Td
(comparable transaction shall not constitute an assignment. In the event either Party) Tj
0 -12 Td
(desires to make such an assignment or other transfer of this Agreement or any rights or) Tj
0 -12 Td
(obligations hereunder, such Party shall deliver a written notice to the other Party) Tj
0 -12 Td
(requesting the other Party's written consent in accordance with this Section 13.2, and the) Tj
0 -12 Td
(other Party shall provide such Party written notice of its determination whether to) Tj
0 -12 Td
(provide such written consent within [***] following its receipt of such written notice) Tj
0 -12 Td
(from such Party. Notwithstanding the foregoing, \(a\) either Party may, without the other) Tj
0 -12 Td
(Party's consent, assign this Agreement and its rights and obligations hereunder in whole) Tj
0 -12 Td
(or in part to an Affiliate; and \(b\) Dova may assign this Agreement to a successor in) Tj
0 -12 Td
(interest in connection with the sale or other transfer of all or substantially all of) Tj
0 -12 Td
(Dova's assets or rights relating to the Product; provided that such assignee shall remain) Tj
0 -12 Td
(subject to all of the terms and conditions hereof in all respects and shall assume all) Tj
0 -12 Td
(obligations of Dova hereunder whether accruing before or after such assignment. Any) Tj
0 -12 Td
(permitted assignee shall assume all assigned obligations of its assignor under this) Tj
0 -12 Td
(Agreement. Any attempted assignment not in accordance with this Section 13.2 shall be) Tj
0 -12 Td
ET
endstream
endobj
94 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 93 0 R >>
endobj
95 0 obj
<< /Length 3822 >>
stream
BT
/F1 10 Tf
72 720 Td
(void. This Agreement shall be binding on, and inure to the benefit of, each Party, and its) Tj
0 -12 Td
(permitted successors and assigns.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.3 Severability. If any one or more of the provisions contained in this Agreement is) Tj
0 -12 Td
(held invalid, illegal or unenforceable in any respect, the validity, legality and) Tj
0 -12 Td
(enforceability of the remaining provisions contained herein shall not in any way be) Tj
0 -12 Td
(affected or impaired thereby, unless the absence of the invalidated provision\(s\) adversely) Tj
0 -12 Td
(affects the substantive rights of the Parties. The Parties shall in such an instance use) Tj
0 -12 Td
(reasonable efforts to replace the invalid, illegal or unenforceable provision\(s\) with) Tj
0 -12 Td
(valid, legal and enforceable provision\(s\) which, insofar as practical, implement the) Tj
0 -12 Td
(purposes of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.4 Notices. All notices which are required or permitted hereunder shall be in writing) Tj
0 -12 Td
(and sufficient if delivered personally, sent by e-mail \(and promptly confirmed by personal) Tj
0 -12 Td
(delivery, registered or certified mail or overnight courier\), sent by nationally-) Tj
0 -12 Td
(recognized overnight courier, or sent by registered or certified mail, postage prepaid,) Tj
0 -12 Td
(return receipt requested, addressed as follows:) Tj
0 -12 Td
() Tj
0 -12 Td
(if to Dova, to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707) Tj
0 -12 Td
(Attention: Chief Executive Officer Email: asapir@dova.com) Tj
0 -12 Td
() Tj
0 -12 Td
(With a copy to: Dova Pharmaceuticals, Inc. 240 Leigh Farm Road, Suite 245 Durham, NC 27707) Tj
0 -12 Td
(Attention: General Counsel Email: mbanjak@dova.com) Tj
0 -12 Td
() Tj
0 -12 Td
(if to Valeant, to: Valeant Pharmaceuticals North America LLC 400 Somerset Corporate) Tj
0 -12 Td
(Boulevard Bridgewater, NJ 08807 Attention: XXXXXXXXX Email: XXXXXXXX) Tj
0 -12 Td
() Tj
0 -12 Td
(With a copy to: XXXXXXXX Attention: XXXXXXXX Fax: XXXXXXXX Email: XXXXXXXX) Tj
0 -12 Td
() Tj
0 -12 Td
(or to such other address\(es\) as the Party to whom notice is to be given may have furnished) Tj
0 -12 Td
(to the other Party in writing in accordance herewith. Any such notice shall be deemed to) Tj
0 -12 Td
(have been given: \(a\) when delivered if personally delivered; \(b\) on the) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(Business Day after dispatch if sent by nationally-recognized overnight courier; or \(c\) on) Tj
0 -12 Td
(the fifth \(5th\) Business Day following the date of mailing, if sent by mail.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.5 Governing Law. This Agreement and any and all matters arising directly or indirectly) Tj
0 -12 Td
(herefrom shall be governed by and construed and enforced in accordance with the internal) Tj
0 -12 Td
(laws of the [***] applicable to agreements made and to be performed entirely in such) Tj
0 -12 Td
(state, including its statutes of limitation but without giving effect to the conflict of) Tj
0 -12 Td
(law principles thereof.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.6 Dispute Resolution.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.6.1 JSC; Escalation for Other Disputes. Except for disputes resolved by the procedures) Tj
0 -12 Td
(set forth in Section 3.4, if a dispute arises between the Parties in connection with or) Tj
0 -12 Td
(relating to this Agreement or any document or instrument delivered in connection herewith) Tj
0 -12 Td
(\(a "Dispute"\), then either Party shall have the right to refer such dispute to the Senior) Tj
0 -12 Td
(Officers who shall confer within [***] after such Dispute was first referred to them to) Tj
0 -12 Td
ET
endstream
endobj
96 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 95 0 R >>
endobj
97 0 obj
<< /Length 4419 >>
stream
BT
/F1 10 Tf
72 720 Td
(attempt to resolve the Dispute by good faith negotiations. Any final decision mutually) Tj
0 -12 Td
(agreed to by the Senior Officers in writing shall be conclusive and binding on the) Tj
0 -12 Td
(Parties. If such Senior Officers do not agree on the resolution of an issue within [***]) Tj
0 -12 Td
(after such issue was first referred to them, either Party may, by written notice to the) Tj
0 -12 Td
(other Party, initiate arbitration for resolution of such Dispute pursuant to Section) Tj
0 -12 Td
(13.6.2.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.6.2 Arbitration of Other Disputes. If a Dispute is not resolved by the Senior Officers) Tj
0 -12 Td
(pursuant to Section 13.6.1, such Dispute shall be submitted to and finally settled by) Tj
0 -12 Td
([***] The Parties hereby submit to the exclusive jurisdiction of the federal and state) Tj
0 -12 Td
(courts located in [***] for the purposes of an order to compel arbitration, for) Tj
0 -12 Td
(preliminary relief in aid of arbitration and for a preliminary injunction to maintain the) Tj
0 -12 Td
(status quo or prevent irreparable harm prior to the appointment of the arbitrators and to) Tj
0 -12 Td
(the non-exclusive jurisdiction of such courts for the enforcement of any ward issued) Tj
0 -12 Td
(hereunder.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.7 Waiver of Jury Trial. EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ANY AND ALL RIGHT) Tj
0 -12 Td
(TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATED TO THIS AGREEMENT OR) Tj
0 -12 Td
(THE TRANSACTIONS CONTEMPLATED HEREBY.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.8 Entire Agreement; Amendments. This Agreement, together with the Schedules and) Tj
0 -12 Td
(Exhibits hereto, contains the entire understanding of the Parties with respect to the) Tj
0 -12 Td
(subject matter hereof. Any other express or implied agreements and understandings,) Tj
0 -12 Td
(negotiations, writings and commitments, either oral or written, in respect to the subject) Tj
0 -12 Td
(matter hereof \(including the Confidentiality Agreement, but solely with respect to) Tj
0 -12 Td
(information which is deemed Confidential Information hereunder\) are superseded by the) Tj
0 -12 Td
(terms of this Agreement. The Exhibits to this Agreement are incorporated herein by) Tj
0 -12 Td
(reference and shall be deemed a part of this Agreement. This Agreement may be amended, or) Tj
0 -12 Td
(any term hereof modified, only by a written instrument duly executed by authorized) Tj
0 -12 Td
(representative\(s\) of both Parties hereto.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.9 Headings. The captions to the several Articles, Sections and subsections hereof are) Tj
0 -12 Td
(not a part of this Agreement, but are merely for convenience to assist in locating and) Tj
0 -12 Td
(reading the several Articles and Sections hereof.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.10 Independent Contractors. It is expressly agreed that Valeant and Dova shall be) Tj
0 -12 Td
(independent contractors and that the relationship between the two Parties shall not) Tj
0 -12 Td
(constitute a partnership, joint venture or agency. Neither Valeant nor Dova shall have the) Tj
0 -12 Td
(authority to make any statements, representations or commitments of any kind, or to take) Tj
0 -12 Td
(any action, which shall be binding on the other Party, without the prior written consent) Tj
0 -12 Td
(of the other Party.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.11 Third Party Beneficiaries. Except as set forth in ARTICLE 11, no Person other than) Tj
0 -12 Td
(Dova or Valeant \(and their respective Affiliates and permitted successors and assignees) Tj
0 -12 Td
(hereunder\) shall be deemed an intended beneficiary hereunder or have any right to enforce) Tj
0 -12 Td
(any obligation of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.12 Waiver. The waiver by either Party hereto of any right hereunder, or of any failure) Tj
0 -12 Td
(of the other Party to perform, or of any breach by the other Party, shall not be deemed a) Tj
0 -12 Td
(waiver of any other right hereunder or of any other breach by or failure of such other) Tj
0 -12 Td
(Party whether of a similar nature or otherwise.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.13 Cumulative Remedies. No remedy referred to in this Agreement is intended to be) Tj
0 -12 Td
(exclusive, but each shall be cumulative and in addition to any other remedy referred to in) Tj
0 -12 Td
(this Agreement or otherwise available under law.) Tj
0 -12 Td
ET
endstream
endobj
98 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 97 0 R >>
endobj
99 0 obj
<< /Length 3627 >>
stream
BT
/F1 10 Tf
72 720 Td
() Tj
0 -12 Td
(13.14 Waiver of Rule of Construction. Each Party has had the opportunity to consult with) Tj
0 -12 Td
(counsel in connection with the review, drafting and negotiation of this Agreement.) Tj
0 -12 Td
(Accordingly, the rule of construction that any ambiguity in this Agreement shall be) Tj
0 -12 Td
(construed against the drafting Party shall not apply.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.15 Use of Names. Except as otherwise provided herein, neither Party shall have any) Tj
0 -12 Td
(right, express or implied, to use in any manner the name or other designation of the other) Tj
0 -12 Td
(Party or any other trade name, trademark or logo of the other Party for any purpose in) Tj
0 -12 Td
(connection with the performance of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.16 Further Actions and Documents. Each Party agrees to execute, acknowledge and deliver) Tj
0 -12 Td
(all such further) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(instruments, and to do all such further acts, as may be reasonably necessary or) Tj
0 -12 Td
(appropriate to carry out the intent and purposes of this Agreement.) Tj
0 -12 Td
() Tj
0 -12 Td
(13.17 Certain Conventions. Any reference in this Agreement to an Article, Section,) Tj
0 -12 Td
(subsection, paragraph, clause, or Exhibit shall be deemed to be a reference to an Article,) Tj
0 -12 Td
(Section, subsection, paragraph, clause, or Exhibit, of or to, as the case may be, this) Tj
0 -12 Td
(Agreement, unless otherwise indicated. Unless the context of this Agreement otherwise) Tj
0 -12 Td
(requires, \(a\) words of any gender include each other gender, \(b\) words such as "herein",) Tj
0 -12 Td
("hereof", and "hereunder" refer to this Agreement as a whole and not merely to the) Tj
0 -12 Td
(particular provision in which such words appear, \(c\) words using the singular shall) Tj
0 -12 Td
(include the plural, and vice versa, \(d\) whenever any provision of this Agreement uses the) Tj
0 -12 Td
(term "including" \(or "includes"\), such term shall be deemed to mean "including without) Tj
0 -12 Td
(limitation" \(or "includes without limitations"\), and \(e\) references to any Articles or) Tj
0 -12 Td
(Sections include Sections and subsections that are part of the references' Article or) Tj
0 -12 Td
(Section \(e.g., a section numbered "Section 2.2.1" would be part of "Section 2.2", and) Tj
0 -12 Td
(references to "ARTICLE 2" or "Section 2.2" would refer to material contained in the) Tj
0 -12 Td
(subsection described as "Section 2.2.1"\).) Tj
0 -12 Td
() Tj
0 -12 Td
(13.18 Counterparts. This Agreement may be executed in two or more counterparts, each of) Tj
0 -12 Td
(which shall be deemed an original, but all of which together shall constitute one and the) Tj
0 -12 Td
(same instrument. Counterparts may be delivered via facsimile or electronic mail \(including) Tj
0 -12 Td
(pdf\) and any counterpart so delivered shall be deemed to have been duly and validly) Tj
0 -12 Td
(delivered and be valid and effective for all purposes and shall have the same force and) Tj
0 -12 Td
(effect as original signatures.) Tj
0 -12 Td
() Tj
0 -12 Td
([signature page follows]) Tj
0 -12 Td
() Tj
0 -12 Td
([Signature page to Co-Promotion Agreement]) Tj
0 -12 Td
() Tj
0 -12 Td
(IN WITNESS WHEREOF, the Parties have executed this Agreement as of the Effective Date.) Tj
0 -12 Td
() Tj
0 -12 Td
(DOVA PHARMACEUTICALS, INC.) Tj
0 -12 Td
() Tj
0 -12 Td
(By: __/s/ Alex C. Sapir______________________) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
100 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 99 0 R >>
endobj
101 0 obj
<< /Length 3418 >>
stream
BT
/F1 10 Tf
72 720 Td
(Name: Alex C. Sapir) Tj
0 -12 Td
() Tj
0 -12 Td
(Title: CEO) Tj
0 -12 Td
() Tj
0 -12 Td
(VALEANT PHARMACEUTICALS NORTH AMERICA LLC) Tj
0 -12 Td
() Tj
0 -12 Td
(By: ___/s/ Joseph C. Papa_______________) Tj
0 -12 Td
() Tj
0 -12 Td
(Name: Joseph C. Papa) Tj
0 -12 Td
() Tj
0 -12 Td
(Title: Chief Executive Officer and President) Tj
0 -12 Td
() Tj
0 -12 Td
(9) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(EXHIBIT A) Tj
0 -12 Td
() Tj
0 -12 Td
(Joint Press Release) Tj
0 -12 Td
() Tj
0 -12 Td
(DURHAM, N.C. and BRIDGEWATER, N.J., Sept. 27, 2018 \(GLOBE NEWSWIRE\) -- Dova) Tj
0 -12 Td
(Pharmaceuticals, Inc. \("Dova"\) \(DOVA\), a specialty pharmaceutical company focused on) Tj
0 -12 Td
(acquiring, developing, and commercializing drug candidates for diseases where there is a) Tj
0 -12 Td
(high unmet need, and Salix Pharmaceuticals \("Salix"\), one of the largest specialty) Tj
0 -12 Td
(pharmaceutical companies in the world committed to the prevention and treatment of) Tj
0 -12 Td
(gastrointestinal diseases and its parent company, Bausch Health Companies Inc. \(NYSE/TSX:) Tj
0 -12 Td
(BHC\), today announced that they have entered into an exclusive agreement to co-promote) Tj
0 -12 Td
(Dova's DOPTELET \(avatrombopag\) in the United States \(U.S.\). The U.S. Food and Drug) Tj
0 -12 Td
(Administration \("FDA"\) approved DOPTELET on May 21, 2018 for the treatment of) Tj
0 -12 Td
(thrombocytopenia in adult patients with chronic liver disease \(CLD\) who are scheduled to) Tj
0 -12 Td
(undergo a procedure. DOPTELET represents the first thrombopoietin \(TPO\) receptor agonist) Tj
0 -12 Td
(approved in the United States for this indication.) Tj
0 -12 Td
() Tj
0 -12 Td
(Thrombocytopenia, a condition in which patients have a low platelet count, is the most) Tj
0 -12 Td
(common hematological abnormality in patients with CLD that often worsens with the severity) Tj
0 -12 Td
(of liver disease. It is estimated that approximately 15 percent of the 7.5 million) Tj
0 -12 Td
(patients with CLD have some form of thrombocytopenia. In a study published in 2010,) Tj
0 -12 Td
(patients with severe thrombocytopenia \(<75,000/ L\) had a 31 percent incidence of) Tj
0 -12 Td
(procedure-related bleeding. As a result of the associated increased rate of bleeding,) Tj
0 -12 Td
(there is an increased risk for the CLD patient when undergoing common scheduled medical) Tj
0 -12 Td
(procedures such as liver biopsy, colonoscopy, endoscopy, and routine dental procedures.) Tj
0 -12 Td
() Tj
0 -12 Td
(As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales) Tj
0 -12 Td
(specialists who will promote DOPTELET to gastroenterology healthcare professionals. The) Tj
0 -12 Td
(Salix sales force will begin selling DOPTELET in mid-October 2018. Dova will continue its) Tj
0 -12 Td
(commercial efforts targeting primarily hepatologists and interventional radiologists and) Tj
0 -12 Td
ET
endstream
endobj
102 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 101 0 R >>
endobj
103 0 obj
<< /Length 4372 >>
stream
BT
/F1 10 Tf
72 720 Td
(certain other specialties. Pursuant to the agreement, Dova will pay Salix a quarterly fee) Tj
0 -12 Td
(based on net sales \(as defined in the agreement\) of DOPTELET prescribed by) Tj
0 -12 Td
(gastroenterologists in the U.S.) Tj
0 -12 Td
() Tj
0 -12 Td
("We are delighted to be working with Salix, a company considered by many to have the) Tj
0 -12 Td
(preeminent gastroenterology sales force in the United States," said Alex C. Sapir,) Tj
0 -12 Td
(president and chief executive officer, Dova Pharmaceuticals. "Given Salix's presence and) Tj
0 -12 Td
(strong reputation within large gastroenterology group practices coupled with the early) Tj
0 -12 Td
(interest we are seeing among the gastroenterology community, we are excited to see the) Tj
0 -12 Td
(impact this partnership will bring to DOPTELET and to patients.") Tj
0 -12 Td
() Tj
0 -12 Td
("Salix considers liver disease a strategic therapeutic area of focus, given our history) Tj
0 -12 Td
(and knowledge with XIFAXAN  \(rifaximin\), an innovative medicine indicated for the) Tj
0 -12 Td
(treatment of overt hepatic encephalopathy \(HE\), a condition that is often a consequence of) Tj
0 -12 Td
(chronic liver disease," said Mark McKenna, president, Salix Pharmaceuticals. "Adding) Tj
0 -12 Td
(DOPTELET to our portfolio will enable our sales force to promote yet another innovative) Tj
0 -12 Td
(product that addresses a true unmet need in the marketplace.") Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(About DOPTELET  DOPTELET \(avatrombopag\) is a second generation, once daily, orally) Tj
0 -12 Td
(administered TPO receptor agonist approved for the treatment of thrombocytopenia in adult) Tj
0 -12 Td
(patients with CLD who are scheduled to undergo a procedure. DOPTELET is designed to mimic) Tj
0 -12 Td
(the effects of TPO, the primary regulator of normal platelet production.) Tj
0 -12 Td
() Tj
0 -12 Td
(Two global Phase 3, double-blind, placebo-controlled trials \(ADAPT-1 [N=231] and ADAPT-2) Tj
0 -12 Td
([N=204]\), conducted in adults with thrombocytopenia \(platelet count of less than 50,000/) Tj
0 -12 Td
(L\) and CLD, supported the FDA approval. Patients were assigned to either 40 mg or 60 mg of) Tj
0 -12 Td
(avatrombopag daily for five days based on their Baseline platelet counts \(40 to <50,000/) Tj
0 -12 Td
(mL or <40,000/ mL, respectively\). Avatrombopag was shown to be superior to placebo in) Tj
0 -12 Td
(increasing the proportion of patients not requiring platelet transfusions or rescue) Tj
0 -12 Td
(procedures for bleeding up to seven days following a scheduled procedure in both trials in) Tj
0 -12 Td
(both the 40 mg \(ADAPT-1, 88% vs. 38%, p <0.0001; ADAPT-2, 88% vs. 33%; p<0.0001\), and 60) Tj
0 -12 Td
(mg \(ADAPT-1, 66% vs. 23%, p <0.0001; ADAPT-2, 69% vs. 35%; p=0.0006\) treatment groups.) Tj
0 -12 Td
(Avatrombopag was also superior to placebo at the two secondary efficacy endpoints in each) Tj
0 -12 Td
(trial. In the avatrombopag treatment groups, there was an increased proportion of patients) Tj
0 -12 Td
(achieving the target platelet count of  50,000/ mL on procedure day, and a greater) Tj
0 -12 Td
(magnitude of the change in mean platelet count from baseline to procedure day; all) Tj
0 -12 Td
(treatment differences between the avatrombopag and placebo treatment groups for each) Tj
0 -12 Td
(secondary endpoint were highly statistically significant with p values <0.0001. The most) Tj
0 -12 Td
(common adverse reactions with avatrombopag included pyrexia, abdominal pain, nausea,) Tj
0 -12 Td
(headache, fatigue and edema peripheral. Portal vein thromboses have been reported in) Tj
0 -12 Td
(patients with CLD and in patients receiving TPO receptor agonists. One treatment-emergent) Tj
0 -12 Td
(event of portal vein thrombosis was reported in the ADAPT trials in an avatrombopag-) Tj
0 -12 Td
(treated patient.) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
104 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 103 0 R >>
endobj
105 0 obj
<< /Length 3189 >>
stream
BT
/F1 10 Tf
72 720 Td
(INDICATION) Tj
0 -12 Td
() Tj
0 -12 Td
(DOPTELET \(avatrombopag\) is indicated for the treatment of thrombocytopenia in adult) Tj
0 -12 Td
(patients with chronic liver disease who are scheduled to undergo a procedure.) Tj
0 -12 Td
() Tj
0 -12 Td
(IMPORTANT SAFETY INFORMATION) Tj
0 -12 Td
() Tj
0 -12 Td
(WARNINGS AND PRECAUTIONS) Tj
0 -12 Td
() Tj
0 -12 Td
(DOPTELET is a thrombopoietin \(TPO\) receptor agonist and TPO receptor agonists have been) Tj
0 -12 Td
(associated with thrombotic and thromboembolic complications in patients with chronic liver) Tj
0 -12 Td
(disease. Portal vein thrombosis has been reported in patients with chronic liver disease) Tj
0 -12 Td
(treated with TPO receptor agonists. In the ADAPT-1 and ADAPT-2 clinical trials, there was) Tj
0 -12 Td
(one treatment- emergent event of portal vein thrombosis in a patient \(n=1/430\) with) Tj
0 -12 Td
(chronic liver disease and thrombocytopenia treated with DOPTELET.) Tj
0 -12 Td
() Tj
0 -12 Td
(Consider the potential increased thrombotic risk when administering DOPTELET to patients) Tj
0 -12 Td
(with known risk factors for thromboembolism, including genetic prothrombotic conditions) Tj
0 -12 Td
(\(Factor V Leiden, Prothrombin 20210A, Antithrombin deficiency or Protein C or S) Tj
0 -12 Td
(deficiency\).) Tj
0 -12 Td
() Tj
0 -12 Td
(DOPTELET should not be administered to patients with chronic liver disease in an attempt) Tj
0 -12 Td
(to normalize platelet counts.) Tj
0 -12 Td
() Tj
0 -12 Td
(CONTRAINDICATIONS: None) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(ADVERSE REACTIONS) Tj
0 -12 Td
() Tj
0 -12 Td
(Most common adverse reactions \(  3%\) were: pyrexia, abdominal pain, nausea, headache,) Tj
0 -12 Td
(fatigue, and edema peripheral.) Tj
0 -12 Td
() Tj
0 -12 Td
(Please see full Prescribing Information for DOPTELET \(avatrombopag\) www.doptelet.com) Tj
0 -12 Td
() Tj
0 -12 Td
(About XIFAXAN  XIFAXAN is a nonsystemic* antibiotic that slows the growth of bacteria in) Tj
0 -12 Td
(the gut that are believed to be linked to symptoms of overt hepatic encephalopathy \(HE\).) Tj
0 -12 Td
(It has been proven to reduce the risk of overt HE recurrence and HE-related) Tj
0 -12 Td
(hospitalizations in adults.) Tj
0 -12 Td
() Tj
0 -12 Td
(*There is an increased systemic exposure in patients with severe \(Child-Pugh Class C\)) Tj
0 -12 Td
(hepatic impairment. Caution should be exercised when administering XIFAXAN to these) Tj
0 -12 Td
(patients.) Tj
0 -12 Td
() Tj
0 -12 Td
(INDICATION  XIFAXAN \(rifaximin\) 550 mg tablets are indicated for the reduction in risk of) Tj
0 -12 Td
(overt hepatic encephalopathy \(HE\) recurrence in adults and for the treatment of irritable) Tj
0 -12 Td
ET
endstream
endobj
106 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 105 0 R >>
endobj
107 0 obj
<< /Length 3671 >>
stream
BT
/F1 10 Tf
72 720 Td
(bowel syndrome with diarrhea \(IBS-D\) in adults.) Tj
0 -12 Td
() Tj
0 -12 Td
(IMPORTANT SAFETY INFORMATION) Tj
0 -12 Td
() Tj
0 -12 Td
(XIFAXAN is not for everyone. Do not take XIFAXAN if you have a known hypersensitivity to) Tj
0 -12 Td
(rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN.) Tj
0 -12 Td
() Tj
0 -12 Td
(If you take antibiotics, like XIFAXAN, there is a chance you could experience diarrhea) Tj
0 -12 Td
(caused by an overgrowth of bacteria \(C. difficile\). This can cause symptoms ranging in) Tj
0 -12 Td
(severity from mild diarrhea to life-threatening colitis. Contact your healthcare provider) Tj
0 -12 Td
(if your diarrhea does not improve or worsens.) Tj
0 -12 Td
() Tj
0 -12 Td
(Talk to your healthcare provider before taking XIFAXAN if you have severe hepatic \(liver\)) Tj
0 -12 Td
(impairment, as this may cause increased effects of the medicine.) Tj
0 -12 Td
() Tj
0 -12 Td
(Tell your healthcare provider if you are taking drugs called P-glycoprotein and/or OATPs) Tj
0 -12 Td
(inhibitors \(such as cyclosporine\) because using these drugs with XIFAXAN may lead to an) Tj
0 -12 Td
(increase in the amount of XIFAXAN absorbed by your body.) Tj
0 -12 Td
() Tj
0 -12 Td
(In clinical studies, the most common side effects of XIFAXAN were: HE: Peripheral edema) Tj
0 -12 Td
(\(swelling, usually in the ankles or lower limbs\), nausea \(feeling sick to your stomach\),) Tj
0 -12 Td
(dizziness, fatigue \(feeling tired\), and ascites \(a buildup of fluid in the abdomen\)) Tj
0 -12 Td
(IBS-D: Nausea \(feeling sick to your stomach\) and an increase in liver enzymes) Tj
0 -12 Td
() Tj
0 -12 Td
(XIFAXAN may affect warfarin activity when taken together. Tell your healthcare provider if) Tj
0 -12 Td
(you are taking warfarin because the dose of warfarin may need to be adjusted to maintain) Tj
0 -12 Td
(proper blood-thinning effect.) Tj
0 -12 Td
() Tj
0 -12 Td
(If you are pregnant, planning to become pregnant, or nursing, talk to your healthcare) Tj
0 -12 Td
(provider before taking XIFAXAN because XIFAXAN may cause harm to an unborn baby or nursing) Tj
0 -12 Td
(infant. You are encouraged to report negative side effects of prescription drugs to the) Tj
0 -12 Td
(FDA. Visit www.fda.gov/medwatch or call 1-800- FDA-1088.) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(For product information, adverse event reports, and product complaint reports, please) Tj
0 -12 Td
(contact:  Salix Product Information Call Center  Phone: 1-800-321-4576  Fax:) Tj
0 -12 Td
(1-510-595-8183  Email: salixmc@dlss.com  Please click here for full Prescribing) Tj
0 -12 Td
(Information.) Tj
0 -12 Td
() Tj
0 -12 Td
(About Dova Pharmaceuticals, Inc.  Dova is a pharmaceutical company focused on acquiring,) Tj
0 -12 Td
(developing, and commercializing drug candidates for rare diseases where there is a high) Tj
0 -12 Td
(unmet need, with an initial focus on addressing thrombocytopenia. Dova's proprietary) Tj
0 -12 Td
(pipeline includes one commercial product, DOPTELET, for the treatment of thrombocytopenia) Tj
0 -12 Td
(in adult patients with CLD scheduled to undergo a procedure.) Tj
0 -12 Td
() Tj
0 -12 Td
ET
endstream
endobj
108 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 107 0 R >>
endobj
109 0 obj
<< /Length 4426 >>
stream
BT
/F1 10 Tf
72 720 Td
(About Salix  Salix is one of the largest specialty pharmaceutical companies in the world) Tj
0 -12 Td
(committed to the prevention and treatment of gastrointestinal diseases. For almost 30) Tj
0 -12 Td
(years, Salix has licensed, developed, and marketed innovative products to improve) Tj
0 -12 Td
(patients' lives and arm health care providers with life-changing solutions for many) Tj
0 -12 Td
(chronic and debilitating conditions. Salix currently markets its product line to U.S.) Tj
0 -12 Td
(health care providers through an expanded sales force that focuses on gastroenterology,) Tj
0 -12 Td
(hepatology, pain specialists, and primary care. Salix is headquartered in Bridgewater, New) Tj
0 -12 Td
(Jersey.) Tj
0 -12 Td
() Tj
0 -12 Td
(About Bausch Health  Bausch Health Companies Inc. \(NYSE/TSX: BHC\) is a global company) Tj
0 -12 Td
(whose mission is to improve people's lives with our health care products. We develop,) Tj
0 -12 Td
(manufacture and market a range of pharmaceutical, medical device and over-the-counter) Tj
0 -12 Td
(products, primarily in the therapeutic areas of eye health, gastroenterology and) Tj
0 -12 Td
(dermatology. We are delivering on our commitments as we build an innovative company) Tj
0 -12 Td
(dedicated to advancing global health. More information can be found at) Tj
0 -12 Td
(www.bauschhealth.com.) Tj
0 -12 Td
() Tj
0 -12 Td
(Dova Pharmaceuticals Cautionary Notes Regarding Forward-Looking Statements  Any statements) Tj
0 -12 Td
(contained in this press release that do not describe historical facts may constitute) Tj
0 -12 Td
(forward-looking statements as that term is defined in the Private Securities Litigation) Tj
0 -12 Td
(Reform Act of 1995. These statements may be identified by words such as "anticipated",) Tj
0 -12 Td
("believe", "expect", "may", "plan", "potential", "will", and similar expressions, and are) Tj
0 -12 Td
(based on Dova's current beliefs and expectations. These forward-looking statements include) Tj
0 -12 Td
(the potential benefits of the collaboration, the timing of the Salix sales force beginning) Tj
0 -12 Td
(to sell DOPTELET and other information relating to the transaction between Dova and Salix.) Tj
0 -12 Td
(These statements involve risks and uncertainties that could cause actual results to differ) Tj
0 -12 Td
(materially from those reflected in such statements. Risks and uncertainties that may cause) Tj
0 -12 Td
(actual results to differ materially include uncertainties inherent in the conduct of) Tj
0 -12 Td
(clinical trials, increased regulatory requirements, Dova's reliance on third parties over) Tj
0 -12 Td
(which it may not always have full control, and other risks and uncertainties that are) Tj
0 -12 Td
(described in Dova's Annual Report on Form 10-K for the year ended December 31, 2017, filed) Tj
0 -12 Td
(with the U.S. Securities and Exchange Commission \(SEC\) on February 16, 2018, and Dova's) Tj
0 -12 Td
(other periodic reports filed with the SEC. Any forward-looking statements speak only as of) Tj
0 -12 Td
(the date of this press release and are based on information available to Dova as) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(of the date of this release, and Dova assumes no obligation to, and does not intend to,) Tj
0 -12 Td
(update any forward-looking statements, whether as a result of new information, future) Tj
0 -12 Td
(events or otherwise.) Tj
0 -12 Td
() Tj
0 -12 Td
(Bausch Health Forward-looking Statements  This news release may contain forward-looking) Tj
0 -12 Td
(statements, which may generally be identified by the use of the words "anticipates,") Tj
0 -12 Td
("expects," "intends," "plans," "should," "could," "would," "may," "will," "believes,") Tj
0 -12 Td
("estimates," "potential," "target," or "continue" and variations or similar expressions.) Tj
0 -12 Td
(These statements are based upon the current expectations and beliefs of management and are) Tj
0 -12 Td
ET
endstream
endobj
110 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 109 0 R >>
endobj
111 0 obj
<< /Length 3457 >>
stream
BT
/F1 10 Tf
72 720 Td
(subject to certain risks and uncertainties that could cause actual results to differ) Tj
0 -12 Td
(materially from those described in the forward- looking statements. These risks and) Tj
0 -12 Td
(uncertainties include, but are not limited to, risks and uncertainties discussed in the) Tj
0 -12 Td
(Bausch Health's most recent annual or quarterly report and detailed from time to time in) Tj
0 -12 Td
(Bausch Health's other filings with the Securities and Exchange Commission and the Canadian) Tj
0 -12 Td
(Securities Administrators, which factors are incorporated herein by reference. In) Tj
0 -12 Td
(addition, certain material factors and assumptions have been applied in making these) Tj
0 -12 Td
(forward-looking statements, including that the risks and uncertainties outlined above will) Tj
0 -12 Td
(not cause actual results or events to differ materially from those described in these) Tj
0 -12 Td
(forward-looking statements. Bausch Health believes that the material factors and) Tj
0 -12 Td
(assumptions reflected in these forward-looking statements are reasonable, but readers are) Tj
0 -12 Td
(cautioned not to place undue reliance on any of these forward-looking statements. These) Tj
0 -12 Td
(forward-looking statements speak only as of the date hereof. Bausch Health and Salix) Tj
0 -12 Td
(undertake no obligation to update any of these forward-looking statements to reflect) Tj
0 -12 Td
(events or circumstances after the date of this news release or to reflect actual outcomes,) Tj
0 -12 Td
(unless required by law.) Tj
0 -12 Td
() Tj
0 -12 Td
(Dova Investor Contacts:  Mark W. Hahn  Chief Financial Officer  mhahn@dova.com  \(919\)) Tj
0 -12 Td
(338-7936) Tj
0 -12 Td
() Tj
0 -12 Td
(Salix Investor Contact:  Arthur Shannon  Arthur.Shannon@bauschhealth.com  514-856-3855) Tj
0 -12 Td
(877-281-6642 \(toll free\)) Tj
0 -12 Td
() Tj
0 -12 Td
(Westwicke Partners  John Woolford  john.woolford@westwicke.com  \(443\) 213-0506) Tj
0 -12 Td
() Tj
0 -12 Td
(Salix Media Contacts:  Lainie Keller  Lainie.Keller@bauschhealth.com  908-927-0617) Tj
0 -12 Td
() Tj
0 -12 Td
(Karen Paff) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(Karen.Paff@salix.com  908-927-1190) Tj
0 -12 Td
() Tj
0 -12 Td
(AkaRx, Inc., a wholly owned subsidiary of Dova Pharmaceuticals, Inc., is the exclusive) Tj
0 -12 Td
(licensee and distributor of DOPTELET  in the United States and its territories.  2018) Tj
0 -12 Td
(DOPTELET  is a registered trademark of AkaRx, Inc.) Tj
0 -12 Td
() Tj
0 -12 Td
(PM-US-DOP-0072) Tj
0 -12 Td
() Tj
0 -12 Td
(The Xifaxan 550 mg product and the Xifaxan trademark are licensed by Alfasigma S.p.A.to) Tj
0 -12 Td
(Salix Pharmaceuticals or its affiliates.) Tj
0 -12 Td
() Tj
0 -12 Td
(SAL.0103.USA.18) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
ET
endstream
endobj
112 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 111 0 R >>
endobj
113 0 obj
<< /Length 1156 >>
stream
BT
/F1 10 Tf
72 720 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
() Tj
0 -12 Td
(Schedule 1.65) Tj
0 -12 Td
() Tj
0 -12 Td
(Third Party Agreements) Tj
0 -12 Td
() Tj
0 -12 Td
(1. Stock Purchase Agreement dated March 29, 2016 \(as amended\) between PBM AKX Holdings,) Tj
0 -12 Td
(LLC and Eisai, Inc.) Tj
0 -12 Td
() Tj
0 -12 Td
(2. License Agreement dated August 15, 2005 \(as amended\) between Astellas Pharma Inc. and) Tj
0 -12 Td
(AkaRx, Inc.) Tj
0 -12 Td
() Tj
0 -12 Td
(CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE COPY FILED) Tj
0 -12 Td
(HEREWITH OMITS THE INFORMATION SUBJECT TO A CONFIDENTIALITY REQUEST. OMISSIONS ARE) Tj
0 -12 Td
(DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE) Tj
0 -12 Td
(SECURITIES AND EXCHANGE COMMISSION.) Tj
0 -12 Td
() Tj
0 -12 Td
(Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018) Tj
0 -12 Td
ET
endstream
endobj
114 0 obj
<< /Type /Page /Parent 2 0 R /MediaBox [0 0 612 792] /Resources << /Font << /F1 115 0 R >> >> /Contents 113 0 R >>
endobj
115 0 obj
<< /Type /Font /Subtype /Type1 /BaseFont /Helvetica >>
endobj
xref
0 116
0000000000 65535 f 
0000000009 00000 n 
0000000058 00000 n 
0000000509 00000 n 
0000002401 00000 n 
0000002529 00000 n 
0000004517 00000 n 
0000004645 00000 n 
0000006456 00000 n 
0000006584 00000 n 
0000008339 00000 n 
0000008468 00000 n 
0000010795 00000 n 
0000010925 00000 n 
0000014911 00000 n 
0000015041 00000 n 
0000018890 00000 n 
0000019020 00000 n 
0000022805 00000 n 
0000022935 00000 n 
0000026709 00000 n 
0000026839 00000 n 
0000030275 00000 n 
0000030405 00000 n 
0000033741 00000 n 
0000033871 00000 n 
0000037689 00000 n 
0000037819 00000 n 
0000041593 00000 n 
0000041723 00000 n 
0000045806 00000 n 
0000045936 00000 n 
0000050581 00000 n 
0000050711 00000 n 
0000055037 00000 n 
0000055167 00000 n 
0000058795 00000 n 
0000058925 00000 n 
0000063411 00000 n 
0000063541 00000 n 
0000068016 00000 n 
0000068146 00000 n 
0000072220 00000 n 
0000072350 00000 n 
0000077322 00000 n 
0000077452 00000 n 
0000081436 00000 n 
0000081566 00000 n 
0000086491 00000 n 
0000086621 00000 n 
0000091384 00000 n 
0000091514 00000 n 
0000095792 00000 n 
0000095922 00000 n 
0000100996 00000 n 
0000101126 00000 n 
0000105510 00000 n 
0000105640 00000 n 
0000110906 00000 n 
0000111036 00000 n 
0000115517 00000 n 
0000115647 00000 n 
0000119419 00000 n 
0000119549 00000 n 
0000124612 00000 n 
0000124742 00000 n 
0000128996 00000 n 
0000129126 00000 n 
0000134282 00000 n 
0000134412 00000 n 
0000139023 00000 n 
0000139153 00000 n 
0000143799 00000 n 
0000143929 00000 n 
0000148803 00000 n 
0000148933 00000 n 
0000152872 00000 n 
0000153002 00000 n 
0000157038 00000 n 
0000157168 00000 n 
0000161829 00000 n 
0000161959 00000 n 
0000166096 00000 n 
0000166226 00000 n 
0000170337 00000 n 
0000170467 00000 n 
0000175239 00000 n 
0000175369 00000 n 
0000180035 00000 n 
0000180165 00000 n 
0000184214 00000 n 
0000184344 00000 n 
0000189168 00000 n 
0000189298 00000 n 
0000193868 00000 n 
0000193998 00000 n 
0000197873 00000 n 
0000198003 00000 n 
0000202475 00000 n 
0000202605 00000 n 
0000206285 00000 n 
0000206416 00000 n 
0000209888 00000 n 
0000210020 00000 n 
0000214446 00000 n 
0000214578 00000 n 
0000217821 00000 n 
0000217953 00000 n 
0000221678 00000 n 
0000221810 00000 n 
0000226290 00000 n 
0000226422 00000 n 
0000229933 00000 n 
0000230065 00000 n 
0000231275 00000 n 
0000231407 00000 n 
trailer << /Size 116 /Root 1 0 R >>
startxref
231479
%%EOF
